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ZUSAMMENFASSUNG 
Hintergrund: C-reaktives Protein (CRP), das klassische Akute Phase Protein, zeigt, unabhängig 
von anderen bekannten Risikofaktoren wie Body Mass Index (BMI), Alter und 
Cholesterinspiegel, einen Zusammenhang mit kardiovaskulären Ereignissen. Bei Patienten mit 
kardiovaskulärem Risikoprofil werden einer auf CRP basierenden Therapieentscheidung meist 
ein oder zwei CRP-Messungen zugrunde gelegt. Die Variabilität von CRP in bestimmten 
Untergruppen der Bevölkerung wurde jedoch bisher noch nicht im Detail betrachtet.  
Ein Ziel dieser Arbeit war es, zeitunabhängige Einflussgrößen im Zusammenhang mit der 
mittleren CRP Konzentration und ihrer Variabilität in einem gemeinsamen Ansatz zu 
untersuchen. Zusätzlich wurden Parameter, die das CRP beeinflussen könnten, wie beispielsweise 
Passivrauchen, Alkoholkonsum oder extremer Stress in den 24 Stunden vor der Blutabnahme 
betrachtet. Weiterhin wurde der kurzfristige Einfluss von Außenluftschadstoffen auf die Höhe des 
CRPs untersucht.  
Methoden: Diese Arbeit beruht auf Daten der AIRGENE Studie, die in sechs europäischen 
Städten durchgeführt wurde. Bei 1003 Herzinfarktpatienten wurde im Abstand von vier bis sechs 
Wochen bis zu achtmal hochsensitives (hs) CRP gemessen. Bei der ersten Untersuchung wurden 
Blutdruck und BMI gemessen, Blutproben entnommen und mittels eines Fragebogens Daten zu 
Gesundheitszustand, Medikation und Rauchstatus erfasst. Bei allen Untersuchungen wurde 
jeweils eine Blutprobe zur Messung von hs-CRP entnommen und Daten zu Einflussfaktoren auf 
das hs-CRP in den 24 Stunden vor der Blutabnahme gesammelt. In jeder Stadt wurden die 
Anzahl von ultrafeinen Partikeln, Schwebstaub mit einem Durchmesser von <10 µm (PM10), 
Feinstaub mit einem Durchmesser von <2.5 µm (PM2.5), gasförmige Schadstoffe sowie 
meteorologische Daten auf stündlicher Basis erfasst.  
Ergebnisse: BMI zeigte sich als einer der stärksten Einflussfaktoren, mit höheren Mittelwerten 
für hs-CRP bei übergewichtigen und adipösen Patienten. Hinsichtlich des Alters fand sich ein U-
förmiger Zusammenhang mit den niedrigsten hs-CRP Werten in der Gruppe der 50 bis 59 
jährigen.  
Die intra-individuelle Variabilität von hs-CRP war nur geringfügig niedriger als die inter-
individuelle. Patienten mit Angina Pectoris, Emphysem oder Herzschwäche zeigten eine 
niedrigere Variabilität des CRP (-11,0; -24,9 bzw. -41,6% Variation) während der Mittelwert bei 
allen drei Diagnosen nicht beeinflusst schien. Für Patienten, deren Wert für glykosyliertes 
Hämoglobin (HbA1c) zu Beginn der Studie bei 6,5% oder höher lag, zeigten die Daten eine 
erhöhte hs-CRP Konzentration (geometrisches Mittel: 26,2; Konfidenzinterval: 7,2;48,6) sowie 
eine höhere Variabilität (20,7% Variation, p-Wert 0,0034). Ähnliche, wenn auch nicht so 
ausgeprägte Ergebnisse fanden sich für Patienten mit Typ 2 Diabetes.  
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Die Variabilität war zudem höher bei Männern und Rauchern (24.8 bzw. 27.3%) verglichen mit 
Frauen bzw. Nichtrauchern, mit geringerer mittlerer Konzentration bei Männern, aber einer 
höheren mittleren Konzentration bei Rauchern. Patienten, die Statine oder andere Blutfett 
senkende Medikamente einnahmen, zeigten signifikant niedrigere mittlere CRP Werte und zudem 
eine geringere Variabilität. Dagegen fand sich eine höhere Variabilität bei Patienten, die Hemmer 
des Angiontensin-konvertierenden Enzyms (ACE-Hemmer) einnahmen, während die mittlere 
CRP-Konzentration nicht beeinflusst schien. Von den untersuchten Variablen zum Verhalten in 
den 24 Stunden vor der Blutabnahme zeigte keine einen größeren kurzfristigen Effekt auf hs-
CRP. Zudem wurde kein Zusammenhang zwischen Außenluftschadstoffen und der CRP-
Konzentration gefunden.  
Folgerungen: Diese Arbeit bestätigt und erweitert bereits publizierte Zusammenhänge zwischen 
Patientencharakteristiken sowie Medikation und der Höhe des CRP in Herzinfarktüberlebenden 
beiderlei Geschlechts. Die hohe Variabilität, speziell bei Männern, Rauchern und Personen mit 
erhöhten HbA1c Werten, deuten darauf hin, dass eine einzige CRP Messung als Basis für 
präventive Maßnahmen unter Umständen nicht ausreicht. Zudem ist vorstellbar, dass Individuen 
mit einer generell höheren CRP Konzentration und/oder einer höheren Variabilität, z.B. Patienten 
mit Typ 2 Diabetes, stärker auf Umweltfaktoren, wie beispielsweise Luftschadstoffe, reagieren. 
Der fehlende Zusammenhang zwischen Luftschadstoffen und CRP in diesen Daten lässt sich 
vermutlich auf die weit verbreitete Einnahme von Statinen in der untersuchten Personengruppe 
von Herzinfarktüberlebenden zurückführen. 
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SUMMARY 
Background: C-reactive protein (CRP), a sensitive marker of the acute phase response, has been 
associated with future cardiovascular endpoints independent of other risk factors such as body 
mass index (BMI), age and cholesterol levels. Risk assessment in populations at risk of 
cardiovascular disease is usually based on one or two measurements. Variation of CRP among 
certain subgroups of the population, however, has not been examined in detail. The purpose of 
this thesis is to study associations between time-invariant patient characteristics and mean high 
sensitivity (hs)-CRP concentrations and parameters that influence the variation of hs-CRP in a 
joint analysis. Additionally, associations between parameters that might impact hs-CRP in the 24 
hours before the blood draw, such as environmental tobacco smoke exposure, alcohol 
consumption or extreme stress or anger, were examined. Moreover, the short-term impact of 
ambient air pollution on hs-CRP was studied. 
Methods: This thesis is based on AIRGENE, a multi centre study conducted in six European 
cities. Hs-CRP was measured repeatedly up to eight times every four to six weeks in 1,003 
myocardial infarction (MI) survivors. At the first visit data on health status, medication intake 
and smoking history were collected by questionnaire. Blood pressure and BMI were measured 
and a blood serum sample was drawn. An additional blood sample was drawn at each visit for the 
determination of hs-CRP and data on life-style in the 24 hours before the visit were collected. In 
each city, hourly data on particle number concentrations, mass concentrations of particulate 
matter (PM) <10µm (PM10) and <2.5µm (PM2.5), gaseous pollutants and meteorological data 
were collected at central monitoring sites. 
Results: BMI was one of the strongest determinants with higher geometric mean hs-CRP 
concentrations in overweight and obese patients. Regarding age, a U-shaped relationship with the 
lowest hs-CRP level in the group of 50 to 59 year olds was found. Variation of hs-CRP within 
patients was only slightly lower than between patients. Patients who reported the presence of 
angina pectoris, emphysema and congestive heart failure showed a lower variation (-11.0, -24.9 
and -41.6% variation, respectively) while the geometric mean concentration seemed not to be 
affected. For patients with baseline glycosylised haemoglobin (HbA1c) levels of 6.5% and above, 
on the other hand, our data revealed higher hs-CRP (geometric mean: 26.2, confidence interval: 
7.2; 48.6) and a higher variation (20.7% variation, p-value 0.0034). Results were similar, 
although not as pronounced, for the diagnosis of type 2 diabetes. Variation was also higher in 
males compared to females and smokers compared to non-smokers (24.8 and 27.3%, 
respectively) with a lower geometric mean concentration in males and a higher one in smokers. 
Patients reporting the intake of statins or other lipid-lowering drugs showed significantly lower 
hs-CRP and also less variation. Patients using angiotensine converting enzyme (ACE)-inhibitors 
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on the other hand, a higher variation was found while geometric mean concentrations seemed not 
to be associated with medication intake.  
Life-style parameters in the 24 hours preceding blood draw did not have a major impact on hs-
CRP. No association was seen between ambient air pollutants and hs-CRP concentrations.  
Conclusion: This work confirms and extends published results on the association between patient 
characteristics and intake of medication and hs-CRP concentrations in a panel of male and female 
MI survivors. The higher variation found in males, smokers and subjects with elevated HbA1c 
concentrations indicates that basing preventive medical measures on a single measurement of hs-
CRP might not be sufficient. It is conceivable that individuals with a generally higher level of 
inflammatory markers, and/or a higher variation, for example patients with diabetes, might react 
more strongly to environmental factors such as air pollution. The lack of association between air 
pollution and hs-CRP in these data is possibly due to a widespread intake of statins in this 
population of MI survivors.  
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1 INTRODUCTION 
Cardiovascular disease is the main cause of death in developed countries. In 2005, an estimated 
17.5 million people died from cardiovascular disease, representing 30% of all global deaths 
(WHO, 2009). In recent years, atherosclerosis, the precursor of cardiovascular disease, has been 
recognised as inflammatory disease, as inflammation plays a crucial role in plaque formation, 
progression and rupture. Interest has emerged in the potential of inflammatory biomarkers, 
especially C-reactive protein (CRP), for the prediction of cardiovascular risk in individuals 
(Koenig, 2005). 
1.1 Inflammation 
Inflammation is a protective reaction by the body with the aim of limiting tissue damage, 
eliminating foreign substances and starting repair mechanisms so that the body can return to its 
normal functions. An inflammatory process starts when tissue is destroyed by infections or 
injuries. Whenever the first barrier of defence, such as skin, mucosa or cilia on the lung is broken, 
foreign substances enter the body and the inflammatory process is activated. Inflammatory 
mediators, such as cytokines and chemokines, lead to an enhancement of the inflammatory 
response. Their main task is the recruitment of inflammatory cells such as polymorphe 
granulocytes, monocytes and thrombocytes at the site of foreign substances or cell damage 
(Thomas, 1998). 
The first step in inflammation is called acute phase response. In a narrower sense, it is regarded 
as the change in the concentration of a large number of plasma proteins which reflect the gene-
expression of secretory proteins during an inflammatory response. The acute phase response 
happens in the first few hours of an inflammatory response and can be triggered by 
microbiological agents, cytotoxic antibodies or mechanical trauma. Involved proteins can be 
divided into negative acute phase proteins, like albumin, transferrin and alpha-fetoprotein, which 
decrease during an acute phase response, and positive acute phase proteins, which increase. 
Coeruloplasmin, for example, increases up to 50%, fibrinogen two to five-fold and serum 
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amyloid A (SAA) and CRP up to 1000-fold during an acute inflammation. CRP was one of the 
first acute phase proteins to be described and represents one of the most extensively studied 
proinflammatory molecules (Thomas, 1998). 
1.2 CRP, the classical acute phase protein 
CRP was first described by Tillet and Francis in 1930 (Tillet et al., 1930) as a substance in the 
serum of patients with acute inflammation that reacted with the C polysaccharide of 
streptococcus pneumoniae. It is a member of the pentraxin family of proteins, due to its disc-like 
pentrametric structure of five identical sub-units. The pentraxins are calcium and phospholipid 
binding proteins with immuno-defence properties.  
CRP is almost exclusively synthesised in the liver upon stimulation through interleukin-6 (IL-6), 
the key cytokine that stimulates the synthesis of all major acute phase proteins (Woods et al., 
2000). However, recent evidence has suggested that it may also be produced locally in vascular 
smooth muscle cells and macrophages of atherosclerotic lesions (Calabro et al., 2003; Yasojima 
et al., 2001). The normal synthesis rate of 1 to 10 mg per day can increase up to more than 1g per 
day during acute inflammation. It is assumed that CRP is vital, as so far no genetic CRP defect 
has been described (Vigushin et al., 1993). CRP has a half life of 19 hours (Koenig et al., 2003) 
which is identical under all conditions so that the synthesis rate of CRP is the sole determinant of 
its plasma concentration (Vigushin et al., 1993). 
The role of CRP is to clear a large number of exogene and endogene substances from the blood. 
Endogene substances comprise products of used or necrotic cells, e.g. cell membranes which, in 
the presence of calcium, are bound to CRP. This binding only takes place if the normal lipid layer 
structure of a cell is destroyed, and the internal phospholipids of the membrane are presented. 
Exogene substances include cell walls of bacteria, fungi and parasites. After binding, various 
biological systems are activated which leads to an elimination of the CRP-ligand-complex 
through macrophages in tissue, blood and spleen.  
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1.3 CRP as predictor for cardiovascular disease 
Increasing evidence from basic research suggests that atherosclerosis is an inflammatory disease 
(Koenig, 2005) and established risk factors, like smoking, hypercholesterolemia and hypertension 
only explain about half of the incidence of myocardial infarction (MI), angina pectoris and stroke 
(Braunwald, 1997; Koenig et al., 1998). Therefore, interest has emerged in the potential of 
inflammatory biomarkers for the prediction of cardiovascular risk (Koenig, 1999; Koenig, 2005). 
CRP, as measured by high sensitivity (hs) assays, has appeared as a reliable and independent 
predictor of incident cardiovascular events (Koenig et al., 2006; Ridker et al., 1998c; Ridker et 
al., 1998b; Ridker et al., 1998a), although there are also critical voices (Pepys, 2005). A recent 
recommendation by the Centres for Disease Control and Prevention and the American Heart 
Association states that of all inflammatory markers currently used, CRP should be the analyte of 
choice due to its stability, assay precision, accuracy and availability. It suggests measuring CRP 
in those at intermediate risk according to the Framingham Risk Score (Jones et al., 1990). The 
assay should be performed twice, fasting or non-fasting, about two weeks apart. In case of CRP 
>10mg/L, indicating an acute inflammatory process, the respective measurement should be 
discarded and repeated two weeks later (Pearson et al., 2003). 
In the past years, various epidemiological studies showed consistent and independent associations 
between the CRP concentration and diverse future cardiovascular endpoints in diseased and 
initially healthy populations, independent of established risk factors.  
In a large group of patients with stable angina pectoris an approximately two-fold increase in the 
risk of coronary events was observed in patients in the highest quintile of the CRP distribution 
compared to those in the lower ones (Haverkate et al., 1997). Additionally, Liuzzo et al. (1994) 
found that patients with unstable angina pectoris and CRP concentrations above 3.0 mg/L 
experienced more ischaemic periods, required revascularisation more frequently and developed 
an acute MI more often than those with lower concentrations. Berk et al. (1990) reported from a 
prospective study of about 70 participants that 90% of unstable angina pectoris patients exhibit an 
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elevation of CRP concentrations compared to 13% of patients with stable angina. A meta analysis 
of 22 population-based studies, including a total of over 7000 patients with incident coronary 
events, found a modest but statistically significant association (Danesh et al., 2004). 
Regarding apparently healthy populations Koenig et al. (1999) reported an almost three-fold 
increase in risk for a first major coronary event in 936 initially healthy men from a random 
sample of the general population. Moreover, data from the Physicians’ Health Study (Ridker et 
al., 1998b) showed a positive association between CRP and the development of symptomatic 
peripheral arterial occlusive disease and CRP was also found to be predictive of strokes in men 
(Ridker et al., 1997) and of coronary and cerebrovascular events in women (Ridker et al., 2000). 
In additional results from the Physicians’ Health Study (Ridker et al., 1998c) the relative risks of 
future MI among men with high concentrations of both CRP and total cholesterol were more than 
three times greater than the individual risk associated with isolated elevation of CRP and more 
than twice as great as the risk associated with total cholesterol alone. This finding supports the 
value of adding an inflammatory marker, especially CRP, to the conventional risk factor profile. 
1.4 Patient characteristics that affect hs-CRP concentrations 
With CRP gaining importance as a marker for future cardiovascular events, interest has 
developed in patient characteristics as well as life-style factors associated with reduced or 
elevated systemic inflammatory activity.  
Some studies have shown that age and sex determine the concentration of CRP with a positive 
linear relationship between CRP and age (Garcia-Lorda et al., 2006; Hutchinson et al., 2000; 
Sung, 2006), but a lack of association has also been reported (Greenfield et al., 2004). Regarding 
sex, men tend to have lower CRP concentrations, (Frohlich et al., 2003; Geffken et al., 2001; 
Hutchinson et al., 2000; Imhof et al., 2004) however some authors report no difference of the 
CRP concentration by gender (Garcia-Lorda et al., 2006). Furthermore, various measures of body 
composition, such as body mass index (BMI) or waist to hip ratio have been positively associated 
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with increasing CRP concentrations (Garcia-Lorda et al., 2006; Greenfield et al., 2004; Mora et 
al., 2006; Sung, 2006; Thorand et al., 2006; Verdaet et al., 2004). 
A significant amount of research has been conducted regarding the impact of life-style or life-
style changes on the concentration of CRP, among them smoking, physical activity and nutrition. 
Regarding cigarette smoking, most studies show lower CRP concentrations in non-smokers and 
intermediate concentrations in ex-smokers compared to current smokers (Frohlich et al., 2003; 
Garcia-Lorda et al., 2006; Geffken et al., 2001; Greenfield et al., 2004; Ikonomidis et al., 1999; 
Ikonomidis et al., 2005; Verdaet et al., 2004; Wannamethee et al., 2005) and a positive 
association with smoking duration (Frohlich et al., 2003) and pack-years of smoking (Frohlich et 
al., 2003; Wannamethee et al., 2005). Reduction of excess body weight  and regular endurance 
exercise also positively alter the acute phase response (Ditschuneit et al., 1995; Esposito et al., 
2003; Fontana et al., 2007; Mora et al., 2007; Selvin et al., 2007). However, some authors state 
that leisure time physical activity is not an independent predictor of CRP but associated with 
lower body weight in those who exercise (Davis et al., 2007; Fontana et al., 2007; Geffken et al., 
2001; Simpson et al., 2005; Verdaet et al., 2004).  
The impact of nutrition on CRP has been studied in different ways. Whole diet styles, such as a 
Mediterranean or anti-oxidant diet have been examined in addition to single nutrient factors such 
as alcohol, black and green tea or certain vitamins. While some authors state that CRP 
concentrations are only marginally associated with individual dietary factors (Fredrikson et al., 
2004) others report that a so called Mediterranean diet which is high in antioxidants like fruit, 
vegetables, fibre and red wine is inversely correlated with plasma CRP (Albert et al., 2003; 
Brighenti et al., 2005; Chrysohoou et al., 2004; Imhof et al., 2001; Imhof et al., 2004; Lopez-
Garcia et al., 2004; Pitsavos et al., 2007). These results regarding a Mediterranean diet could be 
confirmed in analyses of the AIRGENE population (Panagiotakos et al., 2009). Of single 
nutrients, alcohol intake has been examined extensively, and most authors report a U-shaped 
function between alcohol intake and CRP (Albert et al., 2003; Greenfield et al., 2004; Imhof et 
al., 2001; Imhof et al., 2004). 
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Most of the studies cited above are based on only one or two measurements per patient and only 
few studies have examined the degree of variation in repeated CRP measurements in the same 
subjects within a period of weeks or months with conflicting results (Bogaty et al., 2005; Clark et 
al., 1993; Macy et al., 1997; Ockene et al., 2001).  
1.5 Short term impact on CRP 
The body of literature regarding parameters that impact CRP hours before the blood withdrawal 
is very limited. Only sports medicine has examined the effect of extremely strenuous activities on 
inflammatory markers, among them CRP, with clear increases in CRP concentrations shortly 
after exertion (Davis et al., 2007; Kim et al., 2007; Margeli et al., 2005; Simpson et al., 2005). 
However, other parameters, such as nutrition or extreme anger, seem not yet to have been 
considered. 
1.6 Possible biological mechanisms 
The rupture of an atherosclerotic plaque as the final pathophysiological mechanism leading to 
acute ischaemic syndromes is now universally accepted. The classical “response-to-injury” 
hypothesis postulates that endothelial dysfunction represents the initial step in atherogenesis 
(Koenig, 1999). Endothelial dysfunction can be induced by haemodynamic forces (shear stress), 
by a variety of vasoactive substances, by mediators from blood cells and directly by cigarette 
smoke, atherogenic diet, elevated glucose levels and oxidised or enzymatically modified low-
density lipoprotein (LDL) cholesterol (Rubanyi, 1993). At the site of an endothelial injury, 
invading inflammatory cells which produce numerous proinflammatory factors promote and 
amplify both local and systemic inflammation (Trepels et al., 2006). Moreover, dysfunctional 
endothelial cells produce adhesion molecules that, in turn, interact with inflammatory cells 
(Koenig et al., 2007). Pathological studies show the abundant presence of inflammatory cells at 
the site of rupture or superficial erosion preferably in the shoulder of an atheromatous plaque cap. 
As in other types of tissue injury, acute MI also generates an acute phase response resulting in 
subsequent systemic increases in a number of inflammatory reactants (De Servi et al., 2005; 
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Rosenson, 1993). The deposition of CRP in the infarcted region, co-localising with activated 
fragments of the complement system, the unspecific immune defence system of the body, 
indicates that complement activation may enhance local inflammation during acute MI (Lagrand 
et al., 1997). This can lead to subsequent extension of tissue damage in the myocardium.  
Initially, CRP was merely regarded as an innocent bystander in the atherosclerotic process, and 
there is still no full agreement amongst the scientific community (Pepys, 2005), but current 
evidence argues for the contribution of CRP to the pathogenesis of atherothrombosis (Koenig, 
1999; Koenig et al., 2007). It has, for example, been shown that CRP binds to the plasma 
membranes of damaged cells and that aggregated CRP selectively binds LDL and very-low-
density lipoprotein from whole plasma, thereby possibly participating in their atherogenic 
accumulation. Furthermore, complexed CRP activates the complement system via the classical 
pathway and can be pro-inflammatory (Koenig, 1999). Other proteins augmented during the acute 
phase response include pro-coagulatory proteins such as fibrinogen and plasminogen activator 
inhibitor-1. Thus, inflammation can promote thrombus formation and enhance clot stability by 
inhibiting endogeneous fibrinolysis (Libby et al., 2001). CRP has also been found to stimulate 
tissue factor production by macrophages in vitro. Tissue factor is the main initiator of coagulation 
in vivo, and its local concentration in the arterial wall is clearly related to coronary thrombotic 
events. Therefore, the capacity of CRP to enhance tissue factor production suggests another 
possible causal link between raised CRP values and coronary events (Koenig, 1999). Moreover, 
recent experimental studies suggest that CRP might decrease endothelial nitric oxide (NO) 
synthase expression and increase the production of reactive oxygen species, thereby directly 
interfering with bioavailability of endothelial nitric oxide (Fichtlscherer et al., 2004). 
Fichtlscherer et al. (2004) showed in 75 patients with stable coronary artery disease, that low 
grade inflammation as measured by CRP levels is associated with impaired systemic 
bioavailability of nitric oxide. Endothelium derived nitric oxide is an endogenous vasodilator that 
also has anti-inflammatory properties (Libby et al., 2002). Nitric oxide also inhibits platelet 
aggregation (Loscalzo et al., 1995), and platelet activation and recruitment are tightly regulated 
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by endothelium derived nitric oxide. Therefore, an impaired systemic bioavailability of nitric 
oxide might contribute to the transition from stable coronary artery disease to acute coronary 
syndromes.  
1.7 Response to environmental parameters 
Heavy physical exertion (Albert et al., 2000; Mittleman et al., 1993), extreme anger (Mittleman et 
al., 1995) and cocaine or marijuana use (Mittleman et al., 1999; Mittleman et al., 2001) have been 
reported as triggers for an MI. In addition, it has been shown that environmental factors such as 
noise (Babisch, 2006; Ising et al., 2004; Willich et al., 2006), meteorological variables (Medina-
Ramon et al., 2006; Medina-Ramon et al., 2007; Morabito et al., 2005; Sarna et al., 1977) and air 
pollution (Brook, 2007; Lanki et al., 2006; Mills et al., 2009; O'Toole et al., 2008; Peters et al., 
2001a) are associated with an elevated risk for adverse cardiovascular events. It is conceivable 
that individuals with special characteristics react more strongly to environmental parameters than 
others. A generally higher level of inflammatory markers, and/or a higher variation in 
inflammation might represent one explanation, as persistently elevated concentrations and also 
acute changes in levels of inflammatory markers have been associated with an increased risk of 
cardiovascular events in cohort studies (Koenig et al., 1999; Ridker et al., 1997). In addition, this 
might be one possible link for the reported associations between air pollution and adverse 
cardiovascular outcomes, since particle induced systemic inflammation is one hypothesised 
pathway between air pollution and cardiovascular disease (Peters et al., 1997; Pope et al., 2004; 
Seaton et al., 1999). Furthermore, studies on individuals with diabetes and MI show an enhanced 
susceptibility for air pollution related conditions. This might be the result of increased 
inflammatory processes in these people relating to their underlying disease (Bateson et al., 2004; 
Brook et al., 2008; Goldberg et al., 2001; O'Neill et al., 2007; Zanobetti et al., 2001). Moreover, a 
decrease in temperature has been shown to be associated with elevated inflammatory markers, 
among them CRP in the AIRGENE population (Schneider et al., 2008).  
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Clinical trials indicate that statins and aspirin may be able to modify an inflammatory response. 
In particular, some statins have recently been associated with decreased CRP concentrations  
(Albert et al., 2001a; Dubowsky et al., 2006; Ridker et al., 2001; Ridker et al., 2008; Rosenson et 
al., 2003). CRP lowering effects were also found with acetyl salicylic acid (ASA) (Ikonomidis et 
al., 1999) and angiontensine converting enzyme (ACE) inhibitors (Soriano et al., 2007) while 
hormone replacement therapy (HRT) seems to increase CRP concentrations (Cushman et al., 
1999; Ridker et al., 2000).  
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2 HYPOTHESES 
Despite the vast body of publications, many issues regarding CRP are not completely resolved. 
This thesis uses data from a large European study on MI survivors, whose plasma hs-CRP 
concentrations were measured up to eight times 
1. a) to confirm known associations between time-invariant patient characteristics and hs-
CRP concentrations,  
b) to extend the number of the characteristics published so far and  
c) to study the influence of the same parameters on the variation of hs-CRP hypothesising 
that the diagnosis of certain diseases would be related to higher hs-CRP concentrations 
and a more pronounced variation. 
2. to examine the associations between hs-CRP and time-varying life-style parameters in the 
24 hours before the blood draw, hypothesising that the consumption of tea and alcohol 
would lead to lower hs-CRP concentrations, while extreme stress or anger, active 
smoking and physical activity would show a positive association and 
3. to examine the association of hs-CRP concentrations and environmental parameters, 
especially particulate air pollutants, assuming a positive linear relationship. 
 
MI survivors might react differently compared to the normal healthy population due to their 
preceding disease. However, MI survivors were chosen as study subjects as they have been 
shown to be especially susceptible (Hellermann et al., 2003; McGovern et al., 2001; Rosamond et 
al., 1998) and therefore may require particular protection and public health actions. 
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3 METHODS 
3.1 Study population 
A prospective longitudinal study of post MI patients was performed in six European cities: 
Athens (Greece), Augsburg (Germany), Barcelona (Spain), Helsinki (Finland), Rome (Italy) and 
Stockholm (Sweden). Candidates for the study were identified from population registries of 
patients with MI or from administrative data-bases of hospital admissions. The study design is 
described in detail elsewhere (Peters et al., 2007) (Appendix I). In brief, patients aged 35 to 80, 
preferably current non-smokers, who had experienced an MI between four months and six years 
before the start of the study were recruited. Patients with MI or interventional procedures less 
than three months before the beginning of the study, or chronic inflammatory diseases were not 
included. All partners had the study protocol approved by their local human subjects committees 
and written informed consent was obtained from all patients. All methods used in the study 
centres were conducted according to common standard operating procedures. 
3.2 Clinical measurements 
Patients were invited to participate in six to eight clinical visits between May 2003 and July 2004. 
The visits were scheduled every four to six weeks on the same weekday and at the same time of 
the day to minimize the impact of weekly and circadian variation. At the first visit a baseline 
questionnaire regarding health status, medication intake and smoking history was completed. 
Blood pressure and BMI were measured and a blood serum sample was drawn. At each clinical 
visit a short questionnaire on medication intake and life-style parameters in the past 24 hours, 
such as smoking, exposure to environmental tobacco smoke (ETS), physical activity, extreme 
stress or anger and consumption of tea and alcohol was completed. 
Venous EDTA-plasma samples were drawn for the determination of hs-CRP while sitting. 
Samples were cooled and stored at 4°C until further processing. Plasma aliquots were shipped on 
dry ice to the central laboratory in Ulm, Germany, and analysed by means of latex enhanced 
immunonephelometry (Dade Behring Marburg GmbH, Marburg, Germany). If the hs-CRP 
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concentration was lower than the detection limit of 0.16 mg/L values were set to 0.16 mg/L. 
Details are given in (Ruckerl et al., 2007) (Appendix II). Blood samples of patients who suffered 
from acute infections during the three days before the scheduled visit were excluded from 
analyses. 
3.3 Air pollution and meteorological data 
Air pollution data were collected from fixed monitoring sites representing urban background 
concentrations. Hourly means of mass concentration of particles less than 10µm and less than 
2.5µm in diameter (PM10 and PM2.5, respectively), gaseous air pollutants (carbon monoxide (CO), 
sulphur dioxide (SO2), ozone (O3), nitrogen monoxide (NO), nitrogen dioxide (NO2)) and 
meteorological variables (air temperature, relative humidity, barometric pressure) were obtained 
through the city-specific air monitoring networks and the meteorological services. Particle 
number concentration (PNC) measurements as indicator for ultrafine particles (UFP) were 
performed in all centres. Individual moving 24-hour averages of ambient concentrations of air 
pollutants and meteorogical variables were used to characterize the exposures for each person 
immediately preceding the clinical visit (lag 0) up to four days (lag1-lag4). In addition, the mean 
of lags 0 to 4 was calculated to account for cumulative effects. Details can be found in (Ruckerl 
et al., 2007) (Appendix II). 
3.4 Study design 
The chosen study design of time series analyses uses repeated measurements per subject collected 
over a period of several months. Some of the measured exposure variables vary over the course 
of the study and can then be associated with concurrent hs-CRP concentrations. Figure 1 pictures 
the principle of the repeated measurement design in association with air pollution as an example. 
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Figure 1. Principle of the repeated measurement design: Some of the examinations are conducted on days with 
low air pollution, others on days with high air pollution. The example shows eight repeated measurements in two 
patients and air pollution data from Barcelona, summer 2003 to summer 2004; 
        PNC, particle number concentration;            PM2.5, mass concentration of particles less than 2.5µm in diameter 
 
3.5 Statistical analyses 
All statistical analyses were performed using the Statistical Analysis System (SAS) software 
package (Version 9.1 for Windows, SAS-Institute Inc., Cary, NC, USA). 
Hs-CRP needed to be log-transformed to fulfil the model assumption of residual normality; 
therefore, concentration results are given as the geometric means. Data was analysed using mixed 
effects models with random patient effects accounting for repeated measures. Penalised splines 
(P-splines) in the additive mixed model framework were used to allow for non-parametric 
exposure-response functions (Greven et al. 2006). As the half life of hs-CRP is much shorter than 
the intervals between visits, a compound symmetry structure for the covariance matrix was 
assumed to model the correlation between repeated measures in each patient. All decisions on 
goodness-of-fit were based on Akaike’s Information Criterion (AIC). To account for the large 
number of statistical tests, the significance-level of the p-value was corrected to 0.00125 which 
equals a Bonferroni correction for 40 tests. 
3.5.1 Analysis of hs-CRP concentration and variation  
A confounder model (base model) was built first (Table 1a), which included pre-selected time-
invariant patient characteristics to permit the assumption of a normally distributed random patient 
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intercept. A wide range of variables known from literature to have a possible influence on hs-
CRP such as city, age, gender and BMI were tested on the repeated measurements of the log 
transformed hs-CRP values. Linear variables were added linearly to the model.  
The idea of relating a single baseline measurement of a time-invariant variable to repeated 
measurements rather than an average of these measurements or just the result of the first hs-CRP 
measurement collected at the same point in time might initially seem unnecessarily complicated. 
However, this approach has several advantages.  
First of all, it increases the power if several CRP measurements per person are used rather than 
one. Additionally, the variability and the differing numbers of hs-CRP measurements per patient 
are accounted for. Possible alternatives would be to use only the first hs-CRP measurement or a 
median or mean value of all the hs-CRP measurements of one patient. However, all these 
approaches lead to an unnecessary loss of information. Moreover, the mean is considered to be 
very sensitive to outliers and the number of measurements varies between two and eight, and 
therefore a weighted mean or median would be needed. Also, as soon as time-variant variables 
such as season or trend are added to the model, repeated hs-CRP measurements per person are 
needed as only they reflect the changes over time in the outcome variable.  Finally, the variability 
in various patient groups can only be analysed with repeated measurements. For a consistent 
interpretation, a common approach for all these analyses is necessary.  
Table 1a: Variables of the base model including pre-selected time-invariant patient characteristics 
Categorical  Linear  Cubic  
City, HbA1ca, sex, number of MIb BMIc, log(NT-proBNPd), packyears of smoking, total 
cholesterol 
age 
aHbA1c: glycosylised haemoglobin, bMI: myocardial infarction, cBMI: Body Mass Index, dNT-proBNP: N-terminal proB-type natriuretic peptide 
 
In a second step, further time-invariant variables such as reported diseases, regular medication 
intake and smoking history were added to the base model, always one at a time. To avoid 
overcontrol, pack-years of smoking were removed from the base model when analysing smoking 
status and HbA1c was removed for the analysis of diabetes.  
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The associations of time-invariant patient characteristics are given as percent change from 
geometric mean (GM) of hs-CRP together with 95% confidence intervals (CI). 
Crude coefficients of variation (CV) for hs-CRP were estimated using the UNIVARIATE 
procedure. Differences in variation for the fully adjusted model were calculated with the MIXED 
procedure in SAS using the “repeated/group= “ statement which calculates the within-patient 
variation and a “random/group= “ statement which allows for different intercepts in the defined 
groups, representing the between-patient variation. A likelihood-ratio test was used to determine 
if the differences between the groups were significant. Linear variables were categorised, and 
single variables were then added to the base model. Results are given as variation estimates of log 
transformed hs-CRP between (panel A) and within (panel B) subjects in the figures and relative 
difference (%) in within subject variation compared to the reference group in the tables.  
Sensitivity analyses for co-morbidities that might be associated with an intake of certain 
medication were conducted. A chi²-test was used to evaluate possible associations between co-
morbidities and medication intake. If an association was found (p-value ≤ 0.05) the multivariable 
model was adjusted for the respective medication to investigate whether the co-morbidity effect 
was altered by including medication in the model. To explore the various aspects of different 
smoking variables and ETS exposure in more detail, additional analyses were conducted in- and 
excluding several smoking variables from the model (Ruckerl et al., 2009)(Appendix II).  
As data on baseline LDL cholesterol were only available for men, additional analyses for 770 
men who had complete data on triglycerides, high density lipoprotein (HDL)-, LDL- and total 
cholesterol were performed using the methods described above. Sex was deleted from the base 
model for these analyses as data were limited to men. Different models were calculated as shown 
in table 1b. For some models (models 1 b to d) total cholesterol was also removed. For the first 
model (model 1), cholesterol parameters were added singularly to the adapted base model. 
Additional models including total cholesterol and HDL (model 2), total cholesterol and LDL 
(model 3), total cholesterol, HDL and LDL (model 4) and total cholesterol and triglycerides 
(model 5) were calculated. Additionally, a model that included most of the presented variables at 
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the same time was calculated to identify those variables that led to the greatest increase in 
variation.  
Table 1b: Variables included in the subgroup analyses for 770 men – adjusted for the variables of the base 
model except for sex (x: included in the model --: not included in the model) 
 
3.5.2 Analysis of life-style parameters and hs-CRP 
Life-style parameters were added to the base model, always one at a time. Variables that 
described a time difference, such as time of the last meal before the blood withdrawal, were 
categorised into six hour categories (0 to 5 hours, 6 to 11 hours, 12 to 17 hours and 18 to 23 
hours). Results are given as percent change from GM of hs-CRP together with 95% CI. 
3.5.3 Analysis of air pollution parameters and hs-CRP 
For the analysis of air pollution data, firstly city specific effects were calculated using a more 
parsimonious model selected out of the base model for each city. Additional meteorological 
variables were forced into all models to assure sufficient adjustment for season and 
meteorological impact (Table 1c). In a second step, single air pollutants were added to the model 
and effects estimated linearly. Finally, city-specific effect estimates were combined using meta-
analysis methodology (Van Houwelingen et al. 2002). Additionally, it was examined whether an 
HbA1c level of more than 6.5% modified the effects of air pollution on blood markers. Results of 
the air pollution analysis are based on an increase in air pollution concentrations from the first to 
the third quartile (interquartile range, IQR) and are presented as percent change from GM of hs-
CRP together with 95% CI. For details see (Ruckerl et al., 2007) (Appendix III).  
Model Total cholesterol HDLa cholesterol LDLb cholesterol Triglycerides 
1 a x -- -- -- 
1 b -- x -- -- 
1 c -- -- x -- 
1 d -- -- -- x 
2 x x -- -- 
3 x -- x -- 
4 x x x -- 
5 x -- -- x 
 
aHDL: high density lipoprotein, bLDL: low density lipoprotein 
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Table 1c: Variables of the confounder models for the estimation of air pollution effects, by city 
City Time invariant variables Time variant variables/meteorology 
Athens BMI, log(NT-proBNP), systolic blood 
pressure 
trend, apparent temperature (mean of lags 0 to 1), 
hour of visit 
Augsburg BMI, log(NT-proBNP), total cholesterol, 
chronic bronchitis, packyears of smoking 
trend, apparent temperature (lag 0), relative 
humidity (mean of lags 0 to 1), hour of visit 
Barcelona BMI, log(NT-proBNP), chronic bronchitis, 
cholesterol, packyears of smoking 
trend, apparent temperature (mean of lags 0 to 1) 
Helsinki age, BMI, hypertension, packyears of 
smoking, sex, systolic blood pressure, HbA1c  
trend, apparent temperature (mean of lags 0 to 1) 
Rome BMI, log(NT-proBNP), total cholesterol trend, apparent temperature (mean of lags 0 to 3) 
Stockholm age, BMI, log(NT-proBNP), total cholesterol, 
packyears of smoking, sex, HbA1c  
trend, apparent temperature (mean of lags 0 to 1) 
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4 RESULTS 
In total, 1,003 MI survivors who had at least two valid blood samples were taken for the analyses. 
Of 6,068 samples collected, 255 had to be excluded due to acute infections or surgical procedures 
within three days before the clinic visit. In 75 of the samples from Helsinki, Stockholm, 
Augsburg and Rome the hs-CRP concentration was lower than the detection limit. Overall, 5,813 
plasma samples remained for analysis. The number of visits per patient are shown in Table 2. 
Thirty-eight had only two usable visits; however, more than half of the participants reached the 
aspired number of six visits.  
Table 2: Number of patients and visits in AIRGENE 
 
 
 
 
 
 
Baseline characteristics of the study population in total and separated by gender are presented in 
Table 3, characteristics by city are shown in Table 4. Regarding the whole study population, 
approximately two thirds of the participants were male. Half of the population reported 
hypertension, one third angina pectoris and about 20% were diabetics. Average BMI was high, 
with a very wide range from 17 kg/m² to almost 49 kg/m². Two thirds of the population were 
occasional or former smokers. As expected in a panel of MI survivors, medication intake was 
high, especially of anti-platelet medication, statins and beta blockers.  
A comparison between male and female participants shows that the women in the study 
population were on average significantly older than the men. Considering medical history both 
groups were equal, with a slightly higher percentage of women reporting hypertension. There 
were fewer ex- or occasional smokers among women. Medication intake varied only slightly, 
Number of visits Number of patients 
N (%) 
Total number of visits 
N (%) 
2 38 (3.8) 76 (1.3) 
3 48 (4.8) 144 (2.5) 
4 40 (4.0) 160 (2.8) 
5 82 (8.2) 410 (7.1) 
6 598 (59.6) 3588 (61.7) 
7 141 (14.1) 987 (17.0) 
8 56 (5.6)  448 (7.7) 
total 1003 (100) 5813 (100) 
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with a higher intake of diuretics in women, which is probably a result of the higher percentage of 
hypertensives in this group.  
Regarding the study populations of the different cities, more women participated in the Northern 
European centres Stockholm and Helsinki compared to the other centres. Participants had a 
similar age range; however, a higher proportion of young men were recruited in Athens. A 
history of angina pectoris was more frequent in Athens and Stockholm. Hypertensive and diabetic 
patients were distributed equally among study centres. The best scores with respect to total 
cholesterol and HDL to total cholesterol ratio were observed in Barcelona and Stockholm, while 
the lipid profiles were most disadvantageous in Athens. Only in Augsburg it was possible to 
recruit exclusively current non-smokers, however the number of smokers were also very low in 
Stockholm and Helsinki. Participants from Athens showed the highest percentage of smokers. A 
history of smoking among current non-smokers was more prevalent in the southern European 
centres, particularly in Athens and Barcelona. In all the cities, the majority of the patients were 
treated with beta-blockers, ACE inhibitors, and lipid-lowering drugs, as well as antithrombotic 
therapy (aspirin) to prevent recurrent myocardial infarctions. Treatment was less vigorous in 
Athens. 
Arithmetic mean, median and geometric mean of hs-CRP were not exceptionally high in the 
study population (Table 3, Figures 2a and 2b).  
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Table 3: Baseline characteristics of 1,003 myocardial infarction survivors in total and by gender 
 
amean, with range in brackets, bever physician diagnosed; cHbA1c: glycosylised haemoglobin; dnone”: 0g/day, “moderate”: <20g/day for 
women and <40 g/day for men, “heavy”: ≥20g/day for women and ≥40g/day for men; evalues of CRP below 0.16 could not be measured 
and were set to 0.16; fvalues were calculated as means (median) of patient means (median) and might therefore differ slightly from table 5a 
1Chi-Square-Test, 2t-Test , 3ANOVA using log-transformed values 
 
 
 
Total 
N=1003 
Male 
N=788 
Female 
N=215 
p-Value 
Age [yrs]a 62.2 (37 – 81) 61.4 (37-79) 65.1 (38-81) <0.00012 
MI in family history [%]    0.00141 
Yes (mother and/or father) 35.2 33.1 42.8 0.00851 
No 54.5 57.5 43.7 0.00031 
Information incomplete 10.3 9.4 13.5 0.07941 
Self-reported medical  
history [%]b     
Angina pectoris 34.3 33.9 35.8 0.60541 
Arrhythmia 22.5 21.6 26.1 0.16411 
Hypertension  51.0 49.4 56.7 0.05511 
Diabetes 19.7 20.2 18.1 0.50571 
Body mass index [kg/m²]a 28.4 (17.5 – 48.9) 28.5 (17.6-48.9) 28.1 (17.5-41.6) 0.22332 
Systolic blood pressure 
[mmHg]a 134.3 (81.0-209.0) 134.7 (84.0-202.0) 133.1 (81.0-209) 0.3665
2
 
Diastolic blood pressure 
[mmHg]a 79.1 (45.0-126.0) 80.0 (52.0-126.0) 75.9 (45.0-119.0) <0.0001
2
 
Total cholesterol [mg/dl]a 184.4 (91.1–390.0) 183.0 (91.1-390.0) 
189.4  
(107.0-324.7) 0.0377
2
 
HDL cholesterol [mg/dl]a 50.2 (22.0–119.3) 47.6 (22.0-105.4) 59.9 (30.0-119.3) <0.00012 
HbA1c c  > 6.5% [%] 10.6 10.9 9.4 0.53191 
Smoking status [%]    <0.00011 
Never smoker 26.6 20.1 50.7 0.01071 
Ex or occasional smoker 65.5 70.9 45.6 <0.00011 
Current smoker 7.9 9.0 3.7 0.01071 
Packyears (cigarettes only)a 18.7 (0-205.2) 21.3 (0-205.2) 8.9 (0-62.5) <0.00012 
Alcohol intake [%]d    <0.00011 
None 16.5 13.2 28.4 <0.00011 
Moderate 70.4 73.0 60.9 0.00061 
Heavy 13.1 13.4 10.7 0.24111 
Medication (%)     
Beta-blockers 84.3 84.3 84.2 0.97781 
ACE-inhibitors 60.4 60.4 60.5 0.98751 
Calcium channel blockers 18.3 16.8 24.2 0.01251 
Diuretics 27.6 25.0 37.2 0.00041 
Statins 83.9 84.6 80.9 0.18961 
Anti-platelet medication 97.4 97.5 97.2 0.83631 
CRP [mg/L]e,f     
Arithmetic mean (range) 2.6 (0.16-37.4) 2.6 (0.16-37.4) 2.7 (0.16-30.2) 0.43112 
Median 1.6 1.5 1.7 0.13362 
Geometric mean  1.4 1.3 1.6 0.15053 
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Table 4: Baseline characteristics of 1,003 myocardial infarction survivors by city  
 
 
Helsinki  
N=195 
Stockholm 
N=197 
Augsburg 
N=200 
Rome 
N=134 
Barcelona 
N=169 
Athens 
N=108 p-Value 
Sex = male [%] 68.7  70.6  82.0 86.6 83.4 87.0 <0.00011 
Age [yrs]a 64.6  (45-78) 64.0 (38-76) 61.9 (39-76) 62.7 (39-79) 62.1(37-81) 54.7 (38-75) <0.00015 
MI in family history [%]       <0.00011 
Yes (mother and/or father) 47.7  44.7  30.5 29.1 20.7 34.3 <0.00011 
No 41.0 44.2 58.0 64.2 70.4 54.6 <0.00011 
Information incomplete 11.3 11.2 11.5 6.7 8.9 11.1 0.70101 
Self-reported history [%]b        
Angina pectoris 39.0 47.7  21.0 27.6 29.6 41.7 <0.00011 
Arrhythmia 31.3 20.8 24.0 23.1 13.0 21.3 0.00291 
Hypertension  51.3 49.7 51.0 55.2 46.2 54.6 0.731 
Diabetes 21.0 18.3 17.5 17.2 23.7 21.3 0.631 
Body mass index [kg/m²]a 28.6 (19.1-48.9) 27.6 (17.5-43.2) 28.7 (19.1-48.4) 27.7 (19.0-39.4) 28.8 (19.3-43.5) 28.8 (20.8-46.3) 0.00395 
Systolic Blood Pressure [mmHg]a 139.9 (93.0-209) 137.6 (97.0-196) 128.4 (84.0-198) 134.7 (95-188) 129.5 (81-196) 136.1 (100-190) <.00015 
Diastolic Blood Pressure [mmHg]a 79.5 (52.0-112.0) 80.4 (53.0-112.0) 78.1 (47.0-112.0) 77.6 (54.0-114.0) 77.4 (45.0-126.0) 82.3 (60.0-122.0) 0.00105 
Total cholesterol [mg/dl]a 182.2 (91.1-291.9) 173.4 (96.7-324.7) 181.0 (107.0-316.0) 190.6 (120.0-321.0) 193.2 (119.0-390.0) 195.4 (92.0-293.0) <0.00015 
HDL cholesterol [mg/dl]a 54.0 (22.0-119.3) 53.7 (30.9-116.0) 47.9 (24.0-98.0) 43.7 (25.0-87.0) 52.7 (28.0-105.0) 46.1(24.0-87.0) <0.00015 
HbA1c c > 6.5% [%] 15.9 6.6 9.5 8.2 10.7 14.8 0.0101 
Smoking status [%]       <0.00014 
Never smoker 39.5 29.9 31.0 25.4 14.2 10.2 <0.00011 
Ex or occasional smoker 59.0 69.5 69.0 65.7 72.8 51.9 0.00191 
Current smoker 1.5 0.5 0 9.0 13.0 38.0  <0.00014 
Packyears (cigarettes only)a 9.1 (0-65.0) 12.2 (0-73.8) 15.1 (0-205.2) 21.8 (0-171.8) 28.1 (0-192.3) 35.6 (0-174.0) <0.00013 
Alcohol intake [%]d       <0.00011 
None 14.4 7.1 14.5 19.4 17.2 36.1  <0.00011 
Moderate 76.9 80.7 65.0 67.9 69.2 53.7 <0.00011 
Heavy 8.7 12.2 19.5 I 12.7 13.6 10.2 0.0371 
Medication        
Beta-blocker 95 91 92 75 75 64 < 0.0011 
ACE-inhibitors 50 51 72 81 59 52 < 0.0011 
Calcium channel blockers 14 22 15 26 21 29 0.00551 
Diuretics 23 25 44 33 23 10 < 0.0011 
Statins 83 88 89 79 85 73 0.00241 
Anti-platelet medication 97 97 99 95 98 93 0.061 
CRP [mg/L]e         
  Arithmetic mean (range) 1.98 (0.16-12.15) 2.86 (0.16-37.44) 2.26 (0.16-24.65) 2.56 (0.16-15.33) 3.52 (0.33-30.16) 2.52 (0.23-24.25) 0.00015 
  Median  1.37 1.59 1.40 1.62 2.17  1.49  <0.00012 
  Geometric mean  1.18 1.41 1.18 1.34 1.98 1.34 <0.00016 
amean, with range in brackets, bever physician diagnosed; cHbA1c: glycosylised haemoglobin; dnone”: 0g/day, “moderate”: <20g/day for women and <40 g/day for men, “heavy”: ≥20g/day for women  
and ≥40g/day for men; evalues of CRP below 0.16 could not be measured and were set to 0.16; fvalues were calculated as means (median) of patient means (median) and might therefore differ slightly from table 5a  
1Chi-Square-Test, 2Kruskal-Wallis-Test , 3Median-Test, 4Fisher´s exact test, 5ANOVA, 6ANOVA using log-transformed values 
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                           Figure 2a. Hs-CRP values of the repeated measurements of the AIRGENE population.  
                           Boxplot including 95th and 5th percentiles 
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          Figure 2b. Hs-CRP values of the repeated measurements of the AIRGENE  
population by city. Boxplots including 95th and 5th percentiles 
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Tables 5a shows the arithmetic and geometric mean hs-CRP concentrations of the variables of the 
base model. The mean concentration in Barcelona was 3.4 mg/L, while concentrations for all 
other cities ranged between 2.0 and 2.8. Values were on average higher for women. Age showed 
a U-shaped function, with the lowest hs-CRP concentration for the age group 50 to 59. A clear 
linear relationship was seen for BMI, ranging from 1.0 for underweight to 2.9 for obese. Hs-CRP 
concentrations were also higher in smokers than in non-smokers, and showed a dose-response 
relationship regarding packyears of smoking. Patients with high HbA1c levels or high N-terminal 
proB-type natriuretic peptide (NT-pro BNP) levels had also higher hs-CRP concentrations. For 
total cholesterol on the other hand, patients with an intermediate level showed the highest hs-CRP 
concentration, while those over 250gm/dl and those below 200mg/dl were lower and almost 
similar regarding their arithmetic mean concentrations.  
In terms of diagnosed diseases, slightly higher hs-CRP concentrations in patients with 
emphysema or stroke were found. Clearly higher hs-CRP was seen in patients with chronic 
bronchitis and asthma (Table 5b).  
Concerning smoking and ETS exposure, current regular smokers showed the highest hs-CRP 
concentrations, followed by patients who are constantly exposed to ETS. Surprisingly, occasional 
smokers had the lowest hs-CRP concentrations; however the number of subject in this group was 
very small. Analyses also showed higher hs-CRP concentrations in patients with bad or very bad 
health status and those who claim to be inactive.  
In respect of medication intake, patients reporting the intake of serum lipid reducers, statins, ASA 
and beta blockers had lower hs-CRP concentrations, while in patients on calcium channel 
blockers the concentration was higher (Table 5c). 
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Table 5a: Arithmetic mean, geometric mean* and unadjusted coefficients of variation† of hs-CRP – variables 
of the base model 
Variable  
Arithmetic  
mean of  
hs-CRP [mg/L] 
Geometric 
mean of  
hs-CRP [mg/L] 
Coefficient of 
variation of  
hs-CRP 
n 
 
 
 mean std mean std mean  
City Athens 2.6 5.3 1.3 2.9 55.9 108 
 Augsburg 2.2 4.5 1.2 2.8 56.8 200 
 Barcelona 3.4 5.7 2.0 2.7 59.3 169 
 Helsinki 2.0 3.1 1.2 2.6 53.6 195 
 Rome 2.5 4.0 1.3 2.9 52.3 134 
 Stockholm 2.8 5.1 1.4 3.0 52.0 197 
        
Sex Male 2.5 4.5 1.3 2.9 56.8 788 
 Female 2.8 5.1 1.6 2.8 48.3 215 
        
Age [years] < 50 2.7 4.8 1.5 2.9 56.1 115 
 50-59 2.0 3.3 1.1 2.7 50.2 271 
 60-69 2.8 5.2 1.4 3.0 55.6 348 
 ≥ 70  2.9 5.0 1.6 2.8 58.5 269 
        
BMIa obese  2.9 3.6 1.8 2.5 49.0 999 
 overweight  2.6 5.2 1.3 2.9 56.2 316 
 
normal 2.2 4.9 1.0 2.9 63.4 483 
 
underweight 1.0 1.1 0.7 2.6 29.5 189 
        
Number of MI 2 or more 3.1 4.5 1.7 2.9 60.2 150 
 1 2.5 4.7 1.3 2.8 54.1 853 
 
       
Smoking [packyears]b > 30.75 3.5 5.7 1.9 2.9 55.8 228 
 ≤ 30.75  2.5 4.8 1.3 2.9 55.4 470 
 Never smokers 2.1 3.2 1.2 2.7 53.8 304 
        
HbA1c levelcd High (≥6.5%) 3.2 4.5 1.9 2.8 56.6 108 
 Normal (<6.5%) 2.5 4.5 1.3 2.8 54.4 868 
        
Log NT-pro BNPe 
[pg/ml] ≥ 5.98 3.3 6.2 1.7 3.0 63.0 245 
 
5.97 - 5.12 2.5 4.1 1.3 3.0 51.2 252 
 
5.11 - 4.47 2.2 3.4 1.3 2.6 51.5 250 
 
< 4.47 2.4 4.5 1.3 2.8 54.3 256 
 
       
Total cholesterol 
levelc  High (>250mg/dl) 2.5 3.8 1.5 2.7 53.5 60 
 
At risk (200-250mg/dl) 3.2 5.7 1.7 2.9 57.1 249 
 
Normal (<200mg/dl) 2.4 4.3 1.3 2.8 54.3 689 
aBMI classification according to WHO (2000): obese ≥30 kg/m², overweight ≥25<30 kg/m², normal weight ≥20<25 kg/m²,  
underweight <20 kg/m²; bcategories correspond interquartile ranges; cmeasured at baseline; dHbA1c: glycosylised haemoglobin;  
eNT-pro BNP: N-terminal proB-type natriuretic peptide, categories: quartiles 
*arithmetic and geometric mean based on all repeated measurements taken together and might therefore differ slightly from tables 
3 and 4; †coefficient of variation based on repeated measurements by subject 
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Table 5b: Arithmetic mean, geometric mean* and unadjusted coefficients of variation† of hs-CRP – disease 
history  
aever physician diagnosed; bMI: myocardial infarction; 
*arithmetic and geometric mean based on all repeated measurements taken together;  
†coefficient of variation based on repeated measurements by subject 
 
Variable  
Arithmetic mean of 
hs-CRP  
[mg/L] 
Geometric 
mean of hs-CRP 
[mg/L] 
Coefficient of 
variation of 
hs-CRP 
n 
 
 
 
mean std mean std mean  
Type 2 Diabetesa Yes 2.8 4.2 1.6 2.8 57.2 198 
 No 2.5 4.8 1.3 2.9 54.4 805 
 
       
Angina pectorisa Yes 2.7 4.6 1.5 2.9 52.4 344 
 No 2.5 4.7 1.4 2.8 56.3 658 
 
       
Congestive heart failurea Yes 2.8 3.9 1.7 2.7 48.3 104 
 No 2.6 4.7 1.4 2.9 55.7 899 
        
Emphysemaa Yes 3.0 3.7 1.8 2.8 42.1 23 
 No 2.6 4.7 1.4 2.9 55.3 980 
 
       
Family history of MIb ≥ 1 parent 2.6 4.6 1.4 2.8 53.2 353 
 No 2.6 4.9 1.4 2.9 56.1 547 
 
       
Strokea Yes 3.0 4.9 1.7 2.8 54.0 62 
 No 2.6 4.6 1.4 2.9 55.0 941 
 
       
Hypertensiona Yes 2.6 4.4 1.4 2.9 55.5 511 
 No 2.6 5.0 1.4 2.9 54.4 492 
        
Chronic bronchitisa Yes 4.3 7.5 2.3 3.2 51.7 67 
 No 2.5 4.4 1.3 2.8 55.2 936 
        
Asthmaa Yes 3.1 3.8 1.79 3.02 49.4 47 
 No 2.6 4.7 1.37 2.85 55.2 956 
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Table 5c: Arithmetic mean, geometric mean* and unadjusted coefficients of variation† of hs-CRP – life-style  
variables and medication intake  
Variable  
Arithmetic 
mean of hs-
CRP [mg/L] 
Geometric 
mean of hs-
CRP [mg/L] 
Coefficient of 
variation of 
hs-CRP 
n 
  mean std mean std mean  
Smoking status and 
ETS exposure Current regular smoker 3.4 5.9 1.8 3.1 58.8 72 
excluding packyears of 
smoking from the model Occasional smoker 1.8 2.6 1.0 2.9 50.1 27 
 No current smoker,  
constant ETS exposure 3.2 5.3 1.5 3.3 52.3 136 
 No current smoker, no 
constant ETS exposure 2.4 4.5 1.4 2.8 55.3 767 
 
       
Health status Excellent/good 2.5 4.5 1.4 2.8 54.9 592 
 Moderate 2.5 5.0 1.3 3.1 56.5 342 
 Bad/very bad 3.4 4.5 1.9 2.8 48.1 68 
 
       
Physical activity Inactive 3.3 5.6 1.8 2.9 56.8 219 
 Partly/Irregularly active 2.5 4.5 1.3 2.9 52.4 280 
 Regularly active/trained 2.4 4.2 1.3 2.8 55.5 504 
 
       
HDL cholesterola 
[mg/dl] 
adjusted for total cholesterol 
> 35 2.6 4.6 1.4 2.9 55.4 884 
 
≤ 35 2.7 5.0 1.5 2.7 51.0 114 
 
       
Serum lipid reducers Yes 2.5 2.5 1.3 2.9 54.7 858 
 
No 3.0 4.5 1.71 2.8 56.3  
 
 
     
 
Statins Yes 2.5 4.7 1.3 2.9 54.8 841 
 
No 3.0 4.4 1.7 2.8 55.9  
 
 
     
 
ACEb-inhibitors Yes 2.6 4.6 1.4 2.9 56.9 606 
 
No 2.6 4.7 1.4 2.8 52.1  
 
 
     
 
Systemic anti-
inflammatory 
medication  
 
Yes 
 
2.7 
 
6.0 
 
1.5 
 
2.7 
 
57.6 
 
234 
 
No 2.6 4.5 1.4 2.9 54.2  
  
     
 
Acetylsalicylic acid Yes 2.5 4.7 1.3 2.9 54.8 878 
 
No 3.1 4.7 1.7 2.8 56.5  
  
     
 
Diuretics Yes 2.9 4.8 1.7 2.8 54.5 277 
 
No 2.5 4.6 1.3 2.9 55.1  
  
     
 
Ca2+-channel blockers Yes 3.0 4.7 1.6 3.0 54.2 184 
 
No 2.5 4.6 1.4 2.8 55.1  
 
 
     
 
Beta-blocker Yes 2.5 4.4 1.4 2.9 54.0 845 
 
No 2.9 5.7 1.6 2.9 59.8  
ameasured at baseline, bangiotensin converting enzyme 
*arithmetic and geometric mean based on all repeated measurements taken together;  
†coefficient of variation based on repeated measurements by subject 
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2711 of the examinations were conducted in the morning, before noon, and 3102 in the afternoon. 
Mean concentrations did not show a clear diurnal pattern (Figure 3a) and also also hardly varied 
with season (Figures 3b and 3c).  
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Figure 3a. Hs-CRP values of the repeated measurements of the AIRGENE  
population by time of the day.  
(Morning: before 12.00 a.m., afternoon: after 12.00 a.m.) 
Boxplots including 95th and 5th percentiles 
 
 
Season
Spring Summer Autumn Winter
CR
P 
[m
g/
l]
0
2
4
6
8
10
 
Figure 3b. Hs-CRP values of the repeated measurements of the AIRGENE  
population by season.  
(Spring=March to May, Summer=June to August, Autumn=September to November,  
Winter=December to February). Boxplots including 95th and 5th percentiles 
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Figure 3c. Hs-CRP values of the repeated measurements of the AIRGENE  
population by city and season.  
(Spring=March to May, Summer=June to August, Autumn=September to November,  
Winter=December to February). Boxplots including 95th and 5th percentiles 
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4.1 Patient characteristics that affect hs-CRP concentration and within patient variation 
With few exceptions, the unadjusted CVs of different subgroups of the AIRGENE population as 
shown in Tables 5a to 5c are similar to those of the adjusted model (tables 6a to 6c). The 
associations between the concentration and variation of hs-CRP and patient characteristics as 
derived jointly from the base model are given in Table 6a. Regarding age, a U-shaped 
relationship with the lowest hs-CRP level in the group of 50 to 59 year olds was found (Figure 4). 
A separate analysis showed that this effect was mainly driven by men, whereas women showed a 
positive linear association between hs-CRP and age (data not shown).  
 
 
Figure 4. Function of log hs-CRP and age adjusted for the variables in the base model 
Males had significantly lower hs-CRP concentrations compared to the female participants, 
however a higher variation in hs-CRP (Figure 5a). Bodyweight expressed as BMI was one of the 
strongest determinants with higher geometric mean hs-CRP concentrations in overweight and 
obese patients. Variation decreased with increasing BMI, but was extremely low in underweight 
subjects. Clear positive associations were seen with HbA1c levels above the 6.5% cutoff for 
geometric mean concentration and variation of hs-CRP while a diagnosis of type 2 diabetes was 
positively associated with the variation but not the geometric mean hs-CRP concentration.  
Tables 6b and 6c show the associations between hs-CRP and disease history, life-style factors 
and medication intake. Family history of MI of at least one parent and the diagnosis of chronic 
bronchitis were associated with elevated hs-CRP concentrations. Hs-CRP showed less variation 
Age [years] 
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in patients who reported angina pectoris, congestive heart failure (CHF) (Figure 5a), emphysema 
and at least one parent with a history of MI.   
HDL cholesterol was inversely related to a geometric mean hs-CRP concentration with a higher 
variation in those patients who had an HDL cholesterol level above 35 mg/dl. 
Patients reporting the intake of statins or other lipid-lowering drugs in general showed 
significantly lower geometric mean concentrations of hs-CRP and also less variation. For patients 
using ACE-inhibitors on the other hand, a higher variation was found while geometric mean 
concentrations seemed not to be associated with the intake of this medication (Figure 5b and 
Table 6c) 
With very few exceptions, results for the variation model that included all variables at the same 
time did not differ much from the presented tables. Results showed the largest increases in 
variation for patients with HDL cholesterol concentrations above 35 mg/dl, older age, especially 
above 70, male gender, a log BNP level of ≥ 5.98 [pg/ml],  and intake of anti-inflammatory 
medication (data not shown).  
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Table 6a: Association of time-invariant variables on the mean concentration and variation of hs-CRP. Variables of the base model 
Variable  %-change from GMa CI
b
 lower CI upper p-value GM 
analysis 
Proband group* /  
Reference group (ref) 
[% difference in within-  
patient variation] 
p-value 
variation 
analysis n 
City Athens -29.54 -43.46 -12.19 0.002 12.4 0.0007# 108 
 Augsburg -25.95 -36.83 -13.19 0.0002 19.8  200 
 Barcelona 9.80 -7.61 30.48 0.29 14.9  169 
 Helsinki -26.44 -37.27 -13.75 0.00016# 6.5  195 
 Rome -13.52 -27.74 3.50 0.11 4.1  134 
 Stockholm ref    ref  197 
         
Sex Male -13.28 -23.78 -1.34 0.03 24.8 <0.0001# 788 
 Female ref    ref  215 
         
Age [years] < 50 28.07 6.26 54.35 0.009 25.5 <0.0001# 115 
 50-59 ref    ref  271 
 60-69 18.13 3.39 34.97 0.014 27.8  348 
 ≥ 70  28.26 10.45 48.95 0.001 37.2  269 
         
BMIc Linear: per increase in 5kg/m² 37.80 29.69 46.43 <0.0001# --  999 
 Obese (≥30) 86.02 59.97 116.31 <0.0001# -45.8 <0.0001# 316 
 
Overweight (≥25<30) 33.76 16.51 53.57 <0.0001# -19.9  483 
 
Normal (≥20<25) ref    ref  189 
 
Underweight (<20) -33.83 -59.49 8.10 0.099 -74.8  11 
         
Number of MI 2 or more 13.10 -2.15 30.73 0.010 18.5 0.0027 150 
 1 ref    ref  853 
 
        
Smoking [packyears]d Linear: per increase in 25  16.31 9.65 23.38 <0.0001# --  1002 
 > 30.75 48.04 26.94 72.64 <0.0001# 1.1 0.082 228 
 ≤ 30.75  16.45 3.17 31.44 0.014 5.0  470 
 Never smokers ref    ref  304 
         
HbA1c levele High (≥6.5%) 26.24 7.23 48.61 0.005 20.7 0.0034  108 
 Normal (<6.5%) ref    ref  868 
         
Log NT-pro BNPf [pg/ml] Linear: per increase of  500 NT-pro BNP 38.43 20.61 58.89 <0.0001#   1003 
 ≥ 5.98 26.99 7.74 49.67 0.004 34.2 <0.0001# 245 
 5.97 - 5.12 3.86 -10.94 21.11 0.63 0.03  252 
 5.11 - 4.47 2.77 -11.32 19.09 0.72 -9.0  250 
 < 4.47 ref    ref  256 
 
        
Total Cholesterol levelg Linear: per increase in 40 mg/dl 15.53 9.60 21.79 <0.0001# --  998 
 
High (>250mg/dl) 30.07 15.44 46.55 <0.0001# -6.1 0.052 60 
 
At risk (200-250mg/dl) 23.85 -0.11 53.56 0.051 8.7  249 
 
Normal (<200mg/dl) ref    ref  689 
aGM: geometric mean; Geometric mean is the antilog of arithmetic mean of log-transformed variable, %change: antilog of effect estimate obtained from regression minus one multiplied by 100; bCI: Confidence Interval, 
cBMI: Body mass index, classification according to WHO (2000); dcategories correspond interquartile ranges; eHbA1c: glycosylised haemoglobin; fNT-pro BNP: N-terminal proB-type natriuretic peptide, categories: quartiles; 
gmeasured at baseline # Statistically significant after adjusting for multiple testing (α = 0.00125);  
* Proband group refers to the respective category of the variable, e.g. Athens for city, the reference group is annotated as “ref”, e.g. Stockholm for city 
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Table 6b: Association of disease history on the mean concentration and variation of hs-CRP. Base model + disease history 
 
aGM: geometric mean, geometric mean is the antilog of arithmetic mean of log-transformed variable, %change: antilog of effect estimate obtained from regression minus one 
multiplied by 100; bCI: confidence interval; cever physician diagnosed; dMI: myocardial infarction;  
#statistically significant after adjusting for multiple testing (α = 0.00125) 
* Proband group refers to the group of patients with disease, e.g. Type 2 diabetes = yes, the reference group annotated as “ref” refers to subjects without the respective disease, e.g. 
Type 2 diabetes = no 
Variable  %-change from GMa CI
b
 lower CI upper p-value GM 
analysis 
Proband group* / 
Reference group  
[% difference in within-
patient variation] 
p-value 
variation 
analysis n 
Type 2 Diabetesc Yes 4.22 -8.50 18.70 0.53 11.57 0.0052 198 
excluding HbA1c from the 
model No ref    ref  805 
 
        
Angina pectorisc Yes 2.54 -8.08 14.39 0.65 -11.0 <0.0001# 344 
 No ref    ref  658 
 
        
Congestive heart 
failurec Yes 2.83 -13.66 22.48 0.75 -24.9 <0.0001
#
 104 
 No ref    ref  899 
         
Emphysemac Yes 17.19 -16.64 64.75 0.36 -41.6 0.00024# 23 
 No ref    ref  980 
 
        
Family history of MId ≥ 1 parent 12.49 0.48 25.94 0.04 -20.5 <0.0001# 353 
 No ref    ref  547 
 
        
Strokec Yes -2.77 -21.78 20.86 0.80 1.6 0.094 62 
 No ref    ref  941 
 
        
Hypertensionc Yes -8.32 -17.18 1.48 0.093 6.3 0.061 511 
 No ref    ref  492 
         
Chronic bronchitisc Yes 36.47 10.97 67.81 0.003 -2.7 0.65 67 
 No ref    ref  936 
         
Asthmac Yes 16.81 -7.58 47.64 0.19 -9.5 0.15 47 
 No ref    ref  956 
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Table 6c: Association of life-style factors and medication intake on the mean concentration and variation of hs-CRP. Base model + life-style variables and medication intake 
Variable  %-change from GMa CI
b
 lower CI upper p-value GM 
analysis 
Proband group* / 
Reference group (ref) 
[% difference in within-
patient variation] 
p-value 
variation 
analysis 
n 
Smoking status and ETS exposure Current regular smoker 23.68 -2.19 56.38 0.08 27.3 <0.0001# 72 
excluding packyears of smoking from the  Occasional smoker -27.94 -47.63 -0.86 0.04 -24.6  27 
model No current smoker,  
constant ETS exposure 9.57 -6.31 28.14 0.25 -9.9  136 
 No current smoker,  
no constant ETS exposure ref    ref 
 767 
 
        
Health status Excellent/good 10.46 -1.13 23.39 0.08 6.5 0.067 592 
 Moderate ref    ref  342 
 Bad/very bad 33.06 7.71 64.36 0.008 -11.2  68 
         
Physical activity Inactive 7.06 -7.16 23.46 0.35 7.0 0.0011# 219 
 Partly/Irregularly active 3.09 -8.51 16.16 0.62 -13.1  280 
 Regularly active/trained ref    ref  504 
 
        
HDL cholesterolc [mg/dl]  
adjusted for total cholesterol 
Linear: per increase in 15 
mg/dl -8.15 -13.90 -2.03 0.0010
#
 
--  998 
 
> 35 -16.78 -29.73 -1.45 0.033 36.0 <0.0001# 884 
 
≤ 35 ref    ref  114 
 
        
Serum lipid reducers Yes -18.54 -29.98 -5.23 0.0079 -19.6 0.0015 858 
 
No ref    ref   
 
        
Statins Yes -16.98 -28.28 -3.90 0.013 -18.4 0.00078# 841 
 
No ref    ref   
         
ACEd-inhibitors Yes 5.60 -7.59 20.67 0.42 18.3 0.00028# 606 
 
No ref    ref   
         
Systemic anti-inflammatory medication  Yes 2.71 -8.97 15.88 0.66 6.6 0.14 234 
 
No ref    ref   
         
Acetylsalicylic acid Yes -10.60 -23.55 4.56 0.16 -8.5 0.06 878 
 
No ref    ref   
         
Diuretics Yes 1.08 -10.66 14.36 0.86 4.0 0.03 277 
 
No ref    ref   
         
Ca2+-channel blockers Yes 5.60 -7.59 20.67 0.42 4.1 0.04 184 
 
No ref    ref   
         
Beta-blocker Yes 1.21 -13.01 17.75 0.88 -11.6 0.005 845 
 
No ref    ref   
aGM: geometric mean, geometric mean is the antilog of arithmetic mean of log-transformed variable, %change: antilog of effect estimate obtained from regression minus one multiplied by 100; bCI: confidence interval, cmeasured 
at baseline, dACE: angiotensin converting enzyme; #Statistically significant after adjusting for multiple testing (α = 0.00125); *Proband group refers to the respective category of the variable, e.g. excellent/good for health status; 
the reference group is annotated as “ref”, e.g. moderate for health status
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Figure 5a. Variation of mean hs-CRP between (above) and within subjects (below).  
Individual hs-CRP measurements over time by patient characteristics (sex, body mass index (BMI),  
level of glycosylised haemoglobin (HbA1c) ≥ 6.5% and diagnosis of type 2 diabetes). 
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Figure 5b. Variation of mean hs-CRP between (above) and within subjects (below).  
Individual hs-CRP measurements over time by patient diagnosis of chronic bronchitis or heart failure  
and intake of statins or angiotensin converting enzyme (ACE) inhibitors in 1,003 MI patients from the 
AIRGENE study. 
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As seen in Table 7, additional adjustment for associated medication intake did not change the 
results for co-morbidities. Table 8 summarises the results for different smoking-related variables. 
Twenty-five pack-years of smoking produced an increase of approximately 16% in the geometric 
mean of the hs-CRP concentration, and inclusion of smoking status in the model had little effect 
on this result. Including pack-years of smoking, however, removed the borderline effect for ex-
smokers found in the model not including pack-years of smoking. Examination of the effects of 
smoking and ETS exposure revealed a heterogeneous picture. Current regular smokers and 
nonsmokers who reported regular ETS exposure had higher hs-CRP concentrations, whereas 
occasional smokers seemed to have lower hs-CRP concentrations than nonsmokers not regularly 
exposed to ETS. The results were not statistically significant, however, especially when pack-
years of smoking were included in the model. Also, the numbers of participants were low in 
several of the groups. 
Results of the separate analyses for 770 men regarding cholesterol levels can be found in Table 
9. Compared to the whole AIRGENE population, associations for total cholesterol (model 1a) 
and HDL cholesterol (model 2) were slightly stronger when only males were included in the 
analyses. Strong positive associations were seen for total cholesterol and LDL cholesterol but 
not for HDL cholesterol when parameters were added separately to the base model (models 1a to 
1c). Adjustment for total cholesterol led to significantly negative associations for HDL 
cholesterol (model 2), which were only slightly weaker when additionally adjusted for LDL 
(model 4). No associations were found for triglycerides (models 1d and 5). 
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Table 7: Association of disease history on the mean concentration and variation of hs-CRP. Base model + base model additionally adjusted for medication intake. 
Variable  %-change from GMa CI
b
 lower CI upper p-value GM 
analysis 
Proband group*/ 
Reference group (ref) 
[% difference in within- 
patient variation] 
p-value 
variation 
analysis 
Angina pectorisc Yes 2.54 -8.08 14.39 0.65 -11.0 <0.0001# 
 No ref    ref  
        
Angina pectorisc Yes 2.07 -8.56 13.93 0.72 -11.0 <0.0001# 
additionally adjusted for Ca2+ channel blocker No ref    ref  
Congestive heart failurec Yes 2.83 -13.66 22.48 0.75 -24.9 <0.0001# 
 No ref    ref  
        
Congestive heart failurec Yes 1.75 -14.61 21.25 0.85 -24.9 <0.0001# 
additionally adjusted for ASAd No ref    ref  
 
       
Congestive heart failurec Yes 2.61 -14.26 22.81 0.78 -24.9 <0.0001# 
additionally adjusted for diuretics No ref    ref  
        
Congestive heart failurec Yes 6.11 -10.96 26.45 0.51 -24.9 <0.0001# 
additionally adjusted for ACEe inhibitors No ref    ref  
Emphysemac Yes 17.19 -16.64 64.75 0.36 -41.6 0.00024# 
 No ref    ref  
        
Emphysemac Yes 16.61 -17.13 64.10 0.38 -41.6 0.00023# 
additionally adjusted for systemic anti-
inflammatory medication No ref    
ref  
        
Emphysemac Yes 16.17 -17.37 63.32 0.39 -41.6 0.00023# 
additionally adjusted for ASA No ref    ref  
        
Emphysemac Yes 17.05 -16.79 64.65 0.37 -41.6 0.00024# 
additionally adjusted for diuretics No ref    ref  
        
Emphysemac Yes 19.05 -15.22 67.18 0.31 -41.6 0.00027# 
additionally adjusted for ACE inhibitors No ref    ref  
aGM: geometric mean, geometric mean is the antilog of arithmetic mean of log-transformed variable, %change: antilog of effect estimate obtained from regression minus one multiplied by 100;  
bCI: confidence interval, cever physician diagnosed, dASA: acetyl salicylic acid, eACE: angiotensin converting enzyme;  #Statistically significant after adjusting for multiple testing (α = 0.00125) 
* Proband group refers to the group of patients with disease, e.g. Angina pectoris = yes, the reference group annotated as “ref” refers to subjects without the respective disease, e.g. Angina pectoris = no 
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Table 8: Association of smoking and ETS exposure with the geometric mean level and variation of hs-CRP, adjusted for the variables of the base model 
Variable  % change from GMa CI
b
 lower CI upper p-value GM 
analysis 
Proband group* / 
Reference group (ref)  
[% difference in within-
patient variation] 
p-value 
variation 
analysis 
n 
         
Packyears of smoking 
excluding smoking status from the 
model 
Linear: per increase of 25 
packyears 16.31 9.65 23.38 <0.0001
a
 -- -- 1002 
 
     
   
Packyears of smoking 
including smoking status in the model 
Linear: per increase of 25 
packyears 14.88 7.59 22.67 <0.0001
a
 -- -- 1002 
      
   
Smoking status  
excluding pack years of smoking from 
the model 
Current smoker 
(regular/occasional) 16.33 -5.91 43.85 0.16 10.9 0.095 99 
 
Ex smoker 19.67 5.97 35.16 0.004 -2.4  627 
 
Never Smoker ref    ref  277 
  
       
Smoking status  
including pack years of smoking in 
the model 
Current smoker 
(regular/occasional) 4.59 -15.75 29.83 0.68 10.9 0.116 99 
 
Ex smoker 5.97 -7.32 21.16 0.40 -2.2  627 
 
Never Smoker ref    ref  277 
   
 
   
 
 
Smoking status and ETS 
exposure Current regular smoker 23.68 -2.19 56.38 0.08 27.3 <0.0001
b
 72 
excluding packyears of smoking from 
the model Occasional smoker -27.94 -47.63 -0.86 0.04 -24.6  27 
 
No current smoker,  
constant ETS exposure 9.57 -6.31 28.14 0.25 -9.9  136 
 
No current smoker,  
no constant ETS exposure ref    ref 
 767 
 
 
   
 
 
 
 
Smoking status and ETS 
exposure Current regular smoker 15.23 -8.79 45.59 0.23 26.8 <0.0001
b
 72 
including packyears of smoking in the 
model Occasional smoker -21.20 -42.66 8.29 0.14 -25.0  27 
 
No current smoker,  
constant ETS exposure 6.50 -8.81 24.38 0.43 -10.3  136 
 
No current smoker,  
no constant ETS exposure ref    ref 
 767 
aGM: geometric mean, geometric mean is the antilog of arithmetic mean of log-transformed variable, %change: antilog of effect estimate obtained from regression minus one multiplied by 100; bCI: Confidence interval;  
*Proband group refers to the respective category of the variable, e.g. exsmoker for smoking status; the reference group is annotated as “ref”, e.g. never smoker for smoking status 
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Table 9: Association of cholesterol and triglyceride level on hs-CRP concentration – 770* male post-MI patients (base model without adjustment for sex) 
Variable Total cholesterol per increase in 40mg/dl 
HDL 
per increase in 15mg/dl 
LDL 
per increase in 25mg/dl 
Triglycerides 
per increase in 90mg/dl 
 
% change 
from GMa 
CIb 
lower 
CI 
upper 
% change 
from GM 
CI 
lower 
CI 
upper 
% change 
from GM 
CI 
lower 
CI 
upper 
% change 
from GM 
CI 
lower 
CI 
upper 
Model 1 (a to d) 
Each parameter separately 20.92 13.57 28.73 -0.93 -8.56 7.35 16.23 10.11 22.68 4.95 -1.28 11.58 
 
            
Model 2 
Total cholesterol and HDLc without 
LDLd and triglycerides 
24.24 16.27 32.76 -9.60 -16.80 -1.78 -- -- -- -- -- -- 
             
Model 3  
Total cholesterol and LDL without 
HDL and triglycerides 
14.63 3.77 26.62 -- -- -- 6.09 -2.62 15.57 -- -- -- 
 
            
Model 4 
Total cholesterol, HDL, LDL without 
triglycerides 
20.05 7.75 33.76 -8.81 -16.29 -0.66 3.60 -5.13 13.15 -- -- -- 
 
            
Model 5  
Total cholesterol and triglycerides 
without HDL and LDL 
21.00 13.36 29.16 -- -- -- -- -- -- -0.27 -6.31 6.16 
aGM: geometric mean, geometric mean is the antilog of arithmetic mean of log-transformed variable, %change: antilog of effect estimate obtained from regression minus one multiplied by 100; 
bCI: confidence interval, cHDL: high density lipoprotein, dLDL: low density lipoprotein, 
*only male patients with complete data on total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides were included 
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4.2 Life-style parameters and hs-CRP level 
Life-style in the 24 hours preceding blood draw seemed to have no or a rather low influence on 
hs-CRP concentrations. Negative but not statistically significant associations were seen for 
alcohol and tea consumption and extreme stress or anger (Figure 6). However, the number of 
subjects that contributed to the effect was small, with only 260 patients reporting varying tea 
consumption and 500 reporting varying alcohol intake. While physical activity over the past 24 
hours did not seem to be associated with geometric mean hs-CRP concentrations, a clear time 
course with an increase in hs-CRP was found if the patients were physically active between six 
and eleven hours before the blood withdrawal (Figure 7). For the other time-varying parameters, 
no such time-specific effects were seen. 
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Figure 6. Associations between log hs-CRP and life-style parameters 24 hours before the  
blood withdrawal. *n: number of observations 
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Association between CRP and physical activity, by time window of exposure
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Figure 7. Associations between log hs-CRP and physical activity in 6 hour categories before  
the blood withdrawal. *n: number of observations, 14 missing values; ref: reference category 
 
 
4.3 Air pollutants and hs-CRP concentration 
Twenty four hour average concentrations of the pollutants and the description of the 
meteorological data for the six cities for the study period are given in Table 10. PNC and PM2.5 
were highest in the southern centres and lowest in Stockholm and Helsinki, while Augsburg 
showed intermediate levels (Figure 8) (Ruckerl et al., 2007), (Appendix III).  
For hs-CRP, no associations between ambient air pollution and serum concentrations were 
observed for any of the analysed time lags (Table 11a). IL-6 and Fibrinogen on the other hand, 
which were examined in the same population in previous analyses (Ruckerl et al., 2007), 
(Appendix III), showed positive associations with levels of air pollution. In particular, an increase 
in IL-6 was seen when PNC were elevated 12–17 hours before the clinical visit and an increase in 
fibrinogen in association with a five day cumulative exposure to PM10 (Table 11b). Analyses of 
effect modification showed that for fibrinogen associations remained for the five day average 
exposure to PM10 for patients with elevated HbA1c levels (Figure 9). 
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Table 10. 24-hour average concentrations of the ambient air pollutants and meteorological parameters from 6 European cities during the AIRGENE study period 
 Helsinki Stockholm Augsburg Rome Barcelona Athens 
Study perioda 05.09.03 – 02.06.04 30.08.03 – 24.06.04 14.05.03 – 24.02.04 20.09.03 – 15.07.04 30.08.03 – 16.06.04 08.09.03 – 30.07.04 
 Mean 95th Mean 95th Mean 95th Mean 95th Mean 95th Mean 95th 
PNC [1/cm³] 8534 15077 9748 17578 11876b 25135 35450b 69226 18133b 36526 20589b 47573 
PM2.5 [µg/m³] 8.2 19.4 8.8 19.1 17.4 29.3 24.5b 54.1 24.2b 62.7 23.0b 46.0 
PM10 [µg/m³] 17.1 36.1 17.8 40.3 33.1 56.6 42.1 76.0 40.7b 88.7 38.5 64.6 
CO [mg/m³] 0.31 0.46 0.29 0.43 0.58 1.00 1.40 2.47 0.59 0.92 1.48 3.23 
NO2 [µg/m³] 28.6 49.8 18.6 32.6 40.0 61.2 67.0 90.8 50.5 79.6 50.1 73.0 
NO [µg/m³] 12.5 40.7 4.9 15.5 30.0 80.4 65.7 164.0 37.7 88.4 41.8 144.6 
SO2 [µg/m³] 4.2 10.1 1.9 4.9 3.0 5.7 4.1 9.2 4.7 9.6 10.3 23.2 
O3c [µg/m³] 46.8 89.0 60.6 96.9 54.4 115.3 45.3 99.6 28.2 76.5 59.8 100.2 
Air temperature [°C] 3.1 14.7 4.7 15.1 10.2 25.1 13.4 23.9 15.2 23.2 17.6 29.3 
Relative humidity [%] 76 91 82 94 69 92 80 95 67 86 67 84 
aThe study period started 5 days before the first measurement because air pollution concentrations up to 5 days before the blood withdrawals were considered. 
bData available on less than 95% of the days; cAverage of 8 maximum hourly values within the past 24 hours 
PNC: particle number concentration, PM2.5: mass concentration of particles less than 2.5 µm in diameter; PM10: mass concentration of particles less than 10 µm in diameter; CO: carbon monoxide; NO2: 
nitrogen dioxide; NO: nitrogen monoxide; SO2: sulphur dioxide; O3: ozone; 
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Figure 8. Time series of air pollution (PNC and PM2.5) and air temperature in the six European cities of 
the AIRGENE study 
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Table 11a: Effects of particulate air pollutants on hs-CRP per increase in interquartile range (IQR) of air pollutant 
 
 
Table 11b: Effects of particulate air pollutants on IL-6 and Fibrinogen per increase in interquartile range (IQR) of 
air pollutant 
   
Hs-CRPa (all cities) 
Pollutant Time prior to blood withdrawal IQR 
%-change 
(GMb) 95% CI
c
 
p-value 
heterogeneityd 
    Lower Upper  
PNCe Lag 0 11852 1.33 -3.05 5.90 0.047 
 Lag 1 11852 -1.52 -4.39 1.45 0.19 
 Lag 2 11852 -1.63 -6.70 3.71 0.019 
 5-d-aver. 11003 -0.08 -3.78 3.75 0.12 
       
PM2.5f Lag 0 11.0 0.11 -1.95 2.21 0.71 
 Lag 1 11.0 -0.06 -1.98 1.90 0.70 
 Lag 2 11.0 0.11 -1.80 2.06 0.86 
 5-d-aver. 8.6 -0.13 -2.15 1.92 0.94 
       
PM10g Lag 0 17.4 -0.71 -2.75 1.37 0.16 
 Lag 1 17.4 -0.63 -2.61 1.39 0.23 
 Lag 2 17.4 -1.42 -4.23 1.47 0.086 
 5-d-aver. 13.5 -1.35 -3.45 0.79 0.19 
 
 
 
IL-6h 
(all cities)  
Fibrinogen 
(all cities except Athens) 
Pollutant 
Time prior 
to blood 
withdrawal 
 
IQR 
%-
change 
(GMb) 
95% CI 
p-value 
hetero-
geneityc 
 
%-
change 
(AMi) 
95% CI 
p-value 
hetero-
geneity 
    Lower Upper    Lower Upper  
PNCe Lag 0 11852 1.88† -0.16 3.97 0.72  0.40 -0.40 1.19 0.54 
 Lag 1 11852 -0.67 -2.56 1.25 0.64  0.11 -0.69 0.91 0.12 
 Lag 2 11852 -2.12† -4.03 -0.17 0.055  0.09 -0.71 0.90 0.045 
 5-d-aver. 11003 -0.93 -3.37 1.56 0.084  0.50 -2.20 3.20 0.009 
            
PM2.5f Lag 0 11.0 0.46 -0.89 1.83 0.26  0.05 -0.48 0.58 0.36 
 Lag 1 11.0 -0.39 -1.69 0.93 0.70  0.17 -0.35 0.69 0.55 
 Lag 2 11.0 -0.23 -1.53 1.07 0.57  0.20 -0.32 0.71 0.26 
 5-d-aver. 8.6 0.05 -1.37 1.50 0.66  0.38 -0.21 0.96 0.21 
            
PM10g Lag 0 17.4 -0.34 -1.66 0.99 0.45  0.06 -0.43 0.55 0.53 
 Lag 1 17.4 -0.69 -1.95 0.58 0.43  0.14 -0.35 0.63 0.83 
 Lag 2 17.4 -1.59 -3.99 0.88 0.0030  0.24 -0.24 0.72 0.25 
 5-d-aver. 13.5 -0.87 -2.28 0.55 0.15  0.60* 0.10 1.09 0.26 
aCRP: c-reactive protein; bGM: geometric mean, geometric mean is the antilog of arithmetic mean of log-transformed variable,  
cCI: confidence interval, dheterogeneity determined with χ²-test, α=10%; ePNC: particle number concentration;  fPM2.5: mass 
concentration of particles less than 2.5 µm in diameter; gPM10: mass concentration of particles less than 10 µm in diameter,  
hIL-6: interleukin 6,  iAM: arithmetic mean; *p<0.05; †p<0.1 
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Figure 9. Effect modification of fibrinogen (five day average exposure)  
by glycosylised haemoglobin (HbA1c). 
 
HbA1c level at baseline 
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5 DISCUSSION 
Data from the AIRGENE study, a large European multi-centre study on MI survivors, were used  
1. a) to confirm known associations between time-invariant patient characteristics and hs-
CRP concentrations,  
b) to extend the number of the characteristics published so far and  
c) to study the influence of the same parameters on the variation of hs-CRP, hypothesising 
that the diagnosis of certain diseases would be related to higher hs-CRP concentrations 
and a more pronounced variation. 
2. to examine the associations between hs-CRP and life-style parameters in the 24 hours 
before the blood draw, hypothesising that the consumption of tea and alcohol would lead 
to lower hs-CRP concentrations, while extreme stress or anger, active smoking and 
physical activity would show a positive association and 
3. to examine the association of hs-CRP concentrations and environmental parameters, 
especially particulate air pollutants, assuming a positive linear relationship. 
 
Hs-CRP values measured in the AIRGENE population were on average slightly higher than in 
other studies. Subsamples of the three population based MONICA/KORA studies from 
Augsburg, Glasgow and Lille, for example, showed median concentrations of between 1.30 mg/L 
(Glasgow and Lille) and 1.38 mg/L (Augsburg) (Imhof et al., 2004), while the median hs-CRP 
concentration in the whole AIRGENE population was 1.61 mg/L. Similar concentrations to those 
of the MONICA/KORA populations were also seen in about 4,000 middle aged men and women 
of the Swedisch Malmö Diet and cancer study (Rosvall et al., 2007). The slightly higher 
concentrations in these data might in part be explained by the fact that the AIRGENE population 
consisted of MI survivors, who are likely to have higher hs-CRP concentrations due to their 
disease history. Ridker et al. (Ridker et al., 1998d), for example, reported median concentrations 
of 3.1 mg/L in participants who subsequently had recurrent MI, while their age and sex matched 
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healthy controls had a median concentration of 2.8 mg/L. Moreover, Geffken et al. (2001) 
reported from a study of approximately 6,000 elderly US citicens, that people without clinical 
cardiovascular disease had significantly lower mean hs-CRP concentrations compared to 
participants with clinical cardiovascular disease.  
Considering the different regions of the AIRGENE study, the results of Imhof et al. (2004) for 
Augsburg are almost the same as for the AIRGENE Augsburg subsample. Also, the 
comparatively low levels for the Swedish and the relatively high concentrations for the Spanish 
subpopoulations in AIRGENE were seen in other studies (Garcia-Lorda et al., 2006; Rosvall et 
al., 2007). 
Some studies report mean values, rather than the median; however, these data more or less reflect 
the picture found for the median concentrations. Mean hs-CRP concentrations for the whole 
AIRGENE population was 2.59 mg/L and therefore higher than mean concentration in two large 
studies in healthy voluteers (Geffken et al., 2001; Sung, 2006). Population based data from the 
Greek ATTICA study (Panagiotakos et al., 2004) were again lower than the mean concentrations 
of the Greek subpopulation of AIRGENE, as were data from a Finnish study (Saltevo et al., 
2007).  
As hs-CRP usually shows a skewed distribution, values are often log-transformed for analyses 
and the antilog of arithmetic mean, the geometric mean, is reported. A log-transformation reduces 
skewness in the data (Bland et al., 1996). The geometric mean was 1.39 mg/L in the AIRGENE 
population. A comparison of geometric means from the MONICA studies in Augsburg, Glasgow 
and Lille with the geometric mean of the AIRGENE population showed that the geometric mean 
of MONICA Augsburg was lower than that of the whole AIRGENE population, while those of 
Glasgow and Lille were higher. Again, geometric means of patients with chronic cardiovascular 
disease were higher than for those without (Danesh et al., 2004; Hoffmeister et al., 2001; 
Tuomisto et al., 2006). 
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5.1 Determinants of hs-CRP concentration and variation  
Results of the AIRGENE data mostly confirmed previously published associations between time-
invariant patient characteristics and hs-CRP. In contrast to the initial hypothesis, the diagnosis of 
any of the diseases recorded in this study seemed not to be related to higher hs-CRP levels, with 
the exception of chronic bronchitis. Moreover, the variation of hs-CRP was significantly lower in 
patients with the studied co-morbidities, the only exceptions being the diagnosis of diabetes and a 
baseline level of HbA1c of at least 6.5%.  
A variety of studies have examined influences on the level of hs-CRP and most of the results are 
in line with the results from the AIRGENE dataset, such as for elevated BMI and obesity (Garcia-
Lorda et al., 2006; Greenfield et al., 2004; Sung, 2006; Thorand et al., 2006; Verdaet et al., 
2004), for smokers compared to non-smokers (Frohlich et al., 2003; Garcia-Lorda et al., 2006; 
Geffken et al., 2001; Verdaet et al., 2004) and for subjects with low HDL-cholesterol levels 
(Garcia-Lorda et al., 2006; Greenfield et al., 2004).  
While some investigators did not report any sex differences (Garcia-Lorda et al., 2006), others 
found lower concentrations in men consistent with the results from AIRGENE (Bowden et al., 
2006; Frohlich et al., 2003; Hutchinson et al., 2000; Imhof et al., 2004). Hutchinson et al. (2000) 
hypothesised that the sex difference might be due to oestrogen intake in women and a study on 
diabetic women showed significantly higher hs-CRP concentrations in those receiving HRT 
(Bowden et al., 2006). In the AIRGENE data, intake of HRT showed a slightly positive but non-
significant association with hs-CRP (data not shown), consistent with this hypothesis.  
As for the influence of age on hs-CRP concentrations, some authors found a positive linear 
relationship (Hutchinson et al., 2000) while a lack of association has also been reported 
(Greenfield et al., 2004). It appears that a U-shaped function, as seen in these data, has not been 
reported before; this could be due the way the relationships were modelled and/or to the fact that 
the AIRGENE data were based on MI survivors, while most studies have been conducted in the 
general population.  
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A higher variation in diabetic patients compared to non-diabetics was seen, however geometric 
mean hs-CRP concentrations did not differ significantly, in contrast to results of other authors 
(Pradhan et al., 2001). Subjects with elevated HbA1c (≥ 6.5%), an indicator of glucose control, 
however, showed higher hs-CRP concentrations and higher variation even in this comparatively 
homogeneous population of MI survivors. In this dataset, high levels of HbA1c seem to reflect 
uncontrolled rather than undiagnosed diabetes as 89% of those with HbA1c values above 6.5% 
reported a diagnosis of diabetes. Only half of the AIRGENE population diagnosed with diabetes 
on the other hand met the HbA1c criterion of 6.5%. This might indicate that metabolically stable 
diabetic patients are at less risk compared to unstable diabetics. 
No publication seems to deal with the association between hs-CRP and N-terminal proB-type 
natriuretic peptide (Nt-pro BNP), an indicator for left ventricular dysfunction. However, in 
patients with chronic heart failure a worse New York Heart Association classification was 
associated with higher concentrations of hs-CRP and Nt-pro BNP (Windram et al., 2007). 
Moreover, a study in patients with non-ST elevation acute coronary syndromes showed that 
Troponin T, NT pro-BNP and hs-CRP were predictors of risk for major events such as death, new 
acute coronary syndrome, revascularization and heart failure in a multivariate analysis. The 
authors followed that a multimarker approach based on Troponin T, hs-CRP and NT-proBNP 
provides a more accurate prognosis regarding acute coronary syndrome, with a worse outcome 
for those with two or three elevated biomarkers (Tello-Montoliu et al., 2007). These studies 
indicate, that hs-CRP and Nt-pro BNP have a positive association, as found in the AIRGENE 
population. 
None of the so far published works examines the within-patient variation of hs-CRP 
concentrations among different subgroups such as males and females or patients having certain 
medical conditions. Interestingly, the analysed data showed that an increase in geometric mean 
hs-CRP concentrations and a higher variation were not necessarily related. Subjects that reported 
angina pectoris, CHF or emphysema showed a lower variation compared to participants who did 
not report any of these disorders. These findings remained statistically significant even after 
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adjustment for multiple testing and associated medication intake. Emphysema is often caused by 
smoking (Petty, 2002) and in the AIRGENE population more than 80% of the emphysema 
patients were past or current smokers. As emphysema and early stage CHF do not necessarily 
include an inflammatory component, it is also conceivable that the lower variation of hs-CRP in 
these patients is merely a marker for a different mechanism, such as an underlying genetic 
component. Studies on twins have shown that there is a substantial genetic contribution to 
baseline hs-CRP concentrations (Pepys et al., 2003) and in genetical analyses of the Airgene 
dataset minor alleles of several variants in selected candidate genes such as CRP, Fibrinogen, IL-
6 and IL-10 were found to be significantly associated with intra-individual variation of hs-CRP 
concentrations (Kolz et al., 2007).  
Several studies, also in agreement with the data presented here, have shown that statin therapy 
reduces circulating hs-CRP (Albert et al., 2001a; Albert et al., 2001b; Libby et al., 2002; Ridker 
et al., 2001; Ridker et al., 2008; Rosenson et al., 2003). Clinical trials indicate that the proven 
efficacy of various compounds in primary and secondary prevention of coronary heart disease, 
such as statins and aspirin, may, at least in part, be mediated by modifying the consequences of 
the inflammatory response on vascular risk. In particular, additional non-lipid, anti-
atherothrombotic and anti-inflammatory effects have been suggested for some statins and the 
clinical benefit in several studies occurred too early to be explained simply by an impact on the 
atherosclerotic process (Rosenson et al., 1998). In addition to a change in the lipid profile, 
especially on the LDL cholesterol level, and an improvement in endothelial function, some statins 
reduce inflammatory cells within the plaque. This leads to increased plaque stability as fewer 
enzymes are produced which degrade the extra-cellular matrix and weaken the plaque. Moreover, 
statins improve the haemostatic balance due to a reduction in platelet aggregation and various 
coagulation factors such as tissue factor (Rosenson et al., 1998; Welty et al., 1997). Data from the 
Cholesterol and Recurrent Events (CARE) trial (Ridker et al., 1998d) showed that the relative 
risk of recurrent coronary events was highest in the group with consistent evidence of 
inflammation, indicated by hs-CRP and SAA levels above the 90th percentile, which was assigned 
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to placebo, while the lowest risk was found in the group of patients without signs of inflammation 
who were additionally on statins. The results also demonstrated that statin intake in the group of 
patients with high hs-CRP and SAA levels reduced the risk of a recurrent coronary event by 54% 
to the level of those on placebo but without inflammatory activity. Moreover, the JUPITER 
(Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) 
trial showed for the first time in a prospective study a beneficial effect of statin intake on 
cardiovascular endpoints in addition to reduced CRP and LDL cholesterol levels in people with 
elevated hs-CRP but LDL cholesterol below current treatment levels (Ridker et al., 2008). Further 
evidence has been found in studies indicating a decrease of IL-6 during treatment with some 
statins (Koenig, 1999; Rosenson et al., 1999). A reduction in IL-6 might then lead to a reduced 
production of CRP.  
In addition, CRP lowering effects have been seen with ASA (Ikonomidis et al., 1999), and ACE 
inhibitors (Soriano et al., 2007) however, in the AIRGENE data, associations were not 
significant. An increase in CRP in association with HRT has been reported (Cushman et al., 
1999; Ridker et al., 2000) and could be confirmed in this dataset.  
Cholesterol, which is transported in the form of lipoproteins, plays an important role in the 
development of atherosclerosis. LDL cholesterol serves as the principal carrier, and it provides an 
exogenous source of cholesterol and other cellular nutrients to hepatic and extra hepatic cells 
through LDL receptor-mediated uptake. Early stages of arterial lipoprotein modification, marked 
by generation of bioactive products of lipid peroxidation, can occur with little change in cellular 
receptor recognition. The uptake of these modified products facilitates the intracellular 
accumulation of lipoprotein-derived cholesterol and cholesteryl esters, characteristic of arterial 
foam cell formation, one of the first steps in the development of atherosclerotic lesions. HDL 
cholesterol, on the other hand, is a component of reverse cholesterol transport, which takes 
cholesterol back from extrahepatic tissues to the liver (Hajjar, 1997). Statin therapy has been 
shown to be associated with a regression of coronary artery disease, when LDL is substantially 
reduced and HDL is increased. This might indicate that statin benefits are derived from both 
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reductions in atherogenic lipoprotein levels and increases in HDL (Nicholls et al., 2007). Data of 
770 males of the AIRGENE population showed strong positive associations with CRP for total 
cholesterol and LDL cholesterol but no association for HDL cholesterol when parameters were 
added separately to the base model. HDL and total cholesterol had opposing associations with a 
stronger effect of total cholesterol on hs-CRP. Therefore, the negative association between HDL 
and hs-CRP only became apparent after adjusting the model for total cholesterol. Adjustment for 
LDL, on the other hand, weakened the association for total cholesterol and hs-CRP, while LDL 
cholesterol only showed significantly positive associations without adjustment for total 
cholesterol. In previous studies, HDL was negatively associated with hs-CRP concentrations 
while neither LDL nor total cholesterol showed significant associations, however, the methods 
used in these studies were slightly different to the one used here (Fredrikson et al., 2004; Garcia-
Lorda et al., 2006; Ryu et al., 2005).  
Whether different factors affect each other and, if so, how, remains speculative. It is possible that 
a combination of variables amplifies the variation although it is also conceivable that certain 
combinations of factors may reduce variation. Additionally, factors that are associated with a 
high variation could just be indicators for a different mechanism. For example, the increase in 
variation that was seen in our data in association with medication intake might be a direct effect 
of the medication itself. However, it is more likely that the high variation is due to the underlying 
disease which led to the prescription of the drug. 
5.2 Short-term influences on hs-CRP  
Regarding time-varying life-style parameters, results point in the expected direction for alcohol 
and tea consumption and active smoking, however they were not significant, possibly due to a 
lack of patients with a variation in those endpoints.  
In respect to tea and alcohol consumption, no publication seems to have addressed its effects 
within the 24 hours post-consumption. A slight decrease in hs-CRP in association with tea and 
alcohol intake was found; however the number of subjects that contribute to the effect was small, 
with only 260 patients reporting varying tea consumption and 500 reporting varying alcohol 
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intake. Several authors have shown a hs-CRP lowering effect of regular black tea (De Bacquer et 
al., 2006; Steptoe et al., 2007) and of moderate alcohol consumption (Imhof et al., 2004).  
Several studies have demonstrated that regular moderate to high exercise leads to a decrease in 
hs-CRP concentrations (Elosua et al., 2005; Pitsavos et al., 2007) although results are conflicting 
(Fontana et al., 2007), and some authors assign the detected negative association to a lower BMI 
in those who exercise rather than to a direct effect of physical activity on inflammatory markers 
(Elosua et al., 2005; Verdaet et al., 2004). Short term influences, however, have rarely been 
looked at. Research in sports medicine has examined the effect of extremely strenuous activities 
on inflammatory markers, among them hs-CRP, and studies report a positive association (Kim et 
al., 2007; Margeli et al., 2005). However, the reported studies were conducted in people whose 
activities, even for professional athletes, must be considered extreme, such as a 200 km footrace. 
A short immediate increase in hs-CRP six to eleven hours after physical activity was found in this 
population of MI survivors that quickly returns to baseline concentration. In contrast to these 
findings, a study in post-menopausal women, who conducted light to moderate physical activity, 
did not report any increase in hs-CRP one hour or 24 hours after exercise compared to baseline 
concentrations (Davis et al., 2007). Also, hs-CRP concentrations measured immediately and 48 
hours after a seven km hill race did not differ from baseline (Simpson et al., 2005). These 
conflicting results might be explained by differing level of exercise. It is also possible that they 
are due to different time frames used in the studies. Work on the time course of hs-CRP 
concentrations after surgical procedures showed a rapid increase starting six to eight hours after 
an operation, with the highest peak around 48 hours which returns to baseline between 72 and 
144 hours post intervention (Colley et al., 1983).  
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5.3 Response to environmental factors 
It is still unclear why some subjects develop cardiovascular diseases or suffer from an MI due to 
certain triggers while others do not. Heavy physical exertion (Albert et al., 2000; Mittleman et al., 
1993), extreme anger (Mittleman et al., 1995) and cocaine or marijuana use (Mittleman et al., 
1999; Mittleman et al., 2001) have been reported as causes for an acute MI. Also, environmental 
stimuli such as second hand tobacco smoke (Barnoya et al., 2005) noise (Babisch, 2006), 
meteorology (Medina-Ramon et al., 2006; Medina-Ramon et al., 2007; Morabito et al., 2005; 
Sarna et al., 1977) and air pollution (Lanki et al., 2006; Peters et al., 2001a) are associated with 
an increased risk for adverse cardiovascular events. It is conceivable that individuals with special 
characteristics react in a more pronounced way to environmental factors than others. A generally 
higher level of inflammatory markers, and/or a higher variation in inflammation might represent 
one possible explanation. 
A higher variation was seen in patients with elevated HbA1c and self reported type 2 diabetes. It 
is plausible, but speculative, that these subgroups also show a stronger reaction to environmental 
factors, e.g. a more pronounced inflammatory response.  
5.3.1 Air pollution and hs-CRP  
The current analyses are focused on the association between hs-CRP and air pollution as 
environmental parameter. Hs-CRP has been one of the first acute phase reactants to be examined 
in association with air pollution in literature. Increased concentrations have been shown during an 
air pollution episode in Germany in healthy men (Peters et al., 2001b) and for ambient PM10 
levels currently present in Europe (Seaton et al., 1999). Additionally, in a panel of coronary heart 
disease patients, an increase in hs-CRP above the 90th percentile was found in association with 
ambient particles with a lag of two days (Ruckerl et al. 2006) (Appendix IV). The AIRGENE 
dataset did not show any associations between the measured air pollutants such as PNC, PM2.5, 
PM10 or gaseous pollutants and hs-CRP; however IL-6 and fibrinogen concentrations were 
elevated in association with increased ambient particles (Ruckerl et al., 2007) (Appendix III). A 
possible explanation for the lack of association between hs-CRP and air pollution in these data 
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might be the widespread intake of statins in the AIRGENE population. It has been shown that 
statins reduce CRP through inhibition of its hepatic synthesis (Arnaud et al., 2005). IL-6, which is 
produced upstream to the production of CRP in the liver, is not affected by this compound. Also, 
fibrinogen has been implicated to be reduced by fibrates but not statins (Rosenson et al., 2001).  
This study, in line with many others (Albert et al., 2001a; Dubowsky et al., 2006; Ridker et al., 
2001; Rosenson et al., 2003), showed a clear negative association between statin intake and hs-
CRP concentrations (Peters et al., 2007). It can be hypothesised that the intake of statins 
attenuates the impact of environmental parameters and might therefore, in addition to 
recommended guidelines, be beneficial in certain particularly susceptible subgroups to avoid 
adverse cardiovascular effects of environmental stimuli. Zeka et al. (2006) reported evidence for 
a greater effect of black carbon on inflammatory markers among non-users of statins. However, 
more research in this area is clearly needed.  
5.3.2 Possible biological mechanisms  
The exact mechanisms linking the inhalation of ambient air particles to an acute exacerbation of 
cardiovascular disease are not completely understood (Brook et al., 2004). Increased 
concentrations of hs-CRP are known to predict cardiovascular events in healthy subjects (Pepys 
et al., 2003) and alveolar inflammation induced by particles may either directly or via oxidative 
stress lead to systemic inflammation with increased levels of blood coagulability, progression of 
atherosclerosis, and destabilization or even rupture of vulnerable plaques, resulting in acute 
ischemic events (Brook et al., 2004; Peters et al., 1997; Pope et al., 2004; Seaton et al., 1995; 
Seaton et al., 1999). Hs-CRP, even at lower than medically relevant concentrations, can be 
considered as a sensitive marker reflecting systemic inflammation caused by particles.  
In this dataset, in addition to a higher mean concentration in hs-CRP a higher variation in certain 
subgroups was found (Ruckerl et al., 2007 Appendix II) which might be one possible link for the 
reported associations between air pollution and adverse cardiovascular outcomes. Persistently 
elevated concentrations as well as acute changes in concentrations of inflammatory markers have 
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been associated with an increased risk of cardiovascular events in cohort studies (Koenig et al., 
1999; Ridker et al., 1997).  
MI patients were selected for this study, as it has been shown that individuals with certain 
diseases, such as diabetes and MI, have an enhanced susceptibility for air pollution related 
conditions, possibly due to a disease induced increased inflammatory burden (Bateson et al., 
2004; Brook et al., 2008; Goldberg et al., 2001; Zanobetti et al., 2001). In this dataset, mean hs-
CRP concentrations were not significantly higher in diabetic patients, but a higher variation was 
seen compared to non-diabetics. Furthermore, subjects with increased HbA1c (≥6.5%) showed 
higher hs-CRP concentrations and higher variation. 
Recent analyses demonstrate that diabetics seem to react especially strongly to environmental 
stimuli such as air pollution. O’Neill et al. (2007) report a positive association between air 
pollution and markers of inflammation in a panel of diabetic patients. Dubowsky et al. (2006) 
found that patients with diabetes, obese and especially individuals with metabolic syndrome 
showed stronger associations between air pollution and hs-CRP than subjects without any of 
these conditions. Results were similar for IL-6 (Dubowsky et al., 2006). However, the number of 
individuals was very limited in their analyses. In the AIRGENE dataset, analyses of effect 
modification showed that for fibrinogen associations were slightly higher and almost significant 
for the exposure to PM10 for patients with elevated HbA1c levels compared to patients with 
HbA1c levels below 6.5%. 
The biological mechanisms that apply to the association between air pollution and atherogenesis 
could also promote the development of diabetes. Insulin resistance, the main biological pathway 
that causes type 2 diabetes, is triggered by oxidative stress and proinflammatory mediators at the 
cellular and transduction level. Likewise, autonomic nervous system imbalance and impaired 
endothelial function can also lead to blunted insulin action. Air pollution is capable of causing 
such physiological responses (Brook et al., 2008). However, these hypotheses are still highly 
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speculative and more research on parameters that make a person especially prone to 
cardiovascular disease is needed. 
Hypothesised mechanisms also differ regarding different size fractions of ambient particles. PM10 
is suggested to affect the upper bronchi and therefore lead to an inflammation in the lung, 
whereas the smaller particles potentially transfer into the blood and start a systemic inflammatory 
response. According to Geiser (2002), UFP are rapidly translocated into the blood. It is therefore 
possible that the delay that has been observed in a previous study on hs-CRP and air pollution 
(Ruckerl et al., 2006) is due to the time needed to initiate the acute-phase response after a fast 
UFP translocation.  
5.4 Strengths and limitations of the study design 
The chosen study design, using repeated measurements per subject collected over a period of 
several months, has some unique features making it especially suitable for these analyses.  
Firstly, several repeated measurements per person lead to a more stable estimate of the average 
hs-CRP concentration for the evaluation of the patient characteristics that affect hs-CRP 
concentrations, compared to a single measurement. Although great care was taken in excluding 
blood samples that might have been influenced by a current cold or minor operation at the time of 
blood withdrawal, it is impossible to account for all possible parameters. The statitistical power, 
on the other hand, is weaker than it would be for the same amount of independent measurements.  
Variation in hs-CRP can only be determined if the dataset contains repeated measurements. For 
the analysis of time-variant life-style parameters, the advantage of the repeated measurement 
design lies in the fact that time invariant parameters are automatically controlled for. Possible 
confounders that do not or only slightly change in a period of months, such as sex, age or BMI 
and even unknown factors are accounted for by the study design as each person serves as his or 
her own control. A drawback is, however, that only those patients who report differing exposure 
over the course of the study add to the statistical power. 
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Very similar to the analyses of time-variant parameters, the analysis of air pollutants and hs-CRP 
uses the advantages of the repeated measurements design. While the time invariant parameters 
remain approximately the same, the exposure varies on different examination days. In contrast to 
the aforementioned analyses, subjects have little influence over the level of air pollution to which 
they are exposed.  
It has to be considered that the examined population consists of MI survivors, who differ from a 
healthy or otherwise diseased population. Therefore, the results of these analyses might not be 
generalisable to other population subgroups. Regarding the public health impact, however, MI 
survivors certainly need special attention as despite efficacious interventions to treat acute MI 
(1998a; 1998b; 2002; Freemantle et al., 1999; Latini et al., 1995) and despite declining secular 
trends over the last 25 years, these patients are still at increased risk for recurrent ischemic events 
and CHF. The occurrence of unstable angina and recurrent MI as well as of CHF is particularly 
high during the first half year after the index MI and decreases constantly during the following 
three to five years (Hellermann et al., 2003; Jokhadar et al., 2004; McGovern et al., 2001; 
Rosamond et al., 1998). Therefore, it is very well conceivable that during this vulnerable period, 
triggers such as stress, certain weather conditions or noise (Ising et al., 2004; Mittleman et al., 
1995; Willich et al., 2006) and also exposure to traffic (Peters et al., 2004) might provoke the 
onset of a new cardiac event. 
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6 CONCLUSION 
This work confirms and extends published results on the association between patient 
characteristics and intake of medication and hs-CRP levels in a panel of male and female MI 
survivors. None of the short-term parameters measured in this study seemed to influence hs-CRP 
concentrations. Moreover, in the AIRGENE dataset, ambient air pollution was not associated 
with hs-CRP concentrations, possibly due to a widespread intake of statins in the examined 
subjects.  
In addition, this study is the first to measure within-patient variation in hs-CRP concentration in a 
large study population. It was not possible to trace variation back to one single source in these 
data. Males, elderly individuals, smokers, and patients with increased HbA1c concentrations had 
greater intra-individual variation in repeated measurements of hs-CRP. Of these subgroups, 
elderly, smokers and patients with elevated HbA1c also showed a higher mean concentration 
compared to the reference group. For males, patients with a normal BMI, subjects without history 
of MI and hypertensives, data revealed lower mean concentrations but higher variation. This 
result might indicate that in patients with manifest cardiovascular disease, in particular after MI, 
several hs-CRP measurements may be necessary to adequately characterise their risk, especially 
in defined subgroups.  
The study only included MI survivors, so the conclusions are limited to this subgroup. MI 
survivors are at increased risk for recurrent ischemic events, primarily in the first six months after 
the MI, but also years later. They might therefore be especially vulnerable to environmental 
stimuli that can trigger acute events. However, whether the variation seen in subgroups of the 
study participants makes these patients additionally susceptible to adverse environmental 
variables needs further investigation. It would be interesting to see if the variation in hs-CRP 
found in MI survivors differs from the variation in healthy populations or patients with other 
diseases, such as diabetes. Like patients with cardiovascular disease, diabetics showed higher hs-
CRP concentrations compared to a healthy population. However, nothing is known about the 
variation of hs-CRP in these patients.  
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The effect of medication, especially statins, could not be examined in detail in this study, as 
almost 90% of the participants report an intake of statins. The lack of detectable associations for 
air pollution and hs-CRP, on the other hand may be attributed to exactly this widespread intake of 
statins in our population, which might suggest a protective effect against environmental, 
proinflammatory stimuli. However, to resolve the issue of whether a prophylactic intake of statins 
may protect certain subgroups from adverse environmental parameters, further research is 
needed.  
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Ambient air pollution has been associated with an increased risk
of hospital admission and mortality in potentially susceptible sub-
populations, including myocardial infarction (MI) survivors. The
multicenter epidemiological study described in this report was set
up to study the role of air pollution in eliciting inflammation in MI
survivors in six European cities, Helsinki, Stockholm, Augsburg,
Rome, Barcelona, and Athens. Outcomes of interest are plasma
concentrations of the proinflammatory cytokine interleukin 6 (IL-
6) and the acute-phase proteins C-reactive protein (CRP) and fib-
rinogen. In addition, the study was designed to assess the role of
candidate gene polymorphisms hypothesized to lead to a modifica-
tion of the short-term effects of ambient air pollution. In total, 1003
MI survivors were recruited and assessed with at least 2 repeated
clinic visits without any signs of infections. In total, 5813 blood
samples were collected, equivalent to an average of 5.8 repeated
clinic visits per subject (97% of the scheduled 6 repeated visits).
Subjects across the six cities varied with respect to risk factor pro-
files. Most of the subjects were nonsmokers, but light smokers were
included in Rome, Barcelona, and Athens. Substantial inter- and
intraindividual variability was observed for IL-6 and CRP. The
study will permit assessing the role of cardiovascular disease risk
factors, including ambient air pollution and genetic polymorphisms
in candidate genes, in determining the inter- and the intraindivid-
ual variability in plasma IL-6, CRP, and fibrinogen concentrations
in MI survivors.
Epidemiological research has indicated that ambient air pol-
lution is associated with an increase in mortality and morbidity
of respiratory and cardiovascular diseases (Katsouyanni et al.,
2001; Le Tertre et al., 2002; Zanobetti et al., 2003). Particulate
matter (PM) appears to be the air pollutant most consistently
associated with adverse health outcomes. The inhalable fraction
of ambient aerosols, measured as PM10 or PM2.5 (particles with
an aerodynamic diameter less than 10 μm or less than 2.5 μm),
is considered to be responsible for most of the adverse health
effects. The number of ultrafine particles (0.01 to 0.1 μm) in am-
bient air is hypothesized to be of particular concern (Wichmann
& Peters, 2000).
Coronary heart disease (CHD) is a common chronic health
condition in Western societies (Tunstall-Pedoe et al., 2000). Two
main pathological processes, namely atherosclerosis and throm-
bosis, lead to an acute coronary syndrome (ACS) such as unsta-
ble angina, non-ST-elevation myocardial infarction (NSTEMI),
or ST-elevation myocardial infarction (STEMI) (Naghavi et al.,
2003a, 2003b). The typical atherosclerotic lesion is a fibro-lipid
plaque composed of a pool of lipids covered with a connective
tissue cap (Ross, 1999). Although the plaque narrows the coro-
nary arteries, ACS only occurs when a plaque erodes, fissures,
or ruptures and a thrombus is formed that occludes the arteries,
partially or totally, and impedes blood flow. There is a strong
link between inflammation and CHD since factors involved in
inflammation and infection seem to play a pro-atherogenic role
and inflammation has been identified as a potent risk factor for
the ACS (Ross, 1999). Other risk factors such as cigarette smok-
ing, diabetes, or high body mass index (BMI) have also been
found to be associated with low-grade systemic inflammation
(Woods et al., 2000), providing a further link between inflam-
mation and ACS. On the other hand, factors alleviating systemic
inflammation, such as moderate exercise or weight loss, reduce
the risk of acute coronary events.
Acute-phase proteins, like C-reactive protein (CRP) or fib-
rinogen, have been identified as biomarkers for inflammatory
processes and are important determinants of plaque rupture
(Ridker et al., 2004). CRP may also exert direct pro-atherogenic
effects by various mechanisms (Pasceri et al., 2000). This classi-
cal acute-phase protein has now emerged as a reliable predictive
marker for cardiac events in patients with CHD and in healthy
individuals. Recently, its application in clinical practice has been
recommended by the American Heart Association and the Cen-
ters for Disease Control for subjects being at intermediate risk
of CHD (Pearson et al., 2003).
Ambient particulate matter has been associated with sys-
temic responses, including increases in CRP and fibrinogen
in healthy individuals in cross-sectional settings (Peters et al.,
2001; Schwartz, 2001; Pekkanen et al., 2000). Additionally, in
longitudinal studies changes in ambient particulate air pollu-
tion were associated significantly with changes in the CRP level
(Seaton et al., 1999; Ruckerl et al., 2006).
The multicenter epidemiological study described in this re-
port was set up to study the role of air pollution in eliciting
inflammation in MI survivors in six European cities (Figure 1).
Outcomes of interest are plasma concentrations of the proin-
flammatory cytokine interleukin 6 (IL-6) and the acute-phase
proteins CRP and fibrinogen. IL-6 is thought to play a major role
in mediating stimuli from activated macrophages for example by
smoking (Woods et al., 2000). IL-6 can stimulate the synthesis
of acute-phase proteins, such as CRP and fibrinogen (Figure 2).
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FIG. 1. Location of the study centers in Europe.
Fibrinogen was also considered a risk factor for its contribu-
tion to the formation of blood clots. In addition, the study was
designed to assess the role of candidate gene polymorphisms
hypothesized to lead to a modification of the short-term effects
of ambient air pollution.
METHODS
Study Design
A multicenter longitudinal study of MI survivors was per-
formed in six European cities—Athens (Greece, 3.1 million
inhabitants), Augsburg (Germany; 0.5 million inhabitants),
Barcelona (Spain; 1.5 million inhabitants), Helsinki (Finland;
0.5 million inhabitants), Rome (Italy; 2.7 million inhabitants),
and Stockholm (Sweden; 1.0 million inhabitants)—chosen to
include a variety of geographical conditions and air pollution
levels. At each location, the goal was to recruit 200 post-MI pa-
tients resulting in a study population of 1200 MI survivors. In
each subject 6 repeated clinical examinations were scheduled:
one every 4 weeks. Therefore, in total 7200 clinical examina-
tions were anticipated.
Study Population
Candidates for the study were identified in population reg-
istries of patients with MI [Augsburg (Lowel et al., 2005),
Barcelona, Stockholm] or in administrative databases of hospi-
tal admissions (Athens, Helsinki, Rome). They were contacted
either directly or through their hospitals, depending on the na-
tional ethical requirements.
MI was defined based on the recommendation by the Eu-
ropean Society of Cardiology/American College of Cardiology
Committee (2000). Inclusion criteria were (a) survival of a MI
between 3 mo and 6 yr before entry into the study, correspond-
ing to a MI in the years between 1997 and 2003, and (b) age
between 35 and 80 yr. Exclusion criteria were: (a) a myocar-
dial infarction and/or interventional procedure (PTCA, bypass
surgery) less than 3 mo before the beginning of the study; (b) not
resident in the study area; (c) an extended period of absence from
the study area planned during the study period; (d) any major
illness preventing patients from complying with the study proto-
col; (e) chronic inflammatory diseases and/or anti-inflammatory
medication modifying the biomarkers considered in the study;
and (f) only one or no valid blood sample available per patient. In
addition, if a patient had had a cold/flu, urinary-tract infection,
gastrointestinal infection, respiratory infection, or a surgery or
a major dental procedure in the 3 days before the clinical visit,
then the samples collected at that visit were excluded.
Preferably, currently nonsmoking MI survivors were re-
cruited. Ex-smokers had to have quit 3 months before the start
of the study to be considered as nonsmokers. But light current
smokers were accepted in some centers.
Field Study
All partners received approval of the study protocol by their
local human subjects committees. Informed consent was ob-
tained from all patients at the first clinical visit after a detailed
description of the study protocol.
Clinical Characterization at Baseline
The health status of each patient was assessed at the first visit
at the local study center. The cohorts were characterized with
respect to their cardiovascular risk factor profile. This part was
crucial in order to describe similarities and differences of the
cohorts recruited in the six locations.
The protocol included a history of CHD and other comorbidi-
ties. A baseline questionnaire assessed regular exercise, smok-
ing history, environmental tobacco smoke exposures, socio-
economic status, and alcohol intake. All medication taken was
recorded, including brand name, dose, and intake pattern. Clin-
ical measurements included a blood pressure measurement, the
determination of the BMI, and a resting 12-lead electrocardio-
gram (ECG). A blood serum sample was drawn to determine
serum lipids including total cholesterol, high-density lipoprotein
(HDL) cholesterol, and glycosylated haemoglobin (HbA1c).
Ethylenediamine tetraacetic acid (EDTA)–plasma samples were
collected to assess CRP, fibrinogen, IL-6, and N-terminal proB-
type natriuretic peptide (NT-proBNP, only at baseline). For DNA
analyses a single blood sample was collected in a 9-ml EDTA
tube for each participant at the first visit and stored at –80◦C until
samples were shipped on dry ice for DNA isolation to the lab-
oratory at the GSF-National Research Center for Environment
and Health in Neuherberg, Germany.
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FIG. 2. Role of inflammatory pathways in the development and exacerbation of coronary heart disease (adapted after (Woods
et al., 2000)).
Laboratory results outside the normal range and alarming
ECG or blood pressure measurements were reported to the pa-
tient through the local study center with the advice to see her
or his health care provider for repeated analysis and potential
treatment.
Repeated Clinical Visits
Each clinical visit was to be scheduled on the same day and
at the same time of the week to minimize the impact of circadian
variation and the impact of the day of the week. If the patient was
unable to comply with this criterion, another day of the week
was selected with an appointment at the same hour (plus/minus
1 h). If patients suffered from acute infections such as a cold or
influenza during the 3 days before the scheduled visit, exami-
nations were postponed or blood samples were excluded from
analyses.
At each clinical visit, an EDTA–plasma sample was collected
for inflammatory marker determination (CRP, fibrinogen, and
IL-6) and a short questionnaire was administered. Information
on time-varying factors such as smoking or the time of the
last meal was collected in a short questionnaire. A 7-day re-
call on medication intake was obtained. Venous blood samples
were taken in EDTA tubes according to standardized procedures.
Samples were cooled down and stored at 4◦C until further pro-
cessing, which was within 4 h after blood withdrawal. To obtain
plasma samples, EDTA–blood was centrifuged at 4◦C in a pre-
cooled centrifuge for 20 min at 2500 × g. The plasma was then
collected with a pipette and aliquots for analysis were prepared.
Plasma aliquots were stored in each study centre at –80◦C un-
til they were shipped on dry ice to the central laboratory in
Ulm, Germany. Blood samples were analyzed by means of a
commercial enzyme linked immunosorbent assay (ELISA) for
IL-6 (quantitative high sensitive IL-6 Immunoassay, RD Sys-
tems GmbH, Wiesbaden, Germany), immunonephelometry for
fibrinogen and high sensitivity CRP (Dade Behring Marburg
GmbH, Marburg, Germany). Blood samples from Athens did not
pass the quality assurance assessments for fibrinogen determina-
tions and therefore no fibrinogen data are available for this city.
In addition, most of the patients volunteered to keep a diary
during the course of the study on cardiovascular and respiratory
symptoms, overall health status, smoking behavior, physical ac-
tivity, and times spent outdoors, in traffic, or in rooms where
other people smoked.
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Air Pollution and Meteorological Data
Air pollution data from fixed monitoring sites representing
urban background concentrations were collected for each city
according to standard procedures already employed in several
European studies of air pollution (Katsouyanni et al., 1995).
Measurement of ambient concentrations of air pollutants con-
current with the clinical examinations was used to characterize
the population average exposures. Air pollution concentrations
include the traditional air pollutants such as gaseous pollutants
and particulate matter. In addition, particle number concentra-
tions (PNC) measurements were included by leveraging and
extending previous measurements (Aalto et al., 2005).
Hourly means of the gaseous air pollutants (CO, SO2, O3,
NOx, NO2) and of particles (PM10, PM2.5) and meteorologi-
cal variables (air temperature, relative humidity, air pressure)
were obtained through the city-specific air monitoring networks
and the meteorological services. If data was recorded locally
at smaller units, at least 50% of the data for 1 h needed to be
present in order for the hourly value to be considered useable.
For valid mean values over 8 or 24 h, at least 75% of the obser-
vations needed to be present. All pollutant data were calculated
for individual average exposures, thus taking the time of blood
withdrawal into account.
Genotyping
Genotyping of single-nucleotide polymorphisms (SNPs) and
one deletion/insertion variant was performed in selected candi-
date genes involved in the regulation of inflammatory responses,
which may potentially modify the susceptibility of individuals
to environmental exposures. To get the maximal information of
the genes, we have analyzed several DNA variants per gene. We
selected all haplotype tagging SNPs known at the time, possibly
functional SNPs as well as DNA variants showing an association
in other studies with CVD or related phenotypes.
Genotyping analyses were carried out by using the Mass-
ARRAY system (Sequenom, San Diego, CA) according to
Weidinger et al. (2005). Briefly, genomic DNAs were ampli-
fied by polymerase chain reaction (PCR) using HotStarTaq
DNA polymerase (Qiagen, Hilden, Germany). Genotyping as-
says were carried out using 5 ng genomic DNA. PCR primers
were used at 167 nM final concentrations for a PCR volume of 6
μl. The PCR conditions were a hot start at 95◦C for 15 min, fol-
lowed by denaturing at 95◦C for 30 s, annealing at 56◦C for 30 s,
extension at 72◦C for 1 min for 45 cycles, and finally incubation
at 72◦C for 10 min. PCR products were first treated with shrimp
alkaline phosphatase (SAP; Amersham, Freiburg, Germany) for
20 min at 37◦C to remove excess dNTPs and afterward for 10
min at 85◦C to inactivate SAP. ThermoSequenase (Amersham)
was used for the base extension reactions. Extension primers
were used at a final concentration of 5.4 μM in 10-μl reactions.
The PCR conditions were a hot start at 95◦C for 15 min, fol-
lowed by denaturing at 95◦C for 30 s, annealing at 56◦C for 30
s, extension at 72◦C for 1 min for 45 cycles, and finally incu-
bation at 72◦C for 10 min. All reactions (PCR amplification,
base extension) were carried out in a Tetrad PCR thermal cycler
(MJ Research). The final base extension products were treated
with SpectroCLEAN resin (Sequenom) to remove salts in the
reaction buffer. This step was carried out with a Multimek 96
channel autopipette (Beckman Coulter), and 16 μl of resin/water
suspension was added into each base extension reaction, making
the total volume 26μl. After rapid centrifugation (2000 rpm, 3
min) in an Eppendorf centrifuge 5810, 10 nl of reaction solu-
tion was dispensed onto a 384 format SpectroCHIP (Sequenom)
prespotted with a matrix of 3-hydroxypicolinic acid by using
a SpectroPoint nanodispenser (Sequenom). A modified Bruker
Biflex matrix-assisted laser desorption ionization–time-of-flight
mass spectrometer (Sequenom) was used for data acquisitions
from the SpectroCHIP. Genotyping calls were made in real time
with MassArray RT software (Sequenom).
Quality Assurance Measures for the Field Study
A study manual was developed describing the methods of
the study, including standardized operating procedures (SOPs)
for specific parts of the field study. The SOPs were developed
and approved by all centers. Questionnaires were translated into
the different languages by the local partners. A 2-day training
session in Augsburg instructed the investigators from the cen-
ters on the implementation of the SOPs in the field. Before the
field phase, the personnel who conducted the examinations were
trained locally on the basis of the study manual.
The progress of the field study, including patient recruitment,
training of the study personnel, and the number of clinical visits,
was continuously monitored. At each study center a site visit
was conducted by a scientist of the coordinating partner at the
beginning of the field phase. During this site visit, the study
components were assessed based on a questionnaire, deviations
were discussed with the local investigators, and procedures were
altered if necessary. The process was documented in a quality
assurance report available to all project partners.
RESULTS
Recruitment of Cohort
In total, 1003 MI survivors were recruited, who fulfilled the
inclusion and none of the exclusion criteria and had at least two
valid, repeated blood samples taken (Table 1). These were 84%
of the targeted 1200 patients. Fifty-eight patients had to be ex-
cluded because they did not fulfil the inclusion and exclusion
criteria (a–e). Based on the questionnaire data at the clinical vis-
its, we excluded 255 of 6068 collected blood samples. Blood
samples were excluded when patients had acute respiratory in-
fections or reported surgical procedures in the 3 days before the
clinic visit, since these could have severely altered the concen-
trations of the inflammatory markers. As a result, 69 patients
who had less than 2 valid blood samples remaining were ex-
cluded. Overall, 5813 plasma samples for inflammatory marker
determination were available, which represented 96.6% of the
scheduled six blood samples within 1003 patients. The average
number of repeated visits per study subject ranged from 4.5 in
D
ow
nl
oa
de
d 
B
y:
 [.
] A
t: 
08
:4
7 
4 
O
ct
ob
er
 2
00
7 
166 A. PETERS ET AL.
TABLE 1
Study description
Patients Patients fulfilling Patients with Percent of Blood
recruited for the inclusion and ≥2 usable blood Excluded Usable scheduleda samples:
baseline exclusion (a–e) samples (exclusion blood blood blood mean per
City Study period examinations criteria criterion f) samples samples samples patient
Helsinki 10.09.03–02.06.04 212 202 195 7 1155 99% 5.9
Stockholm 03.09.03–24.06.04 207 201 197 4 1168 99% 5.9
Augsburg 19.05.03–24.02.04 213 207 200 7 1144 95% 5.7
Rome 25.09.03–15.07.04 163 149 134 115c 741 92% 5.5
Barcelona 03.09.03–16.06.04 183 180 169 11 1119 110% 6.6
Athens 13.09.03–30.07.04b 151 132 108 111c 486 75% 4.5
Total 19.05.03–30.07.04 1129 1071 1003 255 5813 97% 5.8
aSix visits were scheduled for all patients included (column 5); however, some patients in Barcelona, Rome, and Stockholm had 7 or 8 visits.
bTwo additional visits on 11/03/05 and 17/03/05.
cBlood withdrawals were conducted in Rome and Athens even though patients had recorded infections to ensure compliance.
Athens to 6.6 in Barcelona. The study period was 9 to 11 mo in
all study centers starting earliest on May 19, 2003, in Augsburg
and ending latest on July 30, 2004, in Athens, with 2 additional
patient visits in spring 2005.
Baseline Characteristics of the Cohort
Table 2 presents the age and sex distribution of the study
participants. More women participated in the Nordic centers
Stockholm and Helsinki compared to the other centers. Partic-
TABLE 2
Baseline characteristics of 1003 myocardial infarction survivors from 6 European cities: Disease history
Helsinki Stockholm Augsburg Rome Barcelona Athens
Parameter N = 195 N = 197 N = 200 N = 134 N = 169 N = 108 p Value
Sex = male (%) 68.7 70.6 82.0 86.6 83.4 87.0 <.00011
Age (yrs)a 64.6 64.0 61.9 62.7 62.1 54.7 <.00014
(45–78) (38–76) (39–76) (39–79) (37–81) (38–75)
Myocardial infarction
First MI (%) 81.5 85.8 87.5 87.3 86.4 80.6 .371
Last MI to study (yrs)a 2.7 2.3 2.1 2.7 2.1 2.4 .00152
(0.6–5.8) (0.6–3.9) (0.5–3.4) (0.4–6.0) (0.4–5.9) (0.5–5.5)
MI in family history (%) overall
<.00011
Yes (mother and/or father) 47.7 44.7 30.5 29.1 20.7 34.3 <.00011
No 41.0 44.2 58.0 64.2 70.4 54.6 <.00011
Information incomplete 11.3 11.2 11.5 6.7 8.9 11.1 .70101
Self-reported history (%)b
Angina pectoris 39.0 47.7 21.0 27.6 29.6 41.7 <.00011
Arrhythmia 31.3 20.8 24.0 23.1 13.0 21.3 .00291
Congestive heart failure 14.9 16.2 13.0 6.0 1.8 5.6 <.00011
Hypertension 51.3 49.7 51.0 55.2 46.2 54.6 .731
Diabetes 21.0 18.3 17.5 17.2 23.7 21.3 .631
Any respiratory disease 7.2 6.6 10.5 22.4 13.6 6.5 <.00011
Hay fever 10.3 14.2 10.0 11.9 4.1 0 <.00013
Chronic renal disease 3.6 2.0 5.0 5.2 9.5 1.9 .0193
Arthrosis 18.5 21.8 17.5 34.3 30.2 1.9 <.00013
Note. Numbers in p value column represent: 1chi-square test, 2median test, 3Fisher’s exact test, and 4ANOVA.
aMean (range).
bEver doctor diagnosed.
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ipants had a similar age range; however, a higher proportion
of young men were recruited in Athens. The proportion of pa-
tients with first MI was similar across centers, but the mean time
since the last MI was shortest in Augsburg and Barcelona and
longest in Rome and Helsinki. Family history of MI was more
frequent in the Nordic countries. A history of angina pectoris was
more frequent in Athens and Stockholm. Diabetic patients were
distributed equally among study centers. A higher proportion of
patients in Rome reported a history of respiratory disease, but
frequency of symptoms at baseline and the use of medication
to treat respiratory diseases were not more frequent in Rome.
Therefore, the self-reported history may reflect the emphasis on
respiratory diseases at Columbus hospital, where the patients
had their baseline visit.
Regarding BMI, 70 to 80% of all participants were over-
weight or obese (Table 3). The proportion of obese subjects
ranged between 22% and 37% in the different cities. The best
scores with respect to total cholesterol and HDL to total choles-
terol ratio were observed in Barcelona and Stockholm, while the
lipid profiles were most disadvantageous in Athens. In addition,
Stockholm showed the lowest prevalence of HbA1c equal or
greater than 6.5%.
Only in Helsinki, Stockholm, and Augsburg was it possi-
ble to avoid recruiting current regular smokers and still reach
the recruitment goals in a reasonable time frame (Table 4).
Also, a history of smoking was more prevalent in the south-
ern European centers among current nonsmokers, particularly
Athens and Barcelona. Self-assessed health status ranged be-
tween “good” and “average,” but was best in Athens. Patients
from Athens and Barcelona reported the highest rates of inac-
tivity, and the highest proportion of physically active subjects
came from Augsburg. Low education was substantially rarer in
Stockholm than in other centers. However, one has to note that
the education was categorized separately by each center, so that
differences might also be attributable to the differences in defi-
nitions. Most of the participants were already retired at the time
of the study, with the highest proportion of working subjects in
Athens. The lowest alcohol consumption was seen among par-
ticipants in Athens, while the highest number of heavy drinkers
was observed in Augsburg. The majority of the patients were
treated with beta-blockers, ACE inhibitors, and lipid-lowering
drugs, as well as antithrombotic therapy with aspirin to prevent
recurrent myocardial infarctions (Table 5). Treatment was less
vigorous in Athens.
Repeated Measurements of Inflammatory Markers
The highest CRP levels were observed in Barcelona, while
the lowest were observed in Helsinki (Table 6). While IL-6 and
fibrinogen were also high in Barcelona, the other cities were
more comparable for these markers. Nevertheless, substantial
between-subject and within-subject variability was observed for
all three blood markers in all cities (Figure 3). CRP and IL-6 dis-
played more skewed distributions than fibrinogen. The propor-
tion of subjects whose CRP levels were always above 3 mg/L var-
ied between cities (6% in Athens, 14% Barcelona, 10% Rome,
7% Augsburg, 7% Helsinki, and 11% Stockholm). Similarly,
the proportion of subjects whose CRP concentrations varied be-
tween below and above 3 mg/L differed between centers (40%
in Athens, 52% Barcelona, 38% Rome, 39% Augsburg, 32%
Helsinki, and 38% Stockholm).
To check the reliability of the laboratory tests, blind dupli-
cates were sampled. During the follow-up examinations, an ad-
ditional EDTA- or citrate-monovette was scheduled to be filled
from the same butterfly or needle from every 30th patient. These
samples were assigned a special identification number but oth-
erwise were to be treated like all other samples. Results for the
original and the duplicate blood sample were compared in up to
35 samples. Overall, the coefficient of variation (CV) between
duplicate samples was smallest for the CRP measurements and
largest for IL-6 (Table 6). The lowest duplicate sample CV was
seen in Augsburg and the highest in Rome.
Genotyping
Based on literature research altogether 13 genes with 111 dif-
ferent SNPs were selected. The candidate genes were C-reactive
protein (CRP), interleukin 6 (IL6), fibrinogen alpha, beta, and
gamma (FGA, FGB, and FGG), interleukin 10 (IL10), inter-
leukin 18 (IL18), toll-like receptor 4 (TLR4), tumor necrosis
factor alpha (TNFa), lymphotoxin alpha (LTA), and the nuclear
factor kappa-B family (NFkB1, RELA, and NFkB1A). For NFkB1
and IL-10 some of the SNPs were not in the Hardy–Weinberg
equilibrium (HWE); therefore, some more SNPs were analyzed
that were in linkage disequilibrium (LD) with the originally
problematic SNPs. For NFkB1 also a deletion (NFkBdel) was
analyzed. For CRP a tri-allelic SNP was included as well.
Altogether 134 SNPs were genotyped. For 11 SNPs no assay
could be established or the assay did not provide valid results
(rs2227439, rs2066864, rs1554286, rs1800896, rs6703630,
rs360723, rs980455, rs1609993, rs4648050, rs2233411,
rs10782383). Three SNPs turned out to be monomorphic in the
investigated study population (rs2069830, rs6051, rs2066870)
and six had an allele frequency of less than 1% (rs2069860,
rs2070034, rs2070033, rs3093544, rs5744263, rs5030710). All
together, 114 SNPs were taken into the statistical analyses. The
average success rate was 99.1%.
For quality control, a sex determination was performed for
all samples by amplification of a partial sequence of the amel-
ogenin gene (AMELX). In addition, sex determination was per-
formed with validated genotyping assays as a second indepen-
dent method. Samples showing inconsistencies were excluded
from further analysis.
Negative controls were included in all assays. To con-
trol for reproducibility of genotyping data 30% of ran-
domly selected samples were genotyped in duplicate. The
discrepancy rate was 0.18%. Each SNP was tested for de-
partures from HWE by means of a chi-square test or
Fisher’s exact test depending on allele frequency. Seventeen
SNPs showed departures from HWE (rs2070011, rs10494879,
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TABLE 3
Baseline characteristics of 1003 myocardial infarction survivors from 6 European cities: Measured CHD risk factors
Helsinki Stockholm Augsburg Rome Barcelona Athens
Parameter N = 195 N = 197 N = 200 N = 134 N = 169 N = 108 p Value
Body mass indexa 28.6 27.6 28.7 27.7 28.8 28.8 .00394
(19.1–48.9) (17.5–43.2) (19.1–48.4) (19.0–39.4) (19.3–43.5) (20.8–46.3)
Body mass index
class (%)b
Overall
.08333
Underweight 1.1 2.0 1.5 1.5 1.2 0.1 0.723
Normal weight 19.5 25.4 14.5 20.9 16.6 15.7 0.101
Overweight 45.6 50.3 48.5 51.5 45.6 47.2 0.891
Obese 32.8 22.3 35.5 26.1 36.7 37.0 .0101
Systolic blood pressure
(mm Hg)a
139.9 137.6 128.4 134.7 129.5 136.1 <.00014
(93–209) (97–196) (84–198) (95–188) (81–196) (100–190)
Diastolic blood pressure
(mm Hg)a
79.5 80.4 78.1 77.6 77.4 82.3 .00104
(52–112) (53–112) (47–112) (54–114) (45–126) (6–122)
WHO/ISI blood
pressure categories
(%)c
Overall
<.00013
Optimal/normal/high
normal
49.7 54.3 73.5 56.7 69.2 53.7 <.00011
Mild/moderate
hypertensive
0.0 42.6 23.0 41.0 27.8 39.8 <.00011
Severe hypertensive 8.7 3.0 3.0 2.2 2.9 3.7 .04313
Blood biomarkers
determined at local
laboratories
Total cholesterol
(mg/dl)a
182.2 173.4 181.0 190.6 193.2 195.4 <.00014
(91.1–291.9) (96.7–324.7) (107.0–316.0) (12.0–321.0) (119.0–390.0) (92.0–293.0)
HDL cholesterol
(mg/dl)a
54.0 53.7 47.9 43.7 52.7 46.1 <.00014
(22.0–119.3) (30.9–116.0) (24.0–98.0) (25.0–87.0) (28.0–105.0) (24.0–87.0)
High ratio total
cholesterol/HDL
cholesterol (%)d
11.8 6.6 16.0 28.4 7.7 34.3 <.00011
HbA1c (%)a 5.9 5.0 5.6 5.4 5.1 5.8 <.00014
(4.7–9.2) (3.8–9.9) (4.7–9.8) (2.8–8.7) (3.8–9.8) (3.7–10.5)
HbA1c ≥ 6.5% (%)e 15.9 6.6 9.5 8.2 10.7 14.8 .0101
Note. Numbers in p value column indicate: 1chi-square test, 2median test, 3Fisher’s exact test, and 4ANOVA.
aMean and range in parentheses.
bGuidelines of German Society for Nutrition (DGE).
c1999 WHO/ISH Guidelines for the management of hypertension: “optimal/normal/high normal” systolic blood pressure (SBP) <140 mm
Hg or diastolic blood pressure (DBP) <90 mm Hg; “mild/moderate hypertensive” 140 mm Hg ≤ SBP <180 mm Hg or 90 mm Hg ≤ DBP
< 110 mm Hg; “severe hypertensive” 180 mm Hg ≤ SBP or 110 mm Hg ≤ DBP. The higher category applies when a patient’s systolic pressure
and diastolic blood pressure fall into different categories.
d
“High” ≥5 mg/dl.
eIndication for diabetes: HbA1c ≥ 6.5%.
rs3024496, rs6676671, rs3024491, rs1800890, rs2069827,
rs230521, rs3774956, rs3774964, rs1801, rs1020759, rs230498,
rs11722146, rs3091257, rs1799724, rs28362491). They were
kept in the data set because this study is investigating a patient
population.
Air Pollution
Concentration of ambient air pollutants and weather pa-
rameters are presented in Table 7. Concentrations of gaseous
as well as particulate air pollutants were higher in the
southern European countries than in the Nordic countries.
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TABLE 4
Baseline characteristics of 1003 myocardial infarction survivors from 6 European cities: CHD risk factors from questionnaire
Helsinki Stockholm Augsburg Rome Barcelona Athens
Parameter N = 195 N = 197 N = 200 N = 134 N = 169 N = 108 p Value
Smoking status (%) <.00013
Never smoker 39.5 29.9 31.0 25.4 14.2 10.2 <.00011
Ex or occasional smoker 59.0 69.5 69.0 65.7 72.8 51.9 .00191
Current smoker 1.5 0.5 0 9.0 13.0 38.0 <.00013
Packyears (cigarettes only)a 9.1 12.2 15.1 21.8 28.1 35.6 <.00012
(0–65.0) (0–73.8) (0–205.2) (0–171.8) (0–192.3) (0–174.0)
Physical activity (%)b Overall
<.00011
Inactive 18.5 7.6 4.0 28.4 42.0 47.2 <.00011
Partly active 19.0 17.3 13.0 14.2 5.9 10.2 .00521
Unregularly active 17.9 22.8 10.5 14.2 8.3 8.3 .00021
Regularly active 33.3 40.1 42.5 38.8 33.7 30.6 0.191
Trained 11.3 12.2 30.0 4.5 10.1 3.7 <.00011
Low education (%)c 26.2 10.7 24.0 23.1 35.5 28.7 <.00011
Employment (%) Overall
.00051
Full-time work 24.1 25.9 28.5 34.3 30.2 45.4 .00271
Part-time work 6.2 14.7 6.5 7.5 7.7 4.6 .0111
No work 69.2 59.4 65.0 58.2 62.1 50.0 .0201
Alcohol intake (%)d Overall
<.00011
None 14.4 7.1 14.5 19.4 17.2 36.1 <.00011
Moderate 76.9 80.7 65.0 67.9 69.2 53.7 <.00011
Heavy 8.7 12.2 19.5 12.7 13.6 10.2 .0371
Health status (%)e
Bad or very bad health 5.1 5.0 9.0 7.4 8.2 5.5 <.00013
Note. Numbers in p value column indicate: 1chi-square test, 2median test, 3Fisher’s exact test.
aMean and range in parentheses.
bSwiss Health Survey 2002.
cPatients were divided into pre- and postwar education according to their age and then center-specific cut points of education years
(sum of school years/professional training/college and university) were applied.
d
“None” 0 g/day, “moderate” <20 g/day for women and <40 g/day for men, “heavy” ≥20 g/day for women and ≥40 g/day for men.
eScale 1 (“excellent”) to 5 (“very bad”).
Nevertheless, sulfur dioxide concentrations were low in all
settings.
DISCUSSION
A group of MI survivors was recruited in six European cities
and characterized at baseline. Although recruitment was a major
challenge to all centers, 94% of the proposed 1200 MI survivors
were recruited and 84% could be included for analyses on the
repeated blood markers. Within patients included in the study,
follow-up was excellent as 97% of the scheduled blood samples
could be collected.
At the outset, the study attempted to recruit nonsmoking MI
survivors to control for additional exposures to particles by ac-
tive smoking and sidestream smoke. However, it only partly suc-
ceeded in restricting recruitment to this group. This may reflect
the prevalence of smoking in MI survivors in southern Europe.
Based on these characteristics and the highly demanding proto-
col, the study participants cannot be considered a random sample
of the population of MI survivors in the six cities.
The majority of patients were treated with lipid-lowering
agents, which stabilize atherosclerotic lesions and reduce
subsequent risk in MI survivors (Koenig, 2005). Statin use has
been implicated to reduce plasma CRP concentrations (Kathire-
san et al., 2006). In addition, patients were also taking systemic
anti-inflammatory medication for the treatment of other diseases
such as for example respiratory disease. A considerable propor-
tion of subjects still had high blood pressure in a standardized
setting, indicating that insufficient treatment of hypertension is
still prevalent even in this group of high-risk patients (Antikainen
et al., 2006).
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TABLE 5
Baseline characteristics of 1003 myocardial infarction survivors from 6 European cities: Treatment
Helsinki Stockholm Augsburg Rome Barcelona Athens
Parameter N = 195 N = 197 N = 200 N = 134 N = 169 N = 108 p Value
Beta blocker (%) 95 91 92 75 75 64 <.0011
ACE inhibitors (%) 50 51 72 81 59 52 <.0011
Calcium channel blockers (%) 14 22 15 26 21 29 .00551
Diuretics (%) 23 25 44 33 23 10 <.0011
Lipid-lowering medication (%) 85 89 90 83 86 74 .00391
Antithrombotic medication (%) 97 97 99 95 98 93 .0582
Other systemic anti-inflammatory
medication (%)
29.2 7.1 22.0 12.7 13.6 2.8 <.00011
Hormone replacement therapy
(women) (%)
8.2 4.6 1.5 0.0 0.0 0.0 <.00012
Note. Numbers in p value column indicate: p value from 1chi-squared test; 2 p value from Fisher’s exact test.
Interindividual variation with respect to the inflammatory
markers was quite high in all six study centers. Also, a
substantial proportion of the subjects had CRP concentra-
tions above 3 mg/L, which is considered to be associated
with a high risk for ACS (Koenig et al., 2004). Intraindi-
vidual variability for CRP and IL-6 was high within re-
peated visits, even in a city that indicated very low variabil-
ity in blind duplicated samples, such as Augsburg. Fibrinogen
TABLE 6
Repeated measurements of inflammatory markers based on 5813 blood samples collected from 1003 myocardial infarction
survivors from 6 European cities
Measured samples
Quality control
Number of Mean CV in
Number of duplicate duplicate
City Blood samples patients Mean Median Mean CVa (%) Median CVa (%) samples samples
CRP (mg/L)
Helsinki 1155 195 1.98 1.37 53.6 35.2 35 1.7
Stockholm 1168 197 2.86 1.59 52.0 42.6 10 4.1
Augsburg 1144 200 2.26 1.40 56.8 31.3 14 2.1
Rome 741 134 2.56 1.62 52.3 36.1 27 7.3
Barcelona 1119 169 3.52 2.17 59.3 35.9 16 1.5
Athens 486 108 2.52 1.49 55.9 36.7 0 —
Fibrinogen (g/L)
Helsinki 1155 195 3.76 3.69 9.5 8.3 35 6.0
Stockholm 1168 197 3.53 3.40 11.1 10.0 10 3.4
Augsburg 1144 200 3.34 3.27 9.0 7.4 14 2.5
Rome 741 134 3.24 3.12 14.5 14.0 27 11.2
Barcelona 1119 169 3.99 4.00 11.9 11.6 16 3.9
Athens — — — — — — — —
IL-6 (pg/mL)
Helsinki 1155 195 3.16 2.32 41.7 28.4 35 13.6
Stockholm 1168 197 2.67 2.07 37.5 38.2 10 23.4
Augsburg 1144 200 2.60 2.17 43.6 29.1 14 3.2
Rome 741 134 3.18 2.33 39.6 30.8 27 21.9
Barcelona 1119 169 3.58 3.01 48.4 29.0 16 6.8
Athens 486 108 3.19 2.53 49.4 30.2 0 —
aCoefficients of variation (CV) were calculated for the repeated measurements of the individuals.
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FIG. 3. Distribution of mean CRP, fibrinogen and IL-6 concentrations and person-specific coefficients of variation by city.
concentrations showed less interindividual as well as intra-
individual variability.
Strengths and Limitations
The study is based on a common protocol and SOPs applied
in six different European cities. Site visits were conducted to
ensure uniform procedures in all centers. The analyses of the
inflammatory markers were done in one central laboratory and
blinded duplicate samples monitored the variability of proce-
dures within centers.
The study was designed to assess the impact of ambient
air pollution in a large cohort of MI survivors and gene–
environment interactions. It applies a repeated measurement
design for assessing the impact of environmental time-varying
factors on inflammatory markers in a potentially susceptible
subgroup. The inflammatory markers assessed have a half-
life of 3 days or less. Therefore, the repeated measurements
taken once every 4 wk can be regarded as being uncorrelated
over time, but more similar within individuals than between
individuals.
Air pollution in all selected cities originates mostly from
motor vehicle traffic; the local weather conditions, population
density and mobility, and pollution control strategies also con-
tribute to the variability in the concentration of the pollutants
and their seasonal patterns. In some cities, long-range transport
plays an additional role in determining short-term variation in
air pollution concentrations (Vallius et al., 2005). The study was
conducted mostly in wintertime, when day-to-day variation is
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TABLE 7
24-Hour average concentrations of the ambient air pollution and weather parameters during the AIRGENE study period from 6
European cities
Helsinki, Stockholm, Augsburg, Rome, Barcelona, Athens,
05.09.03– 29.08.03– 14.05.03– 20.09.03– 29.08.03– 08.09.03–
02.06.04 24.06.04 24.02.04 15.07.04 16.06.04 30.07.04
Study perioda Mean 95th Mean 95th Mean 95th Mean 95th Mean 95th Mean 95th
Particle number
concentrations (PNC)
(1/cm3)
8534 15,077 9748 17,578 11,876b 25,135 35,450b 69,226 18,133b 36,526 20,589b 47,573
PM2.5(μg/m3) 8.2 19.4 8.8 19.1 17.4 29.3 24.5b 54.1 24.2b 62.7 23.0b 46.0
PM10 (μg/m3) 17.1 36.1 17.8 40.3 33.1 56.6 42.1 76.0 40.7b 88.7 38.5 64.6
CO (mg/m3) 0.31 0.46 0.29 0.43 0.58 1.00 1.40 2.47 0.59 0.92 1.48 3.23
NO2 (μg/m3) 28.6 49.8 18.6 32.6 40.0 61.2 67.0 90.8 50.5 79.6 50.1 73.0
NO (μg/m3) 12.5 40.7 4.9 15.5 30.0 80.4 65.7 164.0 37.7 88.4 41.8 144.6
SO2(μg/m3) 4.2 10.1 1.9 4.9 3.0 5.7 4.1 9.2 4.7 9.6 10.3 23.2
O3 (8-h average)
(μg/m3)
46.8 89.0 60.6 96.9 54.4 115.3 45.3 99.6 28.2 76.5 59.8 100.2
Air temperature (◦C) 3.1 14.7 4.7 15.1 10.2 25.1 13.4 23.9 15.2 23.2 17.6 29.3
Relative humidity (%) 76 91 82 94 69 92 80 95 67 86 67 84
aThe study period started 5 days before the first measurement because a priori air pollution concentrations up to 5 days before the blood
withdrawals were considered.
bData on less than 95% of the days available.
highest in European cities for all primary combustion-related
pollutants.
Adverse health effects of ambient air pollution on the gen-
eral population of the six cities have been documented; daily
concentrations of particulate matter and gases have been linked
to mortality (Katsouyanni et al., 1997, 2001; Touloumi et al.,
1994; Michelozzi et al., 1998) and to hospital admissions for
respiratory diseases (Anderson et al., 1997; Spix et al., 1998;
Sunyer et al., 1997; Ponka & Virtanen, 1994). Associations be-
tween daily levels of NO2, CO, SO2, PM10, and particle number
concentrations and hospital admissions for CHD, arrhythmias,
and congestive heart failure (CHF) have been found in Augsburg,
Barcelona, Helsinki, Rome, and Stockholm, separately and com-
bined (Michelozzi et al., 1999; D’Ippoliti et al., 2003; Forastiere
et al., 2005; von Klot et al., 2005; Sahu et al., 2006; Sunyer et al.,
2003). Data collected as part of the WHO-MONICA project in
Augsburg have previously been used to study the association
between air pollution and markers of inflammation which are
predictors of cardiovascular disease (Peters et al., 1997, 2000,
2001). In Helsinki, short-time variations in the concentration of
ultrafine particles have been shown to be associated with declines
in lung function among asthmatic adults (Penttinen et al., 2001)
and increases in the risk of ischemia during moderate exercise in
patients with CHD within the ULTRA project (Pekkanen et al.,
2002). By examining the effects of air pollutant concentrations
on inflammatory markers, this study explores possible pathways
that may help explain the aforementioned observed effects on
health outcomes (Brook et al., 2004; Schulz et al., 2005; Seaton
et al., 1995).
So far, only small studies were conducted to assess the asso-
ciation between ambient air pollution and inflammatory markers
(Ruckerl et al., 2006; Seaton et al., 1999; Riediker et al., 2004).
For example, Ru¨ckerl and colleagues studied 57 patients with
coronary artery disease collecting a total of 579 blood sam-
ples and showed associations between PM10 as well ultrafine
particles and inflammatory markers (Ruckerl et al., 2006). In
Helsinki, Stockholm, Augsburg, and Barcelona, each substudy
increased the number of subjects at least threefold and dou-
bled the number of blood samples, while Rome and Athens
might have not substantially increased power compared to earlier
studies (Ruckerl et al., 2006; Seaton et al., 1999; Riediker et al.,
2004). This large study has been designed to address the variabil-
ity of responses to elevated air pollution concentrations across
Europe and to detect potential susceptible subgroups based on
their genetic susceptibility for an aggravated inflammatory re-
sponse to external stimuli. In an ad hoc power calculation sub-
mitted with the proposal, it was estimated that the study had a
power of 0.80 to detect an association between air pollution and
inflammatory markers as previously reported with a p value of
.05 in subgroups based on SNPs with a frequency of 10% to
15%.
Selection of the study group is a critical point when setting
up a panel study. We chose MI survivors to study a susceptible
subgroup of the population (von Klot et al., 2005). However, cur-
rent treatment specifically with lipid-lowering medication may
counteract the hypothesized air pollution effects. This fact may
weaken our study, but at the same time it would be an impor-
tant fact that may have implications for risk assessments. Also,
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we aimed at including nonsmokers to minimize confounding
by acute smoking. However, that proved to be impossible in
southern Europe, where MI survivors do not quit smoking as
frequently as in northern Europe. Therefore, the analyses will
need to address the long-term as well as short-term impact of
active smoking. In addition, visits of patients were excluded due
to acute diseases that impact inflammation during the course of
the study, such as acute respiratory infections as well as an acute
hepatitis.
The study design makes possible the assessment not only of
short-term adverse health effects of air pollution and the poten-
tial role of genetic polymorphisms in modifying these effects,
but also of the roles of cardiovascular disease risk factors, in-
cluding genetic polymorphisms in candidate genes, in determin-
ing inter- and intraindividual variability in inflammatory marker
concentrations. However, cross-sectional between-city compar-
isons will be problematic as the participants are not a random
sample of the cities’ myocardial infarction survivors. The differ-
ences between the cities as documented in the baseline descrip-
tion in this article reflect a combination of differences in risk fac-
tor profiles between northern and southern Europe and of differ-
ences based on self-selection and different sampling strategies.
In the future, a follow-up of this patient cohort could permit an
evaluation of the role of variation in inflammatory marker con-
centrations as a risk factor in MI survivors. Previously published
studies have only measured inflammatory marker concentrations
once or twice and have assessed their role in predicting future
recurrent CHD events. However, the data collected as part of
this study will be useful in the assessment of repeated measure-
ments as predictors of future events. In addition, the study might
be able to assess the long-term risk associated with ambient air
pollution if further data on the continuing exposure at the place
of residence is collected.
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BACKGROUND: C-reactive protein (CRP), a sensitive
marker of the acute-phase response, has been associ-
ated with future cardiovascular endpoints indepen-
dently of other risk factors. A joint analysis of the role
of risk factors in predicting mean concentrations and
variation of high-sensitivity CRP (hsCRP) in serumhas
not been carried out previously.
METHODS: We used data from 1003 myocardial infarc-
tion (MI) survivors who had hsCRP measured
monthly up to 8 times and multivariate mixed effects
statistical models to study the role of time-variant and
-invariant factors on the geometric mean of and the
intraindividual variation in hsCRP concentrations.
RESULTS: Patients with 6.5% glycosylated hemoglo-
bin (HbA1c) had 26.2% higher hsCRP concentrations
(95% CI, 7.2%–48.6%) and 20.7% greater variation in
hsCRP values (P  0.0034) than patients with lower
baseline Hb A1c values (6.5%). Similar but less pro-
nounced differences were seen in patients with a self-
reported diagnosis of type 2 diabetes. hsCRP concen-
trations showed less variation in patients who reported
angina pectoris, congestive heart failure, or emphy-
sema (11.0%,24.9%, and41.6%, respectively, vs
patients without these conditions) but greater varia-
tion in males and smokers (24.8% and 27.3%, re-
spectively, vs females and nonsmokers). Exposures in
the 24 h before blood sampling, including exposure to
environmental tobacco smoke, alcohol consumption,
and extreme stress, did not have a major impact.
CONCLUSIONS: One or 2 hsCRP measurements may not
be sufficient to adequately characterize different pa-
tient groups afterMIwith similar precisions.We found
hsCRP concentrations to be especially variable in
males, smokers, and patients with increased Hb A1c
values.
© 2008 American Association for Clinical Chemistry
C-reactive protein (CRP),14 a sensitive marker of the
acute-phase response, has attracted increasing atten-
tion in recent years because many epidemiologic stud-
ies have shown consistent positive associations be-
tween high-sensitivity CRP (hsCRP) concentrations in
the peripheral circulation and the risk of future cardio-
vascular events, independently of established risk fac-
tors. Associations have been found with angina pecto-
ris (1 ) and “hard” coronary and cerebrovascular events
in men and women (2 ). Koenig et al. (3 ) reported an
almost 3-fold increase in the risk of a first major coro-
nary event for individuals in the highest quintile of the
hsCRP distribution in a random sample of initially
healthy men from the general population. These find-
ings have led to an ongoing discussion on whether
hsCRP should be measured routinely in individuals at
risk of cardiovascular disease (4 ). The CDC and the
American Heart Association recently recommended
that hsCRP bemeasured in individuals at intermediate
risk (as defined by the Framingham Risk Score), with
the assays to be performed on 2 samples from each
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person, fasting or nonfasting, taken approximately 2
weeks apart. In the case of an hsCRPmeasurement10
mg/L, indicating an acute inflammatory process, the
measurement should be discarded and repeated 2
weeks later (5 ). For routine screening, knowledge of
basic determinants of hsCRP concentrations is essen-
tial. Several determinants have been studied intensively
in the past, including nutrition (6 ), medication (2, 7–
10), smoking (11, 12), body mass index (BMI), and
physical activity (13–15); however, most of these stud-
ies relied on only 1 or 2 measurements per patient.
Only a few studies have examined factors acutely af-
fecting hsCRP concentrations (13, 14, 16) or the de-
gree of within-patient variation in hsCRP concentra-
tion. We used data from a large European study of
myocardial infarction (MI) survivors who had hsCRP
measured up to 8 times in an attempt to conduct, for
the first time, a joint analysis of the role of risk factors in
predicting the mean hsCRP concentration and the in-
traindividual variation in hsCRP. Given that clinical
practice may consider preventive measures based on a
single hsCRP measurement, this study may contribute
important additional information.
Materials andMethods
STUDY POPULATION
The AIRGENE study, a prospective longitudinal study
of post-MI patients, was performed in 6 European cit-
ies—Athens (Greece), Augsburg (Germany), Barce-
lona (Spain), Helsinki (Finland), Rome (Italy), and
Stockholm (Sweden). Candidates for the study were
identified from population registries of MI patients
[Augsburg—Cooperative Health Research in the
Augsburg Region (KORA) (17); Barcelona; Stock-
holm] or from administrative databases of hospital ad-
missions (Athens, Helsinki, Rome).MIwas defined ac-
cording to the Joint European Society of Cardiology/
American College of Cardiology Committee for the
Redefinition of Myocardial Infarction (18); the study
design has been described in detail elsewhere (19). In
brief, the study recruited patients 35–80 years of age
who had experienced an MI between 4 months and 6
years before the start of the study. Patients who had
undergone interventional procedures 3 months be-
fore the beginning of the study or who had chronic
inflammatory diseases were not included. Because
AIRGENE initially was a study of the health effects of
air pollution, the recruitment of current nonsmokers
was preferred, but the inclusion of smokers in some of
the centers was unavoidable. All study partners had the
study protocol approved by their local human-studies
committees, and written informed consent was ob-
tained from all patients. All methods used in the study
centers were conducted according to common stan-
dard operating procedures.
CLINICAL MEASUREMENTS
Patients were invited to participate in 6 to 8 clinical
visits at approximately monthly intervals betweenMay
2003 and July 2004. At the first visit, the patient com-
pleted a baseline questionnaire regarding comorbidi-
ties, regular exercise, smoking history, exposure to en-
vironmental tobacco smoke (ETS), socioeconomic
status, and alcohol intake. Data recorded regarding
medication intake included brand names, doses, and
intake pattern. Clinical measurements included blood
pressure and BMI, and a serum sample was taken to
assess baseline serum lipids, glycosylated hemoglobin
(Hb A1c) (an indicator of glucose control), and N-
terminal pro-B-type natriuretic peptide (a marker of
hemodynamic stress).
Each clinical visit was scheduled at the same time
of the day and on the same day of the week tominimize
the impact of circadian andweekly variation. If patients
had acute infections such as a cold or influenza during
the 3 days preceding the scheduled visit, examinations
were postponed or the blood samples were excluded
from analyses.
The patient was asked to recall medication intake
for the previous 7 days at each clinical visit and to com-
plete a short questionnaire about time-varying vari-
ables in the previous 24 h, such as active and passive
smoking, physical activity, perception of extreme stress
or anger, consumption of alcohol and black or green
tea, and the time of the latest meal before blood draw.
Venous blood samples for preparing EDTA-
plasma for hsCRP measurement were drawn while the
patient was sitting. Samples were cooled and stored at
4 °C for further processing within a maximum of 4
hours. EDTA-containing blood was centrifuged for 20
min at 2500g in a centrifuge precooled to 4 °C. Plasma
aliquots were shipped on dry ice to the central labora-
tory inUlm, Germany, andwere stored at80 °C until
analysis. Blood samples were analyzed for hsCRP by
latex-enhanced immunonephelometry on a BNII ana-
lyzer (Siemens). The interassay CVs for hsCRP were
4.3%, 6.2% and 4.5% at hsCRP concentrations of 1.17
mg/L, 2.38 mg/L, and 13.5 mg/L, respectively.
STATISTICAL ANALYSES
All statistical analyses were performed with the Statis-
tical Analysis System (SAS) software package (Version
9.1 for Windows; SAS Institute).
We calculated hsCRP CVs as described by Bland
and Altman (20) and Fraser and Harris (21). We used
the SAS MIXED procedure to compute estimates of
between- and within-individual variances, assuming
nested normal random-effects models. These compo-
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nents of variation were then transformed into corre-
spondingCVs,whichwere calculated as the square root
of the respective variance-component estimates di-
vided by the overall mean and then expressed as
percentages.
Determinants of mean hsCRP concentrations. hsCRP
data required log-transformation to fulfill the model
assumption of residual normality; therefore, concen-
tration results are given as the geometric mean. To es-
timate the effect of various determinants on the geo-
metric means of hsCRP concentrations, we used
mixed-effects models with random patient effects ac-
counting for repeatedmeasures. Because the half-life of
hsCRP is 19 h (22) and thereforemuch shorter than the
intervals between visits, we assumed a compound sym-
metry structure for the covariance matrix to model the
correlation between repeatedmeasures in each patient.
Penalized splines (P-splines) in the additive mixed-
model framework allowed for nonparametric expo-
sure–response functions (23).
We first built a confounder model (base model),
which included preselected time-invariant patient
characteristics, to permit the assumption of a normally
distributed random patient intercept.We tested a wide
range of variables known from the literature to have a
possible influence on hsCRP, such as city, age, sex, and
BMI. Linear variables were added linearly to themodel.
The decision on whether a specific factor remained in
the model was based on the goodness-of-fit according
to Akaike’s information criterion.
In a second step, additional time-invariant vari-
ables not initially considered for the base model (such
as reported diseases, regular medication intake, and
smoking history) as well as time-varying variables,
such as physical activity or alcohol consumption in the
24 h before the blood draw, were added to the base
model, always one at a time. To avoid overcontrol, we
removed pack-years of smoking from the base model
when we analyzed smoking status, and we removed
Hb A1c for the analysis of diabetes. Variables that de-
scribed a time difference, such as the time of the lastmeal
before the blood sampling, were categorized into 4 inter-
vals of 6 h each: 0–5 h, 6–11 h, 12–17 h, and 18–23 h
before sampling. Results are given as the percent change
in the geometric mean of the hsCRP concentration.
Determinants of hsCRP variation. To calculate differ-
ences in variation, we used the MIXED procedure in
SAS with the “repeated/group ” statement, which
calculates thewithin-patient variation, and a “random/
group ” statement, which allows for different inter-
cepts in the defined groups, representing the between-
patient variation. A likelihood-ratio test was used to
determine if the differences between the groups were
statistically significant. Linear variables were catego-
rized beforehand, usually with interquartile ranges. Re-
sults are given as variance estimates of log-transformed
hsCRP concentrations, with between-individual and
within-individual results presented separately (Fig. 1),
and as the relative difference (in percent) in within-
individual variation compared with the reference
group (see tables).
To account for the large number of statistical tests,
we corrected the significance level of the P value to
0.00125, which equals a Bonferroni correction for 40
variables.
Sensitivity analyses. We conducted sensitivity analyses
for comorbidities that might be associated with the in-
take of certain medications and used a 2 test to evalu-
ate possible associations between comorbidities and
medication intake. If we found an association (P 
0.05), we adjusted the multivariable model for the re-
spective medication to investigate whether the comor-
bidity effect was altered by includingmedication in the
model. Moreover, we calculated a model that included
most of the presented variables to identify those vari-
ables that led to the greatest increase in variation.
Results
STUDY POPULATION
In total, 1003 patients with at least 2 valid blood sam-
ples participated in the study. Of the 6068 collected
samples, 255 had to be excluded because of acute infec-
tions or surgical procedures that occurred shortly be-
fore the clinic visit. Overall, 5813 plasma samples
remained for analysis (see Table 1 in the Data Supple-
ment that accompanies the online version of this article
at http://www.clinchem.org/content/vol55/issue2).
Table 2 in the online Data Supplement summa-
rizes the patient characteristics by center, and Table 3
in the online Data Supplement presents the patient
characteristics according to sex. Mean hsCRP concen-
trations were highest in Barcelona and lowest in Hel-
sinki; however, hsCRP concentrations were not excep-
tionally high on average. In 75 samples, the hsCRP
concentrationwas lower than 0.16mg/L, and these val-
ues were set at 0.16 mg/L. More details are given else-
where (19). The CV was 107% of the overall mean
within individuals and 139% between individuals.
ASSOCIATION BETWEEN TIME-INVARIANT VARIABLES AND hsCRP
Base model. Table 1 shows the associations of patient
characteristics with the geometric mean of the hsCRP
concentration and its variation, as estimated jointly
from the base model. Male participants had signifi-
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Fig. 1. Variation in mean hsCRP concentration between (upper panel) and within (lower panel) individuals for
separate hsCRP measurements made over time.
Variance component values are presented according to patient characteristics (sex, CHF diagnosis, HDL cholesterol concentra-
tion, body weight, and chronic bronchitis). Error bars represent 95% confidence limits.
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Table 1. Association of time-invariant variables with the geometric mean of and the variation in hsCRP
concentration—multivariate base model.
Variable n
Change
from
GM,a %
95% Confidence
limits, %
P,
mean
Variation
(difference from
reference group),
%
P,
variationLower Upper
City
Athens 108 29.54 43.46 12.19 0.002 12.4 0.0007b
Augsburg 200 25.95 36.83 13.19 0.0002 19.8
Barcelona 169 9.80 7.61 30.48 0.29 14.9
Helsinki 195 26.44 37.27 13.75 0.00016b 6.5
Rome 134 13.52 27.74 3.50 0.11 4.1
Stockholm 197 Ref Ref
Sex
Male 788 13.28 23.78 1.34 0.03 24.8 0.0001b
Female 215 Ref Ref
Age, yearsc
50 115 28.07 6.26 54.35 0.009 25.5 0.0001b
50–59 271 Ref Ref
60–69 348 18.13 3.39 34.97 0.014 27.8
70 269 28.26 10.45 48.95 0.001 37.2
BMId,e
Linear: per 5-kg/m2 increase 999 37.80 29.69 46.43 0.0001b —
Obese 316 86.02 59.97 116.31 0.0001b 45.8 0.0001b
Overweight 483 33.76 16.51 53.57 0.0001b 19.9
Normal 189 Ref Ref
Underweight 11 33.83 59.49 8.10 0.099 74.8
Number of MIs
2 150 13.10 2.15 30.73 0.010 18.5 0.0027
1 853 Ref Ref
Smokingc,e,f
Linear: per 25–pack-year increase 1002 16.31 9.65 23.38 0.0001b —
30.75 Pack-years 228 48.04 26.94 72.64 0.0001b 1.1 0.082
30.75 Pack-years 470 16.45 3.17 31.44 0.014 5.0
Never smoker 304 Ref Ref
Hb A1c
c
High (6.5%) 108 26.24 7.23 48.61 0.005 20.7 0.0034
Low (6.5%) 868 Ref Ref
Log-transformed NT-proBNPc,e
Linear: per 2.7-ng/L increase 995 38.43 20.61 58.89 0.0001b
5.98 (ng/L) 498 26.58 7.69 49.41 0.004 4.4 0.0001b
4.47–5.97 (ng/L) 497 3.26 9.53 17.86 0.64 34.2
4.47 (ng/L) Ref Ref
Total cholesterolc,e
Per 1.03-mmol/L increase 998 15.53 9.60 21.79 0.0001b —
High (6.46 mmol/L) 60 30.07 15.44 46.55 0.0001b 6.1 0.052
At risk (5.17–6.46 mmol/L) 249 23.85 0.11 53.56 0.051 8.7
Low (5.17 mmol/L) 689 Ref Ref
a GM, geometric mean; Ref, reference; NT-proBNP, N-terminal pro–B-type natriuretic peptide.
b Statistically significant after adjusting for multiple testing (  0.00125).
c Measured at baseline.
d BMI classification according to the WHO (2000).
e Base model including the linear variable.
f Categories correspond to interquartile ranges.
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cantly lower hsCRP concentrations than female partic-
ipants but had greater variation over time in log hs-
CRP concentration (Fig. 1). This difference was less
pronounced after controlling for the intake of hor-
mone-replacement medications in women. We found
a U-shaped relationship for age with the lowest hsCRP
concentration in the age group of 50–59 years (Fig. 2),
whereasmost other associationswere linear. A separate
analysis showed that this effect was mainly driven by
the results for men; women had a positive linear asso-
ciation between hsCRP concentration and age (data
not shown). In contrast, hsCRP variation was greatest
in the oldest patient group. Overweight and obese pa-
tients (24) had higher hsCRP concentrations than par-
ticipants with normal weights, but the concentrations
in these patients were less variable (Fig. 1). Hb A1c con-
centrations6.5% were positively associated with the
geometricmean of and the variation in hsCRP concen-
tration, whereas a diagnosis of type 2 diabetes was pos-
itively associated with the variation but not with the
geometric mean (Table 2). hsCRP concentrations were
also positively associated with higher concentrations of
N-terminal pro–B-type natriuretic peptide and total
cholesterol.
Additional time-invariant variables and hsCRP. Tables
2 and 3 summarize the associations of hsCRP concen-
tration with disease history, lifestyle, and medication
intake. A family history of MI was associated with
slightly higher hsCRP concentrations. On the other
hand, hsCRP concentrations showed less variation in
patientswho reported angina pectoris, congestive heart
failure (CHF), emphysema, or a family history of MI
(Fig. 1), and these results remained statistically signifi-
cant after adjusting formultiple testing. Time since last
MI did not show any association with the geometric
mean of or the variation in hsCRP concentration (Ta-
ble 2).
Habitual physical activity did not influence hs-
CRP concentrations; however, the variation in hsCRP
concentration seemed to be higher in inactive people
and lower in those whowere partially active, compared
with regularly active study participants. HDL choles-
terol was inversely related to the geometric mean of the
hsCRP concentration; greater variation in hsCRP con-
centration was noted in patients with increased HDL
cholesterol concentrations (Table 3).
Patients reporting the intake of statins or other
lipid-lowering drugs had lower hsCRP concentrations
and less variation. On the other hand, patients taking
angiotensin-converting enzyme inhibitors had greater
variation in hsCRP concentrations, whereas the geo-
metricmeanwas negatively associatedwithmedication
intake (Table 3). Use of acetylsalicylic acid or Ca2-
channel blockers did not affect the geometric mean of
or the variation in hsCRP concentration.
Table 4 summarizes the results for different smok-
ing-related variables. Twenty-five pack-years of smok-
ing produced an increase of approximately 16% in the
Fig. 2. Smooth spline of log hsCRP concentration [f(age)] on patient age in 1003 MI patients from the AIRGENE
study, after adjustment for all of the variables in the base model.
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geometric mean of the hsCRP concentration, and in-
clusion of smoking status in the model had little effect
on this result. Including pack-years of smoking, how-
ever, removes the borderline effect for ex-smokers that
we found in themodel that does not include pack-years
of smoking. Examination of the effects of smoking and
ETS exposure revealed a heterogeneous picture. Cur-
rent regular smokers and nonsmokers who reported
regular ETS exposure had higher hsCRP concentrations,
whereas occasional smokers seemed to have lower hsCRP
Table 2. Association of disease history with the geometric mean of and the variation in hsCRP concentration,
adjusted for the variables of the base model.
Variable n
Change
from
GM,a %
95% Confidence
limits, %
P,
mean
Variation
(difference from
reference group),
%
P,
variationLower Upper
Type 2 diabetes (excluding
Hb A1c from the model)
b
Yes 198 4.22 8.50 18.70 0.53 11.57 0.0052
No 805 Ref Ref
Angina pectorisb
Yes 344 2.54 8.08 14.39 0.65 11.0 0.0001c
No 658 Ref Ref
CHFb
Yes 104 2.83 13.66 22.48 0.75 24.9 0.0001c
No 899 Ref Ref
Emphysemab
Yes 23 17.19 16.64 64.75 0.36 41.6 0.00024c
No 980 Ref Ref
Family history of MI
1 Parent 353 12.49 0.48 25.94 0.04 20.5 0.0001c
No 547 Ref Ref
Time since last MI
Per increase
in 1 year
1003 0.22 4.76 4.54 0.93 —
3 years 266 13.70 17.04 55.83 0.42 6.51 0.15
2.9–1.5 years 481 8.75 9.37 30.49 0.37 0.38
1.5 years 256 Ref Ref
Strokeb
Yes 62 2.77 21.78 20.86 0.80 1.6 0.094
No 941 Ref Ref
Hypertensionb
Yes 511 8.32 17.18 1.48 0.093 6.3 0.061
No 492 Ref Ref
Chronic bronchitisb
Yes 67 36.47 10.97 67.81 0.003 2.7 0.65
No 936 Ref Ref
Asthmab
Yes 47 16.81 7.58 47.64 0.19 9.5 0.15
No 956 Ref Ref
a GM, geometric mean; Ref, reference.
b Ever physician-diagnosed.
c Statistically significant after adjusting for multiple testing (  0.00125).
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Table 3. Association of lifestyle factors and medication intake with the geometric mean of and the variation in
hsCRP concentration, adjusted for the variables of the base model.
Variable n
Change
from
GM,a %
95% Confidence
limits, %
P,
mean
Variation
(difference from
reference group),
%
P,
variationLower Upper
Health status
Excellent/good 592 10.46 1.13 23.39 0.08 6.5 0.067
Moderate 342 Ref Ref
Poor/very poor 68 33.06 7.71 64.36 0.008 11.2
Physical activity
Inactive 219 7.06 7.16 23.46 0.35 7.0 0.0011b
Partly or irregularly active 280 3.09 8.51 16.16 0.62 13.1
Regularly active/trained 504 Ref Ref
HDL cholesterol (adjusted for
total cholesterol)c
Per increase in 0.39 mmol/L 998 8.15 13.90 2.03 0.0010b —
0.91 mmol/L 884 16.78 29.73 1.45 0.033 36.0 0.0001b
91 mmol/L 114 Ref Ref
Lipid-lowering drugs (all)
Yes 858 11.51 20.21 1.87 0.021 19.25 0.0001b
No Ref Ref
Statins
Yes 841 11.17 19.81 1.61 0.023 19.33 0.0001b
No Ref Ref
ACE inhibitors
Yes 606 15.29 22.96 6.85 0.0006b 19.21 0.58
No Ref Ref
Systemic antiinflammatory
medication
Yes 234 9.34 17.91 0.12 0.05 28.23 0.0001b
No Ref Ref
Acetylsalicylic acid
Yes 878 1.52 12.59 10.95 0.80 7.34 0.0001b
No Ref Ref
Diuretics
Yes 277 12.59 1.94 24.36 0.020 0.26 0.0001b
No Ref Ref
Ca2-channel blockers
Yes 184 2.22 9.49 15.43 0.72 2.07 0.014
No Ref Ref
Beta-blockers
Yes 845 0.60 12.16 12.49 0.92 10.52 0.18
No Ref Ref
Hormone-replacement therapy
(women only)
Yes 28 18.65 8.83 54.41 0.20 15.23 0.014
No Ref Ref
a GM, geometric mean; Ref, reference; ACE, angiotensin-converting enzyme.
b Statistically significant after adjusting for multiple testing (  0.00125).
c Measured at baseline.
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concentrations thannonsmokersnot regularly exposed to
cigarette smoke. The results were not statistically signifi-
cant,however, especiallywhenpack-yearsof smokingwas
included in themodel. The numbers of participants were
low in several of the groups (Table 4).
ASSOCIATION BETWEEN TIME-VARYING VARIABLES AND hsCRP
Time-varying variables had either no or a small in-
fluence on hsCRP concentration (Fig. 3A). Recent
alcohol consumption and extreme stress or anger
were associated with lower geometric-mean hsCRP
Table 4. Association of smoking and ETS exposure with the geometric mean of and the variation in hsCRP
concentration, adjusted for the variables of the base model.
Variable n
Change
from
GM,a %
95% Confidence limits, %
P,
mean
Variation
(difference from
reference group),
%
P,
variationLower Upper
Pack-years of smoking:
excluding smoking
status from the
model
Linear: per increase
of 25 pack-years
1002 16.31 9.65 23.38 0.0001b —
Pack-years of smoking:
including smoking
status in the model
Linear: per increase
of 25 pack-years
1002 14.88 7.59 22.67 0.0001b —
Smoking status:
excluding pack-years
of smoking from the
model
Current smoker
(regular/occasional)
16.33 5.91 43.85 0.16 10.9 0.095
Ex-smoker 627 19.67 5.97 35.16 0.004 2.4
Never smoker 277 Ref Ref
Smoking status:
including pack-years
of smoking in the
model
Current smoker
(regular/occasional)
99 4.59 15.75 29.83 0.68 10.9 0.116
Ex-smoker 627 5.97 7.32 21.16 0.40 2.2
Never smoker 277 Ref Ref
Smoking status and
ETS exposure:
excluding pack-years
of smoking from the
model
Current regular
smoker
72 23.68 2.19 56.38 0.08 27.3 0.0001b
Occasional smoker 27 27.94 47.63 0.86 0.04 24.6
Not current smoker,
constant ETS
exposure
136 9.57 6.31 28.14 0.25 9.9
Not current smoker,
no constant ETS
exposure
767 Ref Ref
Smoking status and
ETS exposure:
including pack-years
of smoking in the
model
Current regular smoker 72 15.23 8.79 45.59 0.23 26.8 0.0001b
Occasional smoker 27 21.20 42.66 8.29 0.14 25.0
Not current smoker,
constant ETS
exposure
136 6.50 8.81 24.38 0.43 10.3
Not current smoker,
no constant ETS
exposure
767 Ref Ref
a GM, geometric mean; Ref, reference.
b Statistically significant after adjusting for multiple testing (  0.00125).
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concentrations, but the results were not statistically
significant. Whereas physical activity over the previ-
ous 24 h showed no association with hsCRP concen-
tration (Fig. 3A), physical activity between 6 and 11
hours before blood draw was associated with in-
creased hsCRP concentrations (Fig. 3B). For the
other time-varying variables, no such time-specific
effects were seen.
Fig. 3. Association between log hsCRP concentration and various variables (5813 visits in 1003 AIRGENE patients).
(A), Associations between log hsCRP concentration and lifestyle factors 24 h before blood draw. (B), Associations between log
hsCRP concentration and physical activity in 6-h intervals before blood draw. ref, reference. Error bars represent 95% confidence
limits.
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SENSITIVITY ANALYSES
Additional adjustment for medication did not change
the results for comorbidities (data not shown).
With very few exceptions, the results for the vari-
ationmodel that included all variables at the same time
did not differ much from those described in the pre-
sented tables. The results revealed the largest increases
in hsCRP variation for patients with HDL cholesterol
concentrations0.91mmol/L, an older age (especially
70 years), male sex, a log B-type natriuretic peptide
concentration of 5.98 (ng/L), and intake of anti-
inflammatory medication (data not shown).
Discussion
We investigated repeated measurements of hsCRP in a
population of MI survivors and found that the varia-
tion in hsCRP concentration within patients over time
was only slightly less than the variation between
patients. Moreover, our data revealed that certain sub-
groups had higher geometric-mean hsCRP concentra-
tions and/or greater variation in the hsCRP concentra-
tion, but higher geometric means and greater variation
did not necessarily occur together. Obese and over-
weight patients and certain age groups had higher
hsCRP concentrations but less variation in concentra-
tion. We also found that patients who reported angina
pectoris, emphysema, or CHF had less variation in
hsCRP concentration, whereas the geometric-mean
concentration did not seem to be affected.On the other
hand, for patients with impaired glucose control, as
indicated by increased baseline Hb A1c concentrations
(6.5%), we found a higher hsCRP concentration and
greater hsCRP variation. We saw similar but less pro-
nounced differences for the diagnosis of type 2 diabe-
tes. Short-term exposures in the 24 h preceding blood
draw, such as ETS exposure, alcohol consumption, or
extreme stress or anger, did not have amajor impact on
hsCRP concentration. This study examined MI pa-
tients only, and therefore the results may not be en-
tirely generalizable to a population without cardiovas-
cular disease.
PATIENT CHARACTERISTICS THAT AFFECT hsCRP
CONCENTRATION AND ITS VARIATION
A variety of studies have examined determinants of
hsCRP concentrations. Although some investigators
did not report any sex differences (25), others found
lower concentrations in men (6, 7, 11, 26), in line with
our results. Hutchinson et al. (26) hypothesized that
the sex difference might be due to estrogen intake in
women, and a study of diabetic women has shown sig-
nificantly higher hsCRP concentrations in patients re-
ceiving hormone-replacement therapy (7 ). Our data
revealed that intake of hormone-replacement medica-
tions had a slightly positive but nonsignificant associa-
tion with hsCRP concentration (Table 3), a result that
is consistent with this hypothesis.
As for the influence of age on hsCRP concentra-
tions, some authors have found a positive linear rela-
tionship (26), but a lack of an association has also been
reported (12). As far as we know, a U-shaped function,
as seen in our data, has not previously been reported.
This observation could be due to the way the relation-
ships were modeled and/or to the fact that our data
were based onMI survivors, whereasmost studies have
been conducted with participants from the general
population.
Consistent with our results, others have reported
positive associations of hsCRP concentration with in-
creased BMI and obesity (12, 15, 25), for smokers
compared with nonsmokers (11, 25), and for individ-
uals with lowHDL cholesterol concentrations (12, 25).
Several studies have shown that statin therapy (9, 10)
and treatmentwith angiotensin-converting enzyme in-
hibitors (27) reduce circulating hsCRP concentrations,
results that are in line with our findings. Moreover,
hsCRP–lowering effects have also been seen with ace-
tylsalicylic acid (8 ). Although our findings were con-
sistent with a small reduction in hsCRP concentration
due to acetylsalicylic acid, these associations were not
statistically significant.
To our knowledge, none of the previously pub-
lished studies examined variation in hsCRP concentra-
tion over time among different subgroups or with re-
spect to possible determinants. Interestingly, we found
that an increase of and greater variation in hsCRP con-
centration were not necessarily related. Individuals
who reported angina pectoris, CHF, or emphysema
had less variation in hsCRP concentration compared
with participants who did not report any of these dis-
orders. These findings remained stable for CHF and
emphysema, even after adjustment for multiple testing
and associated medication intake. Emphysema is often
caused by smoking (28), and our data showed that
80% of the emphysema patients were past or current
smokers. Because emphysema and early-stage CHF do
not necessarily include an inflammatory component, it
is also conceivable that the lower variation in hsCRP
concentration in these patients is merely amarker for a
different mechanism, such as an underlying genetic
component. Studies of twins have demonstrated a sub-
stantial genetic contribution to baseline hsCRP con-
centrations (29), and genetic analyses of the AIRGENE
data set revealed thatminor alleles of several variants of
selected candidate genes were significantly associated
with intraindividual variation in hsCRP concentration
(30).
Whether different factors affect each other and, if
so, how they do remain speculative. It is possible that a
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combination of variables amplifies hsCRP variation,
although it is also conceivable that certain combina-
tions of factors can reduce such variation. Additionally,
factors that are associated with high variation could
just be indicators for a differentmechanism. For exam-
ple, the increase in variation associated with medica-
tion intake seen in our data might be a direct effect of
the medication itself; however, it is more likely that the
high variation is due to the underlying disease that led
to the prescription of the drug.
RESPONSE TO ENVIRONMENTAL FACTORS
It is still unclear why some patients develop cardiovas-
cular disease or experience an MI due to certain trig-
gers, whereas others do not. Heavy physical exertion
(31) and extreme anger (32) have been reported as
causes for an acute MI. In addition, environmental
stimuli such as tobacco smoke (33) and air pollution
(34, 35) are associated with an increased risk for ad-
verse cardiovascular events. It is conceivable that indi-
viduals with special characteristics react in a more pro-
nounced way to environmental factors than others. A
generally higher concentration of inflammation mark-
ers, and/or greater variation in inflammationmight of-
fer one possible explanation.
We found that patients with increasedHbA1c con-
centrations and patients with self-reported type 2 dia-
betes have greater variation in hsCRP concentration,
even in this relatively homogeneous population of MI
survivors. It is plausible, but quite speculative, that
these subgroups also had a stronger reaction (e.g., a
more pronounced inflammatory response) to environ-
mental factors. Studies of diabetic patients (7 ) have
shown considerably higher mean hsCRP concentra-
tions than our population, which consisted of only
about 20% diabetic individuals. Persistently increased
hsCRP concentrations as well as acute changes in con-
centrations of inflammation markers have been as-
sociated in cohort studies with an increased risk of
cardiovascular events (2, 3 ). This observation might
represent a possible link for the reported associations
of air pollution and passive smoking with adverse car-
diovascular outcomes, because particle-induced sys-
temic inflammation is one of the hypothesized path-
ways (33, 36). Individuals with certain diseases, such as
diabetes and MI, have been demonstrated to have an
enhanced susceptibility for air pollution–related con-
ditions, possibly due to a disease-induced increased in-
flammatory burden (37).We did not see higher hsCRP
concentrations in diabetic patients, but we did observe
greater variation in hsCRP concentration compared
with nondiabetic patients. Furthermore, patients with
increased Hb A1c concentrations (6.5%) had higher
hsCRP concentrations and greater hsCRP variation.
High Hb A1c concentrations seem to reflect uncon-
trolled rather than undiagnosed diabetes, because 89%
of the participants with Hb A1c values6.5% reported
a diagnosis of diabetes. On the other hand, only half of
the AIRGENE population with diagnosed diabetes met
the Hb A1c criterion of6.5%. This finding might in-
dicate that metabolically stable diabetic patients are at
less risk comparedwith patients with unstable diabetes.
Our study is in line with others (10) in showing a
clear negative association between statin intake and
hsCRP concentration. We hypothesize that the intake
of statins attenuates the impact of environmental vari-
ables, and therefore statin therapy in addition to fol-
lowing recommended guidelinesmight be beneficial in
certain particularly susceptible subgroups to avoid ad-
verse cardiovascular effects of environmental stimuli.
More research in this area is clearly needed, however.
SHORT-TERM INFLUENCES ON hsCRP
Several studies have demonstrated that regular moder-
ate to vigorous exercise leads to a decrease in hsCRP
concentrations, although the results are conflicting and
some authors have attributed the detected negative as-
sociation to a lower BMI in the individuals who exer-
cise rather than to a direct effect of physical activity on
inflammation markers (38). Short-term effects, how-
ever, have been studied only in individuals whose ac-
tivities must be considered extreme, even for profes-
sional athletes (16). Although our population of MI
survivors were expected to perform in only light sport-
ing activities, we found a transient increase in hsCRP
concentration 6 to 11 hours after physical activity that
quickly returned to baseline concentrations. A study of
postmenopausal women did not observe any increase
in hsCRP concentration at 1 h or 24 h after exercise,
compared with baseline concentrations (13). In addi-
tion, hsCRP concentrations measured immediately
and 48 h after a 7-km hill race did not differ from base-
line concentrations (14). These conflicting results
might be explained by different time frames and differ-
ences in exercise intensities. A study of the time course
of hsCRP concentration after surgical procedures
showed a rapid increase starting 6 to 8 hours after the
operation, with the highest peak at about 48 h and the
concentration returning to baseline between 72 h and
144 h after the surgical intervention (39).
Regarding tea and alcohol intake, no publication
has addressed the effects on hsCRP within 24 h after
consumption. We found a slight decrease in hsCRP in
association with tea and alcohol intake; however,
whether this result reflects regular consumption or an
immediate reaction is difficult to determine. Adecrease
in hsCRP concentration after regular consumption of
black tea (40) and moderate amounts of alcohol (6 )
has been shown.
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Conclusion
This study is the first to measure within-patient varia-
tion in hsCRP concentration in a large study popula-
tion. We confirmed and extended published results on
the association of patient characteristics and intake of
medications with hsCRP concentrations in male and
female MI survivors. Short-term influences, however,
did not seem to impact hsCRP concentrations. Males,
elderly individuals, smokers, and patients with in-
creased Hb A1c concentrations had greater intraindi-
vidual variation in repeated measurements of hsCRP.
In patients with manifest cardiovascular disease, in
particular after MI, several hsCRP measurements may
be necessary to adequately characterize their risk, espe-
cially in defined subgroups.Whether this variation also
makes these patients more susceptible to adverse envi-
ronmental variables needs further investigation.
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Research
Ambient air pollution has been associated
with cardiovascular mortality (Forastiere et al.
2005; Peters et al. 2000; Schwartz and
Dockery 1992) and hospital admissions for
various cardiovascular diseases (Burnett et al.
1997; Schwartz 1999). Also, an elevated risk
for acute myocardial infarction (MI) (Lanki
et al. 2006; Peters et al. 2001a) and cardio-
respiratory symptoms (de Hartog et al. 2003)
has been reported in relation to air pollution.
Some studies have suggested that patients
with preexisting coronary heart disease
(CHD) (Goldberger et al. 2001) might be a
particularly susceptible population.
The exact mechanisms linking the inhala-
tion of ambient air particles to an acute exac-
erbation of cardiovascular disease are not
completely understood (Brook et al. 2004).
Alveolar inflammation induced by particles
may either directly or via oxidative stress lead
to systemic inﬂammation with increased lev-
els of blood coagulability, progression of
atherosclerosis, and destabilization or even
rupture of vulnerable plaques, resulting in
acute ischemic events (Brook et al. 2004;
Seaton et al. 1995). 
So far, studies using repeated measures to
assess the association between ambient air
particles and inﬂammatory markers have had
controversial results. In addition, they have
been conducted only on a small scale, with
samples sizes ranging from 9 to 112 (Riediker
et al. 2004; Ruckerl et al. 2006; Seaton et al.
1999). In larger studies, however, associations
have been based on single blood measure-
ments (Zeka et al. 2006), and the examined
populations have encompassed healthy and
diseased subjects, covering a variety of dis-
eases. All these differences might explain the
conﬂicting results. 
For interleukin 6 (IL-6), hypothesized to
play a central role in the triggering of the
inflammatory process (Woods et al. 2000),
associations with high levels of particulate
matter (PM) < 10 μm in aerodynamic diameter
(PM10) have been shown (van Eeden et al.
2001), although a study in elderly subjects in
the United Kingdom (Seaton et al. 1999) did
not reveal signiﬁcant associations with ambi-
ent PM10. The present study was designed to
address the responses of IL-6, ﬁbrinogen, and
C-reactive protein (CRP) to elevated air pollu-
tion levels in a large cohort of MI survivors
across Europe. We were particularly interested
in MI survivors because they are especially
prone to a progression of atherosclerosis and
adverse cardiovascular events. 
Materials and Methods
Study population. A prospective longitudinal
study of post-MI patients was performed in
six European cities—Athens (Greece),
Augsburg [Germany, KORA (Cooperative
Health Research in the Augsburg Region)
(Lowel et al. 2005)], Barcelona (Spain),
Helsinki (Finland), Rome (Italy), and
Stockholm (Sweden)—chosen to include a
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BACKGROUND: Numerous studies have found that ambient air pollution has been associated with
cardiovascular disease exacerbation. 
OBJECTIVES: Given previous findings, we hypothesized that particulate air pollution might induce
systemic inflammation in myocardial infarction (MI) survivors, contributing to an increased vulner-
ability to elevated concentrations of ambient particles. 
METHODS: A prospective longitudinal study of 1,003 MI survivors was performed in six European
cities between May 2003 and July 2004. We compared repeated measurements of interleukin 6
(IL-6), fibrinogen, and C-reactive protein (CRP) with concurrent levels of air pollution. We col-
lected hourly data on particle number concentrations (PNC), mass concentrations of particulate
matter (PM) < 10 µm (PM10) and < 2.5 µm (PM2.5), gaseous pollutants, and meteorologic data at
central monitoring sites in each city. City-specific confounder models were built for each blood
marker separately, adjusting for meteorology and time-varying and time-invariant covariates. Data
were analyzed with mixed-effects models. 
RESULTS: Pooled results show an increase in IL-6 when concentrations of PNC were elevated
12–17 hr before blood withdrawal [percent change of geometric mean, 2.7; 95% confidence inter-
val (CI), 1.0–4.6]. Five day cumulative exposure to PM10 was associated with increased fibrinogen
concentrations (percent change of arithmetic mean, 0.6; 95% CI, 0.1–1.1). Results remained sta-
ble for smokers, diabetics, and patients with heart failure. No consistent associations were found
for CRP.
CONCLUSIONS: Results indicate an immediate response to PNC on the IL-6 level, possibly leading
to the production of acute-phase proteins, as seen in increased fibrinogen levels. This might provide
a link between air pollution and adverse cardiac events.
KEY WORDS: air pollution, C-reactive protein, CRP, epidemiology, fibrinogen, IL-6, inflammation,
myocardial infarction, ultrafine particles. Environ Health Perspect 115:1072–1080 (2007).
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variety of geographic conditions and air pol-
lution characteristics [see Appendix 1 for par-
ticipants; see Supplemental Material (http://
www.ehponline.org/docs/2007/10021/
suppl.pdf) for data]. The study design is
described in detail elsewhere (Peters et al.,
in press). In brief, we recruited patients
35–80 years of age who had experienced an
MI between 4 months and 6 years before the
start of the study. Patients with MI or inter-
ventional procedures < 3 months before the
beginning of the study or with chronic recur-
ring inflammatory diseases such as Crohn’s
disease were not included. 
Preferably, current nonsmokers were
recruited. All partners approved the study pro-
tocol at their local human subjects commit-
tees, and written informed consent was
obtained from all patients. All methods used
in the study centers were conducted according
to common standard operating procedures. 
Clinical measurements. Patients were
invited to participate in six to eight clinical
visits between May 2003 and July 2004. The
visits were scheduled every 4–6 weeks on the
same weekday and at the same time of the
day to minimize the impact of weekly and
circadian variation. At the first visit, a base-
line questionnaire was administered regard-
ing health status, medication intake, and
smoking history. Blood pressure and body
mass index (BMI) were measured and a
blood serum sample was drawn to assess
baseline serum lipids, glycosylized hemo-
globin (HbA1c; an indicator of diabetic sta-
tus) and N-terminal proB-type natriuretic
peptide (NT-proBNP; an indicator for left
ventricular dysfunction). 
At each clinical visit a 7-day recall on medi-
cation intake was obtained. Venous ethylene-
diamine tetraacetic acid (EDTA)–plasma
samples were collected for the determination of
the inflammatory markers. Samples were
cooled and stored at 4°C until further process-
ing within a maximum of 4 hr. The EDTA-
blood was centrifuged at 4°C in a precooled
centrifuge for 20 min at 2,500 × g. Plasma
aliquots were shipped on dry ice to the central
laboratory in Ulm, Germany, and were stored
at –80°C until analysis. Blood samples were
analyzed by means of a commercial enzyme-
linked immunosorbent assay (ELISA) for IL-6
(quantitative high sensitive IL-6 immunoassay;
RD Systems GmbH, Wiesbaden, Germany)
and immunonephelometry for ﬁbrinogen and
high-sensitivity CRP (Dade Behring Marburg
GmbH, Marburg, Germany). Because CRP
and ﬁbrinogen concentrations were measured
by a fully automated assay, only single meas-
urements were available, except for results
above and below the detection limit, which
were double-checked. Within- and between-
patient variability for a number of blood sam-
ples that were tested as quality assurance
measures are described elsewhere (Peters
et al., in press).
Air pollution and meteorologic data. Air
pollution data from fixed monitoring sites
representing urban background concentra-
tions were collected for each city according to
standard procedures already employed in sev-
eral European studies of air pollution (Aalto
et al. 2005; Katsouyanni et al. 1996). We
obtained hourly means of particles [black
smoke (BS), black carbon (BC), mass concen-
tration of PM10, and mass concentration of
particles < 2.5 μm in diameter (PM2.5)],
gaseous air pollutants (carbon monoxide, sul-
fur dioxide, ozone, nitric oxide, nitrogen
dioxide) and meteorologic variables (air tem-
perature, relative humidity, barometric pres-
sure, dew point temperature) through
city-specific air monitoring networks and
meteorologic services. If data were recorded
locally at smaller units, at least 50% of the
data for 1 hr needed to be present for the
hourly value to be considered useable. For
valid 8- or 24-hr mean values, at least 75% of
the observations needed to be present. Particle
number concentration (PNC) measurements
as indicator for ultrafine particles were per-
formed using condensation particle counters
(CPC; 3022A; TSI, Shoreview, MN, USA) in
all centers.
Missing data on the aggregate level
were replaced using a formula adapted from
the APHEA (Air Pollution and Health—A
European Approach) method (Katsouyanni
et al. 1996) [see Supplemental Material
(http://www.ehponline.org/docs/2007/
10021/suppl.pdf)]. We calculated apparent
temperature by using the formula of
Steadman (1984) and Kalkstein and Valimont
(1986).
We used moving averages of ambient
concentrations of air pollutants and mete-
orogic variables to characterize the exposures
by calculating the individual 24-hr average
exposure for each person immediately pre-
ceding the clinical visit (lag 0) up to 4 days
(lag 1–lag 4). In addition, we calculated the
mean of lags 0–4 for the air pollution data
and the mean of lags 0 and 1, the mean of
lags 2 and 3, the mean of lags 0–3, and the
mean of lags 0–4 for the meteorologic
variables, if at least half of the relevant lags
were available.
Statistical analyses. Analytical strategy.
Given previous ﬁndings, we hypothesized that
particulate air pollution induces systemic
inflammation. Specifically, we assumed that
IL-6 would increase in association with
increased levels of ambient particle concentra-
tions of the preceding or same day, because
immediate effects on IL-6 have been shown
before (van Eeden et al. 2001), and the
cytokine has a very short half life (2–6 hr)
(Riches et al. 1992).
We also hypothesized that an acute-phase
response involving de novo synthesis of pro-
teins in the liver would require an induction
time of 1–2 days. This would translate to an
increase in ﬁbrinogen concentrations with ele-
vated particle concentrations of the previous
5 days [half-life 2–3 days (Thomas 1998)]
and an increase in CRP in association with
ambient particle concentrations 2–3 days
before blood withdrawal [half-life 19 hr
(Koenig et al. 2003)]. Similar results have
been shown in previous studies (Ruckerl et al.
2006; Seaton et al. 1999).
Statistical model. We analyzed data using
mixed-effects models with random patient
effects accounting for repeated measures.
Because the half-lives of the markers were
much shorter than the intervals between vis-
its, we assumed a compound symmetry struc-
ture for the covariance matrix to model the
correlation between repeated measures in each
patient. Penalized splines (P-splines) in the
additive mixed-model framework were used
to allow for nonparametric exposure–response
functions (Greven et al. 2006). IL-6 and CRP
needed to be log-transformed to fulfill the
model assumption of residual normality.
City-speciﬁc confounder models without
air pollutants were built for each blood marker
separately. In addition to potential time-vary-
ing confounders, we included time-invariant
patient characteristics associated with the
mean levels of inﬂammatory markers to per-
mit the assumption of a normally distributed
random patient intercept.
In a ﬁrst step, time-invariant factors were
selected for all cities combined. In the second
step, for each city a more parsimonious
model was selected out of the formerly cho-
sen variables [see Supplemental Material,
Table 1 (http://www.ehponline.org/docs/
2007/10021/suppl.pdf)]. With this strategy,
we adjusted for variables that influenced the
mean levels of the respective blood markers
in the single cities, such as age, sex, and BMI.
These variables varied among the cities, pos-
sibly reflecting underlying differences in the
populations across Europe as well as chance
influences. To ensure sufficient adjustment
for season and meteorology, long-term time
trend and apparent temperature were forced
into all models. Additionally, relative humid-
ity, time of day, and day of the week were
included if this adjustment improved the
model ﬁt. We considered lag 0, the mean of
lags 0 and 1, the mean of lags 2 and 3, and
the mean of lag 0–3 for the weather variables;
for fibrinogen, we additionally assessed the
mean of lags 0–4. P-splines were used to
model continuous covariables and were com-
pared with linear terms and polynomials of
degrees 2 and 3. All decisions on goodness-
of-ﬁt were based on Akaike’s Information Cri-
terion (AIC) (Akaike 1973). Only after this
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adjustment did we examine mean changes of
the inﬂammatory markers in association with
air pollution. Single air pollutants were
added and effects estimated linearly. After the
city-speciﬁc data analyses, we assessed hetero-
geneity between centers (Normand 1999).
We combined city-specific effect estimates
using meta-analysis methodology (Van
Houwelingen et al. 2002). Additionally, we
checked whether active smoking, levels of NT-
proBNP > 80 pg/mL (de Lemos et al. 2003),
and HbA1c > 6.5%, respectively, modiﬁed the
effects of air pollution on blood parameters.
Data were analyzed using the statistical
package SAS version 9.1 (SAS Institute Inc.,
Cary, NC, USA). Effect estimates are pre-
sented as percent change of geometric mean
of the blood marker level (IL-6, CRP) and
change of the arithmetic mean level (ﬁbrino-
gen, percent of overall mean) together with
95% confidence intervals (CIs) based on an
increase in air pollution concentrations from
the first to the third quartile [interquartile
range (IQR)].
Sensitivity analyses. We performed sensi-
tivity analyses to explore the robustness of
the models by using a more parsimonious
and an extended model. Also, indicator vari-
ables for season and for potential inflamma-
tion due to diseases or surgery shortly before
the blood withdrawal were added to the
model.
Results
Study population. Baseline characteristics of
the study population are given in Table 1. In
total, 1,003 MI survivors who had at least two
valid repeated blood samples were taken into
the analyses. These were 84% of the targeted
1,200 patients. 
Blood parameters. Of 6,068 collected
blood samples, 255 had to be excluded due to
acute infections or surgical procedures 3 days
before the clinic visit, because they could have
severely altered concentrations of inﬂammatory
Rückerl et al.
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Table 1. Baseline characteristics of 1,003 MI survivors from six European cities.
Characteristic Helsinki (n = 195) Stockholm (n = 197) Augsburg (n = 200) Rome (n = 134) Barcelona (n = 169) Athens (n = 108) p-Value
Percent male 68.7 70.6 82.0 86.6 83.4 87.0 < 0.0001*
Age [mean years (range)] 64.6 (45–78) 64.0 (38–76) 61.9 (39–76) 62.7 (39–79) 62.1 (37–81) 54.7 (38–75) < 0.0001**
BMI [mean (range)] 28.6 (19.1–48.9) 27.6 (17.5–43.2) 28.7 (19.1–48.4) 27.7 (19.0–39.4) 28.8 (19.3–43.5) 28.8 (20.8–46.3) 0.0039**
First MI (%) 81.5 85.8 87.5 87.3 86.4 80.6 0.37*
Self-reported history (%)a
Angina pectoris 39.0 47.7 21.0 27.6 29.6 41.7 < 0.0001*
Arrhythmia 31.3 20.8 24.0 23.1 13.0 21.3 0.0029*
Congestive heart failure 14.9 16.2 13.0 6.0 1.8 5.6 < 0.0001*
Hypertension 51.3 49.7 51.0 55.2 46.2 54.6 0.73*
Diabetes 21.0 18.3 17.5 17.2 23.7 21.3 0.63*
Chronic renal disease 3.6 2.0 5.0 5.2 9.5 1.9 0.019#
Asthma 5.1 5.6 4.5 6.7 4.7 0.0 0.0946#
Any respiratory disease 7.2 6.6 10.5 22.4 13.6 6.5 < 0.0001*
Indication of COPDb 29.2 30.6 20.5 15.7 27.8 13.9 0.007*
Total cholesterol (mg/dL)c (range) 182.2 (91.1–291.9) 173.4 (96.7–324.7) 181.0 (107.0–316.0) 190.6 (120.0–321.0) 193.2 (119.0–390.0) 195.4 (92.0–293.0) < 0.0001**
HDL cholesterol (mg/dL)c (range) 54.0 (22.0–119.3) 53.7 (30.9–116.0) 47.9 (24.0–98.0) 43.7 (25.0–87.0) 52.7 (28.0–105.0) 46.1 (24.0–87.0) < 0.0001**
HbA1c [% (range)]c 5.9 (4.7–9.2) 5.0 (3.8–9.9) 5.6 (4.7–9.8) 5.4 (2.8–8.7) 5.1 (3.8–9.8) 5.8 (3.7–10.5) < 0.0001##
Statins (%) 83 88 89 79 85 73 0.0001*
Lipid-lowering medication (%) 85 89 90 83 86 74 0.0039*
Antithrombotic medication (%) 97 97 99 95 98 93 0.058†
No. of blood samples 1,155 1,168 1,144 741 1,119 486d
IL-6 [mean (pg/mL)] 3.16 2.67 2.60 3.18 3.58 3.19
GM (range)e 2.46 (0.92–19.7) 2.02 (0.48–24.4) 2.16 (0.61–11.8) 2.32 (0.95–61.4) 2.85 (0.76–28.51) 2.52 (0.84–22.40)
Fibrinogen [mean (g/L)] 3.76 3.53 3.34 3.24 3.99 —
GM (range)e 3.69 (2.68–5.63) 3.44 (2.24–6.11) 3.27 (2.00–6.87) 3.14 (1.94–5.18) 3.91 (2.62–6.02) —
CRP [mean (mg/L)]f 1.98 2.86 2.26 2.56 3.52 2.52
GM (range)f 1.18 (0.16–12.15) 1.42 (0.16–37.44) 1.18 (0.16–24.65) 1.40 (0.16–15.33) 2.03 (0.33–30.16) 1.32 (0.23–24.25)
COPD, chronic obstructive pulmonary disease.
aEver physician diagnosed. bEvaluated using a questionnaire on symptoms.cBlood biomarkers determined at local laboratories. dFor fibrinogen N = 0. eGeometric mean of patients’ geo-
metric mean of repeated measurements. fValues of CRP < 0.16 could not be measured and were set to 0.16. p-Values determined with *chi-square test, **ANOVA, #Fisher´s exact test,
##Median-test, †Kruskal-Wallis test.
Table 2. Twenty-four-hour average concentrations of the ambient air pollution concentrations and meteorologic parameters from six European cities during the
AIRGENE study period.a
Helsinki Stockholm Augsburg Rome Barcelona Athens
5 Sep 03–2 Jun 04 30 Aug 03–24 Jun 04 14 May 03–24 Feb 04 20 Sep 03–15 Jul 04 30 Aug 03–16 Jun 04 8 Sep 03–30 Jul 04
Pollutant Mean (95th) Mean (95th) Mean (95th) Mean (95th) Mean (95th) Mean (95th)
PNC (1/cm3) 8,534 (15,077) 9,748 (17,578) 11,876b (25,135) 35,450b (69,226) 18,133b (36,526) 20,589b (47,573)
PM2.5 (µg/m3) 8.2 (19.4) 8.8 (19.1) 17.4 (29.3) 24.5b (54.1) 24.2b (62.7) 23.0b (46.0)
PM10 (µg/m3) 17.1 (36.1) 17.8 (40.3) 33.1 (56.6) 42.1 (76.0) 40.7b (88.7) 38.5 (64.6)
CO (mg/m3) 0.31 (0.46) 0.29 (0.43) 0.58 (1.00) 1.40 (2.47) 0.59 (0.92) 1.48 (3.23)
NO2 (µg/m3) 28.6 (49.8) 18.6 (32.6) 40.0 (61.2) 67.0 (90.8) 50.5 (79.6) 50.1 (73.0)
NO (µg/m3) 12.5 (40.7) 4.9 (15.5) 30.0 (80.4) 65.7 (164.0) 37.7 (88.4) 41.8 (144.6)
SO2 (µg/m3) 4.2 (10.1) 1.9 (4.9) 3.0 (5.7) 4.1 (9.2) 4.7 (9.6) 10.3 (23.2)
O3 [8-hr average ([µg/m3)] 46.8 (89.0) 60.6 (96.9) 54.4 (115.3) 45.3 (99.6) 28.2 (76.5) 59.8 (100.2)
Air temperature (°C) 3.1 (14.7) 4.7 (15.1) 10.2 (25.1) 13.4 (23.9) 15.2 (23.2) 17.6 (29.3)
Relative humidity (%) 76 (91) 82 (94) 69 (92) 80 (95) 67 (86) 67 (84)
95th, 95th percentile.
aThe study period started 5 days before the first measurement because a priori air pollution concentrations up to 5 days before the blood withdrawals were considered. bData available
on < 95% of the days. 
markers. Overall, 5,813 plasma samples
remained. For Athens, ﬁbrinogen levels could
not be assessed. IL-6, fibrinogen, and CRP
showed a moderate correlation, with the
Spearman correlation coefﬁcient ranging from
0.41 to 0.51 for all single measurements and
from 0.49 to 0.55 for the mean values per
patient, with the data of all cities combined.
The single cities showed similar correlation
coefficients, Barcelona being the only excep-
tion, with a low correlation between ﬁbrinogen
and IL-6 (r = 0.22 and 0.25, respectively). 
Air pollutants. The 24-hr average concen-
trations of the pollutants and meteorologic
data are given in Table 2. PNC and PM2.5
were highest in the southern cities and lowest
in Stockholm and Helsinki, whereas Augsburg
showed intermediate levels (Figure 1).
Regression results. The pooled results for
the regression of the three blood markers are
summarized in Table 3. IL-6 showed border-
line significant increases in association with
PNC and NO2 with lag 0, one of the two
a priori speciﬁed lags (Figure 2). Because IL-6
showed positive associations for lag 0, we ana-
lyzed the 24 hr of air pollution exposure
before the blood withdrawal in more detail.
PNC results indicate a time response with a
slight increase 6–11 hr after an exposure, a
clear increase with 12–17 hr after an expo-
sure, and a drop back to the level of 0–5 hr
thereafter (Figure 3). Results for 6–11 as well
as 12–17 hr for all single cities show
clear positive associations, except for Helsinki
and Athens (6–11 hr) and Helsinki and
Stockholm (12–17 hr). 
Fibrinogen was associated with an
increase for the 5-day-average exposure of
PM10. Other pollutants also indicate an
increase for the 5-day-averages, but CIs were
wide. In addition to the effect for the cumula-
tive exposure, we found an increase for fib-
rinogen with lag 3 for PM2.5 and PM10
(Figure 3). For lag 3, results of the single
cities show clear positive associations with
PM2.5 for all cities except for Augsburg,
where no association was seen. For PM10 and
lag 3, results are heterogeneous. Except for
Air pollution and inflammation
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Figure 1. Time series of air pollution (PNC and PM2.5) and air temperature in the six European cities of the AIRGENE study.
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Helsinki Stockholm
Augsburg Rome
Barcelona Athens
PM2.5
PNC
Augsburg, all cities present positive associa-
tions, with Helsinki being the highest.
Associations for PM2.5 and PM10 for the
5-day-average exposures were positive in
all cities.
Analyses of effect modiﬁcation showed that
for fibrinogen associations remained for the
5-day average exposure to PM10 for nonsmok-
ers and patients with elevated NT-proBNP
and HbA1c levels (Figure 4). Results for the
single cities revealed clear positive associations
for patients with elevated HbA1c levels in
Helsinki and Barcelona, and small positive
associations in Augsburg and Rome, whereas
no association was found for Stockholm.
Helsinki and Barcelona showed clear increases
in fibrinogen levels with increased PM10 for
patients with high NT-proBNP levels,
whereas for the other cities only small
increases were found. Active smokers were
present only in Rome and Barcelona, and
interactions with smoking thus were calcu-
lated only for these two cities. The combined
results are driven mainly by the results from
Barcelona, which indicate a strong positive
association for nonsmokers. For CRP, no
associations between ambient air pollution
and serum concentrations were observed for
either the a priori hypothesized time span or
other lags.
Sensitivity analyses. We performed sensi-
tivity analyses for all blood markers, using
selected air pollutants and the a priori speci-
ﬁed lags (Table 4). For IL-6 and PNC, addi-
tional confounders in the model led to a clear
positive result, whereas all other models,
including the chosen model, were more con-
servative. For fibrinogen, overall results
remained clearly positive and stable with
PM10. With PNC a strong yet not signiﬁcant
association was found for the model without
time-independent covariates. For CRP,
results did not change in dependence on
the model. 
Discussion
We measured IL-6, fibrinogen, and CRP,
three blood markers that indicate an inﬂam-
matory response, in MI survivors in six
European cities. Pooled results show an
increase in IL-6 when concentrations of PNC
were elevated 12–17 hr before the clinical
visit. Cumulative exposure to PM10 was
associated with an increase in ﬁbrinogen. No
Rückerl et al.
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Table 3. Effects of air pollution on blood biomarkers per increase in IQR of air pollutant (pooled effect estimates). 
IL-6 (all cities) Fibrinogen (all cities except Athens) CRP (all cities)
Pollutant, Time before % change p-Value % change p-Value % change p-Value 
IQR blood withdrawal (GM) 95% CI heterogeneity (AM) 95% CI heterogeneity (GM) 95% CI heterogeneity
PNCa
11852 Lag 0 1.88** –0.16 to 3.97 0.72 0.40 –0.40 to 1.19 0.54 1.33 –3.05 to 5.90 0.047
11852 Lag 1 –0.67 –2.56 to 1.25 0.64 0.11 –0.69 to 0.91 0.12 –1.52 –4.39 to 1.45 0.19
11852 Lag 2 –2.12** –4.03 to –0.17 0.055 0.09 –0.71 to 0.90 0.045 –1.63 –6.70 to 3.71 0.019
11003 5-day average –0.93 –3.37 to 1.56 0.084 0.50 –2.20 to 3.20 0.009 –0.08 –3.78 to 3.75 0.12
PM2.5b
11.0 Lag 0 0.46 –0.89 to 1.83 0.26 0.05 –0.48 to 0.58 0.36 0.11 –1.95 to 2.21 0.71
11.0 Lag 1 –0.39 –1.69 to 0.93 0.70 0.17 –0.35 to 0.69 0.55 –0.06 –1.98 to 1.90 0.70
11.0 Lag 2 –0.23 –1.53 to 1.07 0.57 0.20 –0.32 to 0.71 0.26 0.11 –1.80 to 2.06 0.86
8.6 5-day average 0.05 –1.37 to 1.50 0.66 0.38 –0.21 to 0.96 0.21 –0.13 –2.15 to 1.92 0.94
PM10c
17.4 Lag 0 –0.34 –1.66 to 0.99 0.45 0.06 –0.43 to 0.55 0.53 –0.71 –2.75 to 1.37 0.16
17.4 Lag 1 –0.69 –1.95 to 0.58 0.43 0.14 –0.35 to 0.63 0.83 –0.63 –2.61 to 1.39 0.23
17.4 Lag 2 –1.59 –3.99 to 0.88 0.0030 0.24 –0.24 to 0.72 0.25 –1.42 –4.23 to 1.47 0.086
13.5 5-day average –0.87 –2.28 to 0.55 0.15 0.60* 0.10 to 1.09 0.26 –1.35 –3.45 to 0.79 0.19
CO
0.34 Lag 0 0.57 –0.63 to 1.79 0.95 0.24 –0.45 to 0.92 0.11 –0.01 –1.72 to 1.73 0.18
0.34 Lag 1 0.44 –0.79 to 1.68 0.72 0.32 –0.35 to 1.00 0.38 –1.51 –3.30 to 0.32 0.19
0.34 Lag 2 –2.36 –4.82 to 0.17 0.0054 –0.44 –1.11 to 0.23 0.078 –2.35 –6.84 to 2.36 0.0025
0.31 5-day average –0.28 –2.53 to 2.02 0.067 0.12 –0.81 to 1.05 0.062 –0.85 –5.37 to 3.90 0.051
NO2
15.9 Lag 0 1.31** –0.24 to 2.89 0.97 0.05 –0.50 to 0.60 0.84 0.41 –1.93 to 2.81 0.68
15.9 Lag 1 0.93 –0.55 to 2.43 0.78 0.04 –0.49 to 0.57 0.64 1.15 –1.18 to 3.54 0.86
15.9 Lag 2 –1.38 –4.35 to 1.68 0.00024 0.05 –0.71 to 0.80 0.056 –0.28 –4.05 to 3.63 0.0081
10.1 5-day average –0.19 –3.08 to 2.78 0.0014 0.24 –0.45 to 0.93 0.057 1.40 –0.92 to 3.79 0.19
Abbreviations: AM, arithmetic mean; GM, geometric mean. A priori specified lags: IL-6: lag 0 and lag 1; fibrinogen: 5-day average; CRP: lag 2. 
aIQR (24-hr, 5-day average), 11852.39408, 11002.9686 n/cm3. bIQR (24-hr, 5-day average), 10.99720847, 8.59343322 µg/m3. cIQR (24-hr, 5-day average), 17.36794382, 13.5380001 µg/m3. 
*p < 0.05; **p < 0.1. 
Figure 2. Association between PNC and PM10 and blood markers for the single cities for the a priori specified lags. (A) IL-6. (B) Fibrinogen. (C) CRP. Abbreviations:
AM, arithmetic mean; GM, geometric mean.
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consistent associations could be detected
for CRP.
Air pollution seems to affect susceptible
subgroups (Goldberg et al. 2001, 2006;
Katsouyanni et al. 2001; Pope et al. 2002).
We therefore examined MI survivors, a sub-
group with an increased risk for readmission
to the hospital (von Klot et al. 2005), in six
European cities, covering a wide range of
gaseous and particulate air pollutants. There
is a strong link between inflammation and
CHD because factors involved in inflamma-
tion and infection seem to play a pro-athero-
genic role, and inflammation has been
identified as a potent risk factor for acute
ischemic syndromes (Ross 1999). Other risk
factors such as cigarette smoking (Danesh
et al. 1999: Fröhlich et al. 2003), diabetes
(Thorand et al. 2007), or high BMI (Danesh
et al. 1999: Thorand et al. 2006) have also
been found to be associated with low-grade
systemic inflammation, providing a further
link between inflammation and acute
coronary events. 
Previous studies have shown an associa-
tion between air pollution and blood markers
of inﬂammation and coagulation. We exam-
ined IL-6 because of its role in the inﬂamma-
tory cascade (Woods et al. 2000). IL-6 is
produced by different cells in the body,
including lymphocytes, monocytes, and
endothelial cells. It is thought to play a major
role in mediating stimuli from activated
macrophages—for example, by smoking. IL-6
is the key cytokine that stimulates the synthe-
sis of all major acute phase proteins, including
CRP and fibrinogen (Woods et al. 2000).
The latter factor induces an increase in blood
viscosity and promotes thrombus formation
(Koenig 2003).
In a study in the United Kingdom (Seaton
et al. 1999), no significant associations were
seen for a 3-day cumulative exposure to ambi-
ent PM10 and IL-6 levels. At high pollution
levels, however, such as in road tunnels or dur-
ing forest ﬁres, positive associations have been
observed (Hilt et al. 2002; van Eeden et al.
2001). Our results indicate an increase in IL-6
within 12 hr after exposure, a requisite first
step in the stimulation of the de novo synthesis
of acute-phase proteins in the liver, triggered
by ambient particles. 
Fibrinogen, an acute-phase protein, also
plays a crucial role in the coagulation cascade.
Studies regarding its association with air pollu-
tion are inconclusive. It has been shown to
increase in association with high levels of ambi-
ent particles such as in an air pollution episode
(Peters et al. 1997) or in controlled human
exposure studies (Ghio et al. 2000). Also, posi-
tive associations, such as for PM10, have been
reported at levels comparable to those meas-
ured in the present study (Pekkanen et al.
2000; Schwartz 2001). However, also null
associations (Pope et al. 2004; Ruckerl et al.
2006) and even decreases in fibrinogen con-
centration in association with air pollutants
have been reported (Khandoga et al. 2004;
Seaton et al. 1999). Our study indicates an
increase in ﬁbrinogen for lag 3 and the 5-day
cumulative exposure for PM10.
CRP, a well-known biomarker of systemic
inﬂammation, has been one of the ﬁrst acute-
phase reactants to be examined in association
with air pollution in several studies. Increased
concentrations have been shown during an air
pollution episode in Germany in healthy
men, 45–64 years of age (Peters et al. 2001b)
as well as for ambient PM10 levels currently
present in Europe (Seaton et al. 1999).
Additionally, in a panel of CHD patients, an
increase in CRP above the 90th percentile
was found in association with ambient parti-
cles (Ruckerl et al. 2006). Similar analyses did
not reveal any effects in our data, which
might be attributed to differences in the two
panels. The AIRGENE panel consisted of
both males and females and was on average
slightly younger, but had more severe diseases
than the subjects studied previously. On the
other hand, the average CRP levels were
lower in the AIRGENE panel. 
Overall, these studies suggest associations
between inﬂammation and ambient air pollu-
tion concentrations, especially particles,
although the effects between studies differ for
individual data. To date, the reason for the
heterogeneity is largely unknown. Different
pollution mixtures, underlying medical con-
ditions, treatments or diets with high anti-
oxidant levels might be possible explanations. 
We observed immediate associations
between PNC and IL-6 and cumulative
effects between PM10 and ﬁbrinogen. This is
a surprising finding, which might be attrib-
uted to chance, because PM10 and PNC were
not highly correlated in most cities. It is,
however, also possible that their mode of
action is different. Ultrafine particles or
attached substances might translocate quickly
into the bloodstream (Geiser 2002) and lead
to the observed changes in IL-6 without hav-
ing a direct impact on the lung. PM10, on the
other hand, might only exert an indirect sys-
temic impact by provoking an inﬂammatory
response in the lung that eventually causes
oxidative stress, leading to the observed
delayed increase in fibrinogen. However,
these explanations are highly speculative.
Further, PNC and PM10 differ not only by
size but also by composition and redox activ-
ity (Cho et al. 2005), but the implications for
the mechanisms are difﬁcult to judge. When
the city-specific results are examined, the
immediate association between IL-6 and
PNC was strongest in Augsburg, whereas the
association between PM10 and ﬁbrinogen was
strongest in Helsinki for the 5-day-average
exposure. Because these city-speciﬁc estimates
were not heterogeneous, this may reflect the
expected variation between independent stud-
ies. It also might point to differences in mea-
surement error with respect to population
average exposures characterized by central
monitoring sites.
One possible explanation for the lack of
associations between air pollutants and CRP
in our data could be the high prevalence of
Air pollution and inflammation
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Figure 4. Effects of PM10 on fibrinogen (5-day aver-
age) as modified by active smoking, levels of NT-
proBNP and HbA1c as indicators of left ventricular
dysfunction and diabetes, respectively. AM, arith-
metic mean. Error bars indicate 95% CIs. 
aActive smokers were only present in Rome and Barcelona;
interaction thus calculated only for these two cities. 
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Figure 3. Pooled effects of PNC on IL-6 (A) and of PM2.5 and PM10 (B) on fibrinogen, different lags.
Abbreviations: AM, arithmetic mean; GM, geometric mean. Error bars indicate 95% CIs.
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lipid-lowering drugs intake, particularly
statins, which have been shown to reduce
CRP through inhibition of its hepatic synthe-
sis (Arnaud et al. 2005). Studies have shown
that long-term therapy with a statin signifi-
cantly lowers plasma levels of CRP (Ridker
et al. 2001; Sandhu et al. 2005). IL-6, which
is produced upstream to the production of
CRP in the liver, is not affected by this com-
pound. Also, ﬁbrinogen has been implicated
to be reduced by fibrates but not statins
(Rosenson et al. 2001). Because the majority
of our patients reported an intake of statins,
subgroup analyses did not seem reasonable. 
Increased concentrations of CRP are
known to predict cardiovascular events in
healthy subjects (Danesh et al. 2000). Also,
elevated levels of IL-6 have been found to be
associated with total mortality (Harris et al.
1999) and with risk of future fatal and nonfa-
tal MI (Ridker et al. 2000). Whether the
short-term increases in IL-6 and fibrinogen
observed in this study actually lead to an
increased risk for an acute coronary syndrome,
however, remains to be shown. A long-term
follow-up study examining cardiovascular end
points might help to answer the question
whether subjects with elevated levels of
inﬂammatory proteins in response to environ-
mental stimuli have an increased risk of acute
ischemic syndromes.
Strengths and limitations. The study is
based on a common protocol and standard
operating procedures applied in six European
cities. Site visits were conducted to ensure uni-
form procedures. The analyses of the inﬂam-
matory markers were done in one central
laboratory, and blinded duplicate samples
were measured for quality assurance. 
Some of the measured biomarkers (e.g.,
CRP) are affected by health-related events
such as acute infection or surgery (Thomas
Rückerl et al.
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Table 4. Sensitivity analyses: results for different models on selected outcomes.
IL-6 (lag 0) Fibrinogen (mean of 5-day average) CRP (lag 2)
Estimate Heterogeneity Estimate Heterogeneity Estimate Heterogeneity
Pollutant, model (% change GM) 95% CI (p-value) (% change AM) 95% CI (p-value) (% change GM) 95% CI (p-value) 
PNC
Main model 1.88 –0.16 to 3.97 0.72 0.5 –2.20 to 3.20 0.009 –1.63 –6.70 to 3.71 0.02
Additional covariatesa 2.16* 0.08 to 4.29 0.85 0.26 –2.96 to 3.48 0.004 –1.64 –7.02 to 4.05 0.01
No time-independent covariates 1.16 –0.85 to 3.21 0.46 2.77 –0.15 to 5.69 0.001 –1.92 –6.93 to 3.36 0.02
Including risk of potential inflammation 1.91 –0.14 to 3.99 0.70 0.48 –2.37 to 3.32 0.01 –1.74 –6.78 to 3.57 0.02
4–7 days before blood withdrawal
Including seasonal interaction 1.97 –0.11 to 4.09 0.61 0.35 –0.80 to 1.51 0.02 –1.18 –6.59 to 4.55 0.01
(season = winter)
PM10
Main model –0.34 –1.66 to 0.99 0.45 0.60* 0.10 to 1.09 0.26 –1.42 –4.23 to 1.47 0.086
Additional covariatesa –0.16 –1.48 to 1.17 0.53 0.81* 0.17 to 1.45 0.19 –1.08 –3.05 to 0.92 0.11
No time-independent covariates –0.64 –1.94 to 0.69 0.44 0.36 –0.77 to 1.48 0.02 –2.04 –5.05 to 1.07 0.04
Including risk of potential inflammation –0.35 –1.66 to 0.99 0.44 0.75 0.12 to 1.38 0.34 –1.43 –4.21 to 1.43 0.09
4–7 days before blood withdrawal
Including seasonal interaction –0.15 –1.71 to 1.42 0.40 0.78 –0.02 to 1.57 0.50 –1.33 –3.61 to 1.00 0.55
(season = winter)
Estimates for CRP and IL-6 are expressed as percent change in expected geometric mean (GM); estimates for fibrinogen are expressed as absolute change in expected mean,
expressed as percent of overall arithmetic mean (AM). 
aAdditional covariates included time-independent variables present in at least two cities, hour of blood withdrawal, and relative humidity. *p < 0.05.
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2000). We therefore carefully excluded blood
samples that might have been strongly inﬂu-
enced by other sources than air pollution
before the statistical analyses. Moreover, thor-
ough confounder adjustment was done to rule
out the possibility that the detected associa-
tions resulted from meteorologic inﬂuences or
seasonal differences, and repeated measures
decreased the chance of confounding by time-
independent variables, because each person
served as his or her own control. 
Even though we included city-specific
patient characteristics to account for differ-
ences in the panels, the city-speciﬁc estimates
of the air pollution effects still varied.
However, for those results indicating an asso-
ciation between air pollution and inflamma-
tion, these variations did not exceed the
expected random variation. But it is also quite
possible that the air pollution mixture, socioe-
conomic factors, or genetic background are
responsible for these modifications. Indeed,
we did observe effect modiﬁcation for patients
with elevated HbA1c and NT-proBNP.
We observed only small changes in the
acute-phase response that are not on the scale
of a bacterial infection (Thomas 2000) or
surgery and presumably do not have any direct
clinical relevance. Other factors, such as 10
pack-years of smoking, in comparison, led to
increases of 2.7% (95% CI, 1.2–4.3) for IL-6,
1.2% (95% CI, 0.7–1.7) for ﬁbrinogen, and
5.5% (95% CI, 3.0–8.0) for CRP in our data.
A higher BMI of 5 kg/m2 was associated with
signiﬁcantly higher levels of IL-6 (16%), ﬁb-
rinogen (3.8%), and CRP (38%). Smoking
and overweight may be of concern in subpop-
ulations, whereas air pollution usually affects
whole populations and there is generally no
voluntary component to the risk. Based on a
publication by Cesari et al. (2003), we esti-
mated that the increase in IL-6 we found in
association with PNC might lead to a 0.7%
(95% CI, –0.06 to 1.5) increased risk of
CHD in elderly people without baseline car-
diovascular risk. Despite the high prevalence
of statin intake, our data still indicate an
inﬂammatory response in association with air
pollution. We therefore hypothesize that
ambient air pollution might increase plaque
vulnerability by these subclinical inﬂammatory
responses. 
Conclusion 
Our results indicate an immediate response of
IL-6 to ambient air pollution, which might
lead to the synthesis of acute-phase proteins, as
indicated by increased ﬁbrinogen levels. The
lack of detectable associations for CRP may be
attributed to a widespread intake of statins in
our population, which might suggest a protec-
tive effect against environmental, proinflam-
matory stimuli—an intriguing phenomenon
that deserves further study.
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Rationale: Ambient air pollution has been shown to be associated
with cardiovascular morbidity and mortality.
Objectives: A prospective panel study was conducted to study the
early physiologic reactions characterized by blood biomarkers of
inflammation, endothelial dysfunction, and coagulation in response
to daily changes in air pollution in Erfurt, Germany.
Methods: Blood parameters were repeatedly measured in 57 male
patients with coronary heart disease during the winter of 2000/
2001. Fixed-effects linear and logistic regression models were ap-
plied, adjusting for trend, weekday, and meteorologic parameters.
Measurements:Hourly data on ultrafine particles (UFPs; number con-
centration of particles from 0.01 to 0.1 m), mass concentration
of particles less than 10 (PM10) and 2.5 m in diameter, elemental
and organic carbon, gaseous pollutants, and meteorologic data
were collected at central monitoring sites.
Main Results: Increased levels of C-reactive protein above the 90th
percentile were observed for an increase in air pollution concentra-
tions of one interquartile range. The effect was strongest for accu-
mulation mode particles, with a delay of 2 d (odds ratio [OR], 3.2;
confidence interval [CI], 1.7, 6.0). Results were consistent for UFPs
and PM10, which also showed a 2-d delayed response (OR, 2.3; CI,
1.3, 3.8; and OR, 2.2; CI, 1.2, 3.8, respectively). However, not all
of the blood markers of endothelial dysfunction and coagulation
increased consistently in association with air pollutants.
Conclusion: These results suggest that inflammation as well as parts
of the coagulation pathway may contribute to the association be-
tween particulate air pollution and coronary events.
Keywords: acute-phase reaction; air pollution; blood coagulation;
cardiovascular diseases; C-reactive protein
Increasing evidence suggests that ambient air pollution may ad-
versely affect the cardiovascular system. It has been shown that
ambient air pollution leads to increased cardiovascular mortality
(1–6), and studies found associations between ambient air pollu-
tion and hospital admissions for various cardiovascular diseases,
including congestive heart failure (7–9). Also, an increased risk
for acute myocardial infarction (MI) (10) and cardiorespiratory
symptoms (11) has been reported in association with particulate
air pollution.
The exact mechanisms linking the inhalation of ambient air
particles to an acute exacerbation of cardiovascular disease are
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not completely understood (12). Seaton and coworkers (13) hy-
pothesized that inhaled particles would lead to alveolar inﬂam-
mation, which increases the level of blood coagulability, thus
leading to an increased risk of ischemic events in susceptible
individuals. DeMeo and colleagues (14) found reduced oxygen
saturation in association with particulate matter of less than
2.5m in diameter (PM2.5). Pope and colleagues (15), who linked
long-term exposure to particulate air pollution to various causes
of mortality, found a strong and robust association between
PM2.5 and cardiovascular disease mortality. They concluded that
exposure to particulate air pollution and cardiopulmonary mor-
tality risk is linked by accelerated pulmonary and systemic in-
ﬂammation. Moreover, Peters and coworkers (16) demonstrated
increased levels of plasma viscosity during an air pollution epi-
sode in central Europe, compared with less polluted days. In-
creased plasma concentrations of C-reactive protein (CRP), the
classic acute-phase protein, were also shown during the 1985 air
pollution episode (17).
There is a strong link between inﬂammation and coronary
heart disease (CHD) because factors involved in inﬂammation
and infection seem to play a proatherogenic role and inﬂamma-
tion has been identiﬁed as a potent risk factor for acute coronary
syndrome. Systemic inﬂammation could result in destabilization
or even rupture of vulnerable atheromatous plaques, leading to
acute ischemic events.
Most of the cited studies have been conducted in the general
population or in elderly healthy subjects. This study looks at a
susceptible subgroup to provide insight into the ways in which
air pollution might precipitate death in persons with underlying
heart disease, based on the hypothesis that particulate air pollu-
tion can alter cardiovascular function.
Repeatedmeasurements of markers of an early inﬂammatory
response, cell recruitment and coagulation, were compared with
concurrent levels of air pollution. Our primary hypothesis was
that CRP, a well-known marker for inﬂammation, would in-
crease in association with a rise in levels of air pollution. More-
over, we analyzed various other markers of inﬂammation (serum
amyloid A [SAA]), cell adhesion (E-selectin, von Willebrand fac-
tor antigen [vWf], intercellular adhesion molecule 1 [ICAM-1]),
and coagulation (ﬁbrinogen, factor VII [FVII], prothrombin
fragment 12, D-dimer) on a more explorative basis hypothe-
sizing that the levels of these blood markers would also go up in
association with higher levels of air pollution, as seen in Figure 1.
Some results have been previously presented in form of an
abstract (18).
METHODS
Study Design
As part of the University of Rochester Particulate Matter Center, a
prospective panel study was conducted between October 15, 2000, and
April 27, 2001, in Erfurt, Germany. The panel consisted of male patients
with CHD who were scheduled for 12 subsequent clinical visits. Each
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Figure 1. Conceptual model showing hypothesized as
well as observed effects of the cellular events linkingpartic-
ulate exposure to cardiopulmonary events. CRP 
C-reactive protein; FVII factor VII; ICAM-1 intercellular
adhesion molecule 1; IL  interleukin; SAA  serum
amyloid A; vWf  von Willebrand factor.
clinical visit included a short interview and the withdrawal of a blood
sample. At the ﬁrst visit, a baseline questionnaire was administered
regarding health status, pulmonary and cardiac symptoms, medication
intake, and smoking history.
Sixty-one nonsmoking men, aged 50 yr or older, with physician-
diagnosed CHD were recruited through a local cardiologist. Patients
with pacemakers, recent ( 3 mo ago) MI, bypass surgery, or balloon
dilatation were not included because the inﬂammatory processes in-
volved in such a procedure might not yet have subsided. Persons with
type 1 diabetes or on anticoagulation therapy (except for antiplatelet
agents) were also not included. A written, informed consent was ob-
tained from all subjects. The study protocol was approved by the
German Ethics Committee of the “Bayerische Landesa¨rztekammer”
in Munich, Germany. All methods used in the study were conducted
according to standard operating procedures and were tested beforehand
in a 2-wk pilot study.
Air Pollution Monitoring
Concentrations of different ambient air pollutants were measured at
one ﬁxed monitoring site in the city center representing urban back-
ground levels. The measurement site was put up especially for carrying
out epidemiologic studies (19, 20) and allmeasurements were conducted
according to the standard operating procedures developed within the
framework of previous studies (21–23).
Continuous ultraﬁne particle (UFP) counts (0.01–0.1 m), accumu-
lation mode particle (AP) counts (0.1–1.0 m), and ﬁne-particle mass
(PM2.5) were measured with the mobile aerosol spectrometer (MAS).
The MAS, described previously (24, 25), consists of two different, com-
mercially available instruments covering different size ranges. Particles
in the size range from 0.01 to 0.5 m were measured using a differential
mobility particle sizer (TSI, Aachen, Germany). Particles in the size
range from 0.1 to 2.5 m were classiﬁed by an optical laser aerosol
spectrometer (PMS, Leonberg, Germany).
PM10 (particulate matter  10 m in diameter) data were collected
by the tapered element oscillating microbalancemethod (TEOM1400a;
Rupprecht and Patashnik,Albany, NY) and continuous data on elemen-
tal (EC) and organic carbon (OC) were measured with an ambient
carbonmonitor (ACM5400; Rupprecht and Patashnick). Data onmete-
orologic variables for this period as well as concentrations of gaseous
air pollutants were collected from existing networks. Missing values of
the ambient UFPs between January 20 and February 13 were imputed
by a linear regression model based on parallel measurements with a con-
densation particle counter and a scanning mobility particle sizer. The
R squares for the regression model was 0.96. Also, between December
2000 and May 2001, approximately 15% of the PM2.5 measurements
by MAS were lost. These missing values were replaced by corrected
data based on parallel measurements with TEOM-PM10 and Harvard
Impactor-PM2.5. (Air Diagnostic and Engineering, Inc., Naples, ME).
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For each person and visit, the individual 24-h average of pollutants
immediately preceding the clinical visit (lag 0) up to Day 5 (lag 1–4)
and 5-d running means before the examination were calculated if more
than two-thirds of the hourly measurements were available for this
period.
Clinical Measurements
The clinical visits were scheduled on the same weekday (Monday to
Friday) and time (8:00 a.m. to 5:00 p.m.) for each patient once every
2 wk.
At each visit, ethylenediaminetetraacetic acid and citrate plasma
samples were drawn (Becton Dickinson, Franklin Lakes, NJ). Samples
were centrifuged and aliquots were immediately stored at 20C until
analysis. CRP (high-sensitivity assay), SAA, and ﬁbrinogen were analyzed
by immunonephelometry (Dade Behring, Marburg, Germany). ICAM-1,
E-selectin (R&D Systems, Wiesbaden, Germany), and prothrombin
fragment 12 (Dade Behring) were measured by means of a commer-
cial ELISA. D-dimer and vWf were analyzed using an immunoturbidi-
metric method and FVII by clotting time measurement (Diagnostica
Stago, Asnieres-sur-Seine, France).
Study Subjects
Fifty-seven of 61 patients were included in the analyses. One patient
refused to participate, and three patients had to be excluded for the
following reasons: two were diagnosed with leukemia or lymphoma
and one patient had constantly elevated levels of white and red blood
cells, indicating an unknown hematologic disorder. Fifty-ﬁve patients
participated in 12, one patient participated in nine, and one patient
participated in eight scheduled visits (99% completeness). Blood sam-
ples of patients reporting an acute infection and/or surgery during the
2 wk before the examination were excluded from the analysis (46 blood
samples [7%] of 19 different patients). Also, 18 blood samples (3%)
in 15 patients showing implausibly low ﬁbrinogen values ( 1.0 g/L)
on nephelometry were excluded from the analysis. Finally, not all pa-
tients were able to give the scheduled amount of blood at each visit.
Therefore, between 544 blood samples (87%) and 581 blood samples
(92%) remained for analysis, depending on the marker.
Statistical Analyses
Continuous concentrations of the blood markers were analyzed using
linear regression models. Also, values above the 90th percentile were
assessed using logistic regression models (17). Generalized additive
models, including pollutant and confounder variables, were used for
ﬁxed-effects regression with individual intercepts for each patient.
Long-term time trend, an indicator variable for each subject, weekday
of the visit, and the meteorologic parameters air temperature, relative
humidity, and barometric pressure, each with lag 0 to lag 3, were consid-
ered as potential confounders. Because the half-life of most markers
is only a couple of hours and the visits took place in 2-wk intervals, it
was assumed that no autocorrelation was present in the patient data,
and no adjustment for autocorrelation was made.
Prothrombin fragment 12, FVII, SAA, CRP, and E-selectin were
log-transformed before analysis because their residuals remained
skewed after multivariate modeling.
Model building was done for each blood parameter separately with-
out an air pollution variable. To explore the shape of the association
between confounders and blood markers, nonparametric smooth func-
tions on the basis of locally weighted least squares were applied for all
confounders. Model ﬁt was rated on the basis of theAkaike information
criterion (AIC). In the ﬁnal model, nonparametric smooth functions
were replaced by appropriate polynomials (degree 2 or 3) or natural
splines based on lowest AIC. After the model ﬁt was completed, dose–
response functions of the confounders were checked visually and in case
implausible shapes were observed, degrees of freedom were decreased.
Each pollutant was added separately to the ﬁnal model.
Data were analyzed using the statistical package SAS version 8.2
(SAS Institute, Inc., Cary, NC) and S-Plus version 6.0 (Mathsoft Engi-
neering and Education, Inc., Cambridge, MA).
Logistic regression models were used to determine whether the
effect was limited to the upper tail of the distribution. Confounder
adjustment was done in the same way as described for the linear regres-
sion models; however, more parsimonious models were used. Sensitivity
analyses were done to explore the inﬂuences of the different confounder
models.
RESULTS
Patient Characteristics
Patient characteristics are summarized in Table 1. The study
population comprised 57 nonsmoking men, aged 51 to 76 yr.
Approximately 84% of them were retired. Except for one per-
son, all patients had stopped smoking at least 1 yr before the
examinations.
Air Pollutants
The distributions of the 24-h average concentrations of the par-
ticulate and gaseous pollutants as well as meteorologic data are
given in Table 2.
PM10, PM2.5, and AP were highly correlated (r  0.90–0.91),
whereas UFPs were only moderately correlated with PM10 and
PM2.5 (r 0.57 and 0.41, respectively). PM2.5 showed a moderate
negative correlation with air temperature (r  0.5; Figure 2).
EC and OC showed high correlation (r  0.96) and were also
highly correlated with all other particle fractions (r 0.63–0.90).
Also, CO and NO2 were highly correlated (r  0.82), whereas
the correlation for UFPs with NO2 was slightly lower than with
CO (r  0.75 and 0.82, respectively).
Blood Parameters
Levels of blood parameters are summarized in Table 3. Parame-
ters of the acute-phase response, SAA and CRP, were corre-
lated (r  0.53), as were the adhesion molecules ICAM-1 and
E-selectin (r  0.53). However, no signiﬁcant correlation was
seen between markers of an acute-phase response and adhesion
molecules (r 0.08 to 0.31). SAA and CRP also showed a moder-
ate correlation with ﬁbrinogen (r  0.44 and 0.34, respectively).
TABLE 1. CHARACTERISTICS OF THE STUDY POPULATION,
57 MEN WITH HISTORY OF CORONARY HEART DISEASE IN
ERFURT, GERMANY, WINTER 2000/2001
Mean (SD)
Age, yr 66 (6.0)
BMI, kg/m2 28 (3.4)
No. (% )
History of
Coronary heart disease 57 (100)
Angina pectoris 40 (68)
Myocardial infarction 43 (75)
Bypass surgery/balloon dilatation 49 (86)
Stroke 3 (5)
Diabetes mellitus 13 (23)
Hypertension 40 (70)
Chronic bronchitis 2 (4)
COPD 5 (9)
Hay fever 2 (4)
Chronic kidney disease 6 (11)
Smoking
Never smoker 15 (26)
Ever smoker 42 (74)
Medication use
Platelet aggregation inhibitors
Acetylsalicylic acid 52 (91)
Thienopyridines 3 (5)
Antihyperlipidemic medication 29 (51)
Definition of abbreviations: BMI bodymass index; COPD chronic obstructive
pulmonary disease.
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TABLE 2. SUMMARY STATISTICS OF DAILY CONCENTRATIONS (24-h AVERAGE) OF AIR POLLUTANTS AND METEOROLOGIC
VARIABLES IN ERFURT, GERMANY, BETWEEN OCTOBER 12, 2000, AND APRIL 27, 2001 (INCLUDING IMPUTED VALUES)
Variable No. Mean ( SD) Min. First Quartile Median Third Quartile Max. IQR IQR (5-d average)
UFPs,*n/cm3 196 12,602 ( 6,455) 2,542 7,326 11,444 17,332 34,294 10,005 6,821
AP, n/cm3 167 1,593 ( 1,034) 328 821 1,238 2,120 4,908 1,299 1,127
PM2.5,† g/m3 197 20.0 ( 15.0) 2.6 9.7 14.9 26.1 83.7 16.4 12.2
PM10, g/m3 154 20.0 ( 13.0) 5.4 10.8 15.6 26.0 74.5 15.2 12.8
Organic carbon, g/m3 126 1.5 ( 0.6) 0.3 1.1 1.4 1.8 3.4 0.7 0.5
Elemental carbon, g/m3 126 2.6 ( 2.4) 0.2 1.0 1.8 3.2 12.4 2.3 1.8
NO2, g/m3 198 34.3 ( 11.4) 8.0 25.3 34.0 42.5 68.4 17.2 9.3
CO, mg/m3 198 0.52 ( 0.29) 0.11 0.33 0.44 0.60 1.93 0.27 0.22
Temperature, C‡ 198 4.1 ( 4.8) 10.4 0.5 4.4 7.9 13.2 7.4 5.9
Barometric pressure, hPa 198 973.4 ( 9.7) 949.5 966.3 972.9 980.0 995.7 13.6 10.8
Relative humidity,§ % 198 83.5 ( 8.8) 55.8 78.9 84.3 88.8 100.0 10.0 9.1
Definition of abbreviations: AP  accumulation mode particles (particles with a size range of 0.1 to 1.0 m); IQR  interquartile range; PM2.5  mass concentration
of particles less than 2.5 m in diameter; PM10  mass concentration of particles less than 10 m in diameter; UFPs  ultrafine particles (number concentration of
particles with a size range of 0.01 to 0.1 m in diameter).
* For UFPs, 13% of the hourly measurements were imputed.
† For PM2.5, 15% of the hourly measurements were imputed.
‡ For temperature, 0.5% of the hourly measurements were imputed.
§ For relative humidity, 0.5% of the hourly measurements were imputed.
Regression Results
Results for the regression of different blood markers are summa-
rized in Table 4 (logistic regression) and Table 5 (linear regression).
Effect estimates are presented together with 95% conﬁdence
intervals (95% CI) based on an increase in air pollution
concentration from the ﬁrst to the third quartile (interquartile
range).
Inﬂammation and adhesion. For CRP, the odds of observing
concentrations above the 90th percentile were consistently in-
creased in association with PM10 and UFPs (Figure 3) as well as
AP, NO2, and CO for lag 2. The highest odds ratio (OR) was
seen with AP, whereas EC and OC showed no signiﬁcant results.
Figure 2. Time series of number concentrations of particles sized 0.01 to 0.1 m (ultrafine particles [UFP]) and mass concentrations of particles
less than 2.5 m in diameter (PM2.5) together with air temperature in Erfurt, Germany, between October 2000 and April 2001.
The OR for observing high ICAM-1 levels increased, espe-
cially for lag 1 and 2. This pattern was seen for PM10 (Figure 3),
AP, EC and OC, and CO. For ICAM-1, a decrease with lag 0
was also found for most pollutants. Results for SAA indicate
an increase in association with particulate air pollution (e.g.,
with UFP concentrations); however, results are not as strong
and consistent as for CRP (Figure 3). Linear regression analyses
looking at the continuous distribution did not reveal signiﬁcant
results for CRP, ICAM-1, and SAA. Also, E-selectin did not
show any association with ambient air pollution (Figure 3).
Linear regression analyses of vWf (Table 5) revealed statistically
signiﬁcant positive associations for most pollutants with lag 0 and
for the 5-d average exposure (Figure 3). For PM2.5 and AP, the
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TABLE 3. BIOMARKERS FOR 57 MALE PATIENTS WITH CORONARY HEART DISEASE IN ERFURT,
GERMANY, WINTER 2000/2001
Parameter No. Mean (SD) Min. Median 90th Percentile Max.
CRP, mg/L 579 3.7 (6.5) 0.2 2.0 8.5 93.2
SAA, mg/L 579 6.9 (35.1) 0.80 3.0 8.5 761
Factor VII, % activity 543 124 (61) 42 118 158 839
vWf, % activity 549 135 (59) 21 134 209 393
Fibrinogen, g/L 577 2.9 (0.70) 1.24 2.90 3.81 5.73
Prothrombin fragments 12, nmol/L 543 1.5 (1.8) 0.7 1.24 1.7 19.6
D-dimer, g/ml 549 0.7 (1.1) 0.2 0.42 1.3 10.0
ICAM-1, ng/ml 578 272 (75.7) 50.0 263 362 717
E-selectin, ng/ml 578 59.2 (122) 1.7 49.2 85.4 2,922
Definition of abbreviations: CRP  C-reactive protein; ICAM-1  intercellular adhesion molecule 1; SAA  serum amyloid A;
vWf  von Willebrand factor antigen.
effect was limited to the 5-d average exposure. Associations for
the 1-d lag were found to be even stronger than for lag 0; how-
ever, this was not consistent throughout all pollutants.
Blood coagulation. In linear regression, a consistent decrease
in the mean of percentage of activity was found with FVII for
almost all pollutants for the 5-d average exposure, indicating a
cumulative effect (Figure 3). With the exception of PM2.5 and
NO2, this decrease was also consistently found for lag 2.
Logistic regression results for FVII were in agreement with
the results of the linear regression.
For prothrombin fragment 12, the logistic regression re-
vealed constant increases of the OR, with lag 4 showing a consis-
tent pattern in all measured pollutants (data not shown). Fibrino-
gen only revealed very few signiﬁcant effects, which might be
due to chance. Analyses of D-dimer revealed a null result in
linear as well as in logistic models (Figure 3).
Sensitivity analyses. Thorough sensitivity analyses were con-
ducted for the logistic regression models comparing different
models with varying number of confounder variables.
ForCRP, adding temperature, relative humidity, and air pres-
sure resulted in higher AIC values. In these models, the results
for the two-lagged effect of UFPs and AP were conﬁrmed; how-
ever, these had generally wider conﬁdence intervals. For pro-
thrombin fragment 12, the AIC was reduced by adding air
pressure to the model. However, estimates were up to twofold
higher and results for the AP destabilized. Therefore, the more
conservative and more stable model was used. Throughout all
models, stable results were found for lag 2 with the UFPs and
with lag 4 for AP, PM10, PM2.5, EC, and OC. The results for
ICAM-1 also remained stable throughout all models. Moreover,
we conducted sensitivity analyses comparing the results for those
patients who were on lipid-lowering drugs, primarily statins, with
those who were not. Results for the linear regression show that
the effects were mainly driven by the patients who were not
on lipid-lowering medication. The effects were larger than the
overall effects but had wide conﬁdence intervals due to reduced
power. Stratiﬁed analyses for CRP showed stronger effects in
the patients taking statins.
We compared the results of a random-effects model with
those of the ﬁxed-effectsmodel for the linear regression, showing
consistent effect estimates (FVII, AP, 5-d average exposure:
OR, 4.3; 95% CI, 8.1, 0.5). Some associations were found
to have a nonlinear exposure response function as marked in
Tables 4 and 5. Nonlinearity weakens the evidence for a strong
inﬂuence of these pollutants; however, for the CRP, all associa-
tions were linear (Table 4).
DISCUSSION
Summary
Our ﬁndings suggest increases in CRP and ICAM-1 in associa-
tion with ambient air particles. For these markers, the effects
were limited to the higher values of the parameters, showing an
increase in the odds of observing high levels of the respective
parameters with elevated levels of air pollution. CRP rose with
a delay of 2 d for all measured pollutants except for EC and
OC. For ICAM-1, a 1- and 2-d delayed increase was associated
with most pollutants.
Mean concentrations of vWf were shifted toward higher val-
ues revealing the strongest effect for the 5-d average exposure
to almost all pollutants. Moreover, a rise in prothrombin frag-
ment 12 in association with all pollutants was seen, which was
consistent for lag 4. For FVII, clear and consistent negative
associations were observed.
UFPs, NO2, and CO were measured simultaneously and
therefore allow a rough estimate on how well the two gases can
be used as surrogates for the exposure to combustion-derived
particles. Our results show a high correlation among these three
pollutants, and also the estimates for the blood markers show
comparable results, especially in logistic regressions. Similar con-
clusions have been drawn by Cyrys and colleagues (26), who
found UFPs, NO2, and CO to be strongly correlated and to
reﬂect motor vehicle trafﬁc.
Possible Mechanisms
This study was based on the following mechanistic hypotheses
(Figure 1): Airway injury or activation of blood cells, such as
monocytes, caused by particles deposited in the alveoli leads to
a release of proinﬂammatory cytokines interleukin (IL)-6 and
IL-8. Increased production of IL-6 and IL-8 activates mononu-
clear as well as endothelial cells, initiating the hepatic synthesis
of acute-phase proteins, such as CRP and SAA, and an up-
regulation of the expression of adhesion molecules as markers
of endothelial dysfunction. An enhanced acute-phase response
as well as endothelial cell activation increase procoagulant activ-
ity, indicated by a rise in coagulation proteins or evidence of
activation of the clotting cascade (27). These changes in blood
parameters, together with plaque instability, may ultimately lead
to a coronary event in susceptible patients.
Inflammatory Pathway
Regarding CRP, Seaton and coworkers (28) observed a positive
association between exposure to ambient PM10 and CRP concen-
trations in elderly subjects in the United Kingdom. For CRP, our
ﬁndings are in accordance with those of Seaton and colleagues
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TABLE 4. EFFECTS OF AIR POLLUTION ON BLOOD
PARAMETERS PRESENTED AS OR FOR AN INCREASE IN THE
BLOOD MARKER ABOVE THE 90th PERCENTILE (LOGISTIC
REGRESSION) PER INCREASE IN INTERQUARTILE RANGE
AIR POLLUTANT IN 57 MEN WITH CORONARY HEART
DISEASE IN ERFURT, GERMANY, WINTER 2000/2001
CRP ICAM-1
Time Period before
Blood Withdrawal OR 95% CI OR 95% CI
PM10 0 to 23 h 1.2 0.8, 1.9 1.3 0.9, 1.8
24 to 47 h 2.0* 1.1, 3.6 3.1*‡ 2.0, 4.8
48 to 71 h 2.2* 1.2, 3.8 3.4* 2.2, 5.2
5-d-mean 2.0* 1.2, 3.7 3.4* 2.2, 5.3
PM2.5 0 to 23 h 1.1 0.7, 1.8 0.7*‡ 0.4, 0.9
24 to 47 h 1.5† 0.9, 2.5 1.3 0.8, 1.8
48 to 71 h 1.2 0.8, 1.9 1.8* 1.2, 2.7
5-d-mean 1.4 0.9, 2.3 1.1 0.8, 1.5
AP 0 to 23 h 0.7 0.5, 1.2 0.6*‡ 0.4, 0.9
24 to 47 h 1.5 0.9, 2.6 1.8* 1.2, 2.8
48 to 71 h 3.2* 1.7, 6.0 1.6† 1.0, 2.5
5-d mean 1.5 0.8, 3.0 0.9 0.6, 1.5
UFPs 0 to 23 h 0.7 0.5, 1.2 0.6* 0.4, 1.0
24 to 47 h 1.2 0.7, 2.0 1.0 0.6, 1.6
48 to 71 h 2.3* 1.3, 3.8 1.3‡ 0.8, 2.2
5-d mean 1.5 0.9, 2.6 0.8 0.5, 1.2
EC 0 to 23 h 1.2 0.7, 2.0 1.0‡ 0.7, 1.6
24 to 47 h 1.3 0.7, 2.4 2.6*‡ 1.7, 3.8
48 to 71 h 1.6 0.9, 2.7 4.0* 2.5, 6.1
5-d mean 1.2 0.7, 2.1 2.2*‡ 1.4, 3.3
OC 0 to 23 h 1.2 0.7, 1.9 0.9‡ 0.6, 1.3
24 to 47 h 1.3 0.8, 2.1 2.0*‡ 1.3, 3.2
48 to 71 h 1.4 0.8, 2.4 3.0* 1.8, 4.8
5-d mean 1.2 0.7, 1.8 1.3‡ 0.8, 2.0
NO2 0 to 23 h 1.1 0.7, 1.8 0.6† 0.4, 1.0
24 to 47 h 1.4 0.9, 2.3 1.0‡ 0.7, 1.6
48 to 71 h 2.0* 1.2, 3.3 1.0‡ 0.6, 1.5
5-d mean 1.4† 1.0, 2.0 0.8‡ 0.6, 1.1
CO 0 to 23 h 0.9 0.7, 1.2 0.8* 0.6, 1.0
24 to 47 h 1.0 0.7, 1.5 1.5* 1.2, 1.9
48 to 71 h 1.5* 1.1, 2.1 1.7*‡ 1.3, 2.3
5-d mean 1.1 0.8, 1.6 1.2‡ 1.0, 1.6
Definition of abbreviations: AP  accumulation mode particles (particles with a
size range of 0.1 to 1.0 m); CI  confidence interval; CRP  C-reactive protein;
EC  elemental carbon; ICAM-1  intercellular adhesion molecule 1; OC 
organic carbon; OR  odds ratio; PM2.5  mass concentration of particles less
than 2.5 m in diameter; PM10  mass concentration of particles less than
10 m in diameter; UFPs  ultrafine particles (number concentration of particles
with a size range of 0.01 to 0.1 m).
* p  0.05.
† p  0.1.
‡ Nonlinearity observed in the model.
Finalmodels: CRP, adjusted for relative humidity lag 4, ns (df2) temperature
lag 3, ns (df  2)  trend (linear)  ID; ICAM-1, adjusted for temperature
lag 0, ns (df  4)  trend (linear)  ID.
and are also consistent with those previously reported from
Augsburg, Germany (17). Increased concentrations of CRP are
known to predict cardiovascular events in healthy subjects (29).
Also, elevated levels of IL-6 have been found to be associated
with total mortality (30) andwith risk of future fatal and nonfatal
MI (31). PM10 is suggested to affect the upper bronchi and there-
fore lead to an inﬂammation in the lung, whereas the smaller
particles potentially transfer into the blood and start a systemic
inﬂammatory response. Our data indicate a systemic delayed
response to air pollution. According to Geiser (32), particles are
rapidly translocated into the blood. It is therefore possible that
the delay we observed is due to the time needed to initiate the
acute-phase response after a rapid UFP translocation. With a
half-life of 19 h (33), CRP is down-regulated rapidly and there-
fore does not show any elevation 3 to 4 d after an increase in
air pollution.
Endothelial Dysfunction
Adhesion molecules, such as ICAM-1, mediate the contact be-
tween circulating leukocytes and endothelial cells. ICAM-1 in-
duces a tight binding of leukocytes to the endothelium. In this
way, leukocytes can leave the blood stream and enter the suben-
dothelial space (34–37). ICAM-1 has been shown to predict
acute coronary events as well as angina pectoris in a prospective
cohort of apparently healthy men (38). Also, an increase in
ICAM-1 in association with diesel exhaust was shown in bron-
chial biopsies in a panel of 15 human volunteers (39). Moreover,
particles collected in Provo, Utah (40), enhanced the expression
of ICAM-1 in primary cultures of human epithelium. Our data
are in accordance with the literature indicating an up-regulation
in ICAM-1 expression primarily with lag 1 and 2.
In addition, vWf may serve as a marker of endothelial dys-
function. In healthy mice, increased vWf expression on hepatic
endothelium was detected after application of UFPs (41). vWf
reﬂects endothelial cell release and probably vascular reactivity.
Vascular reactivity could be secondary to inﬂammation, and
because vWf canmediate platelet adhesion to damaged endothe-
lium, this could be a predictor of coronary events (34, 42).
Coagulation Pathway
In contrast to our initial hypothesis, the various clotting factor
levels showed no consistent pattern in association with air
pollution.
FVII, one of the key enzymes of the extrinsic system of the
coagulation cascade, is activated by tissue factor. Complexes of
tissue factor with factor VIIa are central to the activation of
factor X and to the formation of thrombin, which mediates the
conversion of ﬁbrinogen to ﬁbrin (43). Results for FVII in the
literature are inconsistent (28, 44). In our study, FVII activity
decreased signiﬁcantly in association with most pollutants.
Regarding ﬁbrinogen levels, we did not ﬁnd any consistent
results in association with air pollution. Controlled human expo-
sure studies (45, 46) as well as epidemiologic studies (47, 48)
demonstrated positive associations between ﬁbrinogen or plasma
viscosity and air pollution. However, decreases in ﬁbrinogen levels
also have been reported and the signiﬁcance of these results is
unknown (28, 41).
Prothrombin fragment 12 is cleaved from prothrombin
when it is activated to thrombin by factor Xa, thereby represent-
ing a marker of activation of the coagulation pathway (34, 49,
50). Our data indicate an increased concentration in association
with ambient air pollutants. This signiﬁcant increase indicates
that an early step of blood coagulation has been activated. How-
ever, this activation was not associated with increased formation
of ﬁbrin, as would be detected by elevated D-dimer levels. The
elevated levels of prothrombin fragment 12 are an important
ﬁnding that shows that air pollution not only induces inﬂamma-
tion but also coagulation.
The large number of blood markers measured in this study
revealed inconsistencies that were already observed in previous
studies (13). One possible explanation is that various particle
fractions or components differ in their effects. CRP, for example,
did not show any association with EC and OC, whereas other
blood markers showed quite strong effects. Moreover, diverse
time patterns in the reaction to air pollution, due to the differing
biological mechanisms, are conceivable and were also seen in
the data.
While the results for inﬂammation and air pollution seem
consistent, inhomogeneity exists in terms of coagulation mark-
ers. Our data strongly indicate that the pathway that links airway
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TABLE 5. EFFECTS OF AIR POLLUTION ON BLOOD PARAMETERS PRESENTED AS PERCENTAGE OF
CHANGE FROM THE MEAN/GEOMETRIC MEAN IN THE BLOOD MARKER (LINEAR REGRESSION)
PER INCREASE IN INTERQUARTILE RANGE AIR POLLUTANT IN 57 MALE PATIENTS WITH
CORONARY HEART DISEASE IN ERFURT, GERMANY, WINTER 2000/2001
vWf FVII
Time Period before % Change % Change
Blood Withdrawal (mean) 95% CI (GM)§ 95% CI
PM10 0 to 23 h 4.0 0.6, 8.5 6.6* 10.4, 2.5
24 to 47 h 6.0* 0.6, 11.5 8.4*† 12.3, 4.3
48 to 71 h 1.1† 4.9, 7.0 5.9* 9.6, 2.0
5-d mean 6.1 0.6, 12.8 8.0* 12.4, 3.4
PM2.5 0 to 23 h 3.9 0.3, 8.1 2.5 6.2, 1.4
24 to 47 h 3.1 1.6, 7.8 2.8 6.1, 0.6
48 to 71 h 3.6† 1.1, 8.3 2.3 5.0, 0.6
5-d mean 5.6* 0.5, 10.8 3.5* 6.4, 0.4
AP 0 to 23 h 4.8*† 0.2, 9.3 0.0 2.9, 3.0
24 to 47 h 5.9*† 0.4, 11.5 2.9‡ 6.1, 0.4
48 to 71 h 7.0* 0.7, 13.4 3.6* 6.8, 0.3
5-d mean 13.5* 6.3, 20.6 4.1* 7.9, 0.3
UFPs 0 to 23 h 3.4 2.2, 9.0 1.3† 2.3, 5.1
24 to 47 h 3.5 2.7, 9.7 6.6* 10.6, 2.4
48 to 71 h 3.1 3.4, 9.6 6.4* 10.4, 2.3
5-d mean 7.8* 1.4, 14.3 6.6* 10.7, 2.3
EC 0 to 23 h 5.0* 0.0, 10.1 5.7* 10.5, 0.7
24 to 47 h 7.6* 1.4, 13.7 6.9*† 11.2, 2.3
48 to 71 h 1.1† 5.2, 7.4 4.2‡ 8.4, 0.2
5-d mean 5.7†‡ 0.5, 12.0 6.0* 10.5, 1.2
OC 0 to 23 h 5.5* 0.2, 10.8 6.1* 10.6, 1.4
24 to 47 h 8.0* 2.1, 13.9 7.2* 11.4, 2.8
48 to 71 h 3.5† 2.6, 9.6 3.8 8.2, 0.9
5-d mean 7.4*† 2.0, 12.8 5.6* 9.8, 1.1
NO2 0 to 23 h 5.7* 0.7, 10.7 3.0 6.7, 0.9
24 to 47 h 4.1 1.2, 9.4 2.0† 5.5, 1.7
48 to 71 h 3.9 1.5, 9.4 1.5† 4.8, 1.9
5-d mean 5.7* 1.6, 9.8 2.8‡ 5.5, 0.0
CO 0 to 23 h 4.4* 1.4, 7.5 1.4 3.8, 1.1
24 to 47 h 2.7† 0.8, 6.1 2.6*† 4.8, 0.3
48 to 71 h 2.0† 1.7, 5.8 2.8* 5.1, 0.4
5-d mean 4.9* 1.0, 8.8 3.0* 5.5, 0.4
Definition of abbreviations: EC  elemental carbon; FVII  factor VII; OC  organic carbon; PM2.5  mass concentration of
particles less than 2.5 m in diameter; PM10  mass concentration of particles less than 10 m in diameter; UFPs  ultrafine
particles (number concentration of particles with a size range of 0.01 to 0.1 m); vWf  von Willebrand factor antigen.
* p  0.05.
† Nonlinearity observed in the model.
‡ p  0.1.
§ Percentage of change per interquartile range increase in air pollution.
Final models: vWf: air pressure, lag 1, ns (df  2)  relative humidity, lag 1, ns (df  4)  air temperature, lag 3, ns (df  5) 
trend, ns (df  3) ID  weekday; factor VII: air pressure, lag 3, ns (df  4)  relative humidity, lag 0, ns (df  5)  air
temperature, lag 1, ns (df  3)  trend, ns (df  4)  ID  weekday.
injury from air pollution and coronary events may include in-
creased expression of adhesionmolecules and a proinﬂammatory
response. Furthermore, the coagulation system (prothrombin
fragment 12) is activated, although not sufﬁciently enough to
cause increased ﬁbrin formation, as would have been reﬂected
by elevated D-dimer levels. We do not have an explanation
for the decreased concentrations of ﬁbrinogen and FVII, but,
whatever the cause, theymay act to protect against clinical events
secondary to coronary thrombosis. Our study represents mea-
surements of background levels of blood markers and does not
reﬂect changes that might relate to acute clinical events.
Strengths and Limitations
A strength of this study is the achievement of 99% of all sched-
uled visits. Moreover, a wide range of markers, reﬂecting differ-
ent pathways, were measured within the same setting. All of the
measured biomarkers may increase in response to a number of
unspeciﬁc stimuli, such as infectious diseases or surgery. CRP
is particularly sensitive and can increase a thousandfold within
a short time in response to such triggers (34). Therefore, we
excluded all blood samples that potentially might have been
affected by sources other than air pollution. All patients were
asked about infections and surgery in the 2 wk before the blood
withdrawal. Reasons for physician visits aswell as hospital admis-
sions were recorded, and study nurses documented signs of an
acute respiratory infection in the patient during regular clinic
visits. None of the samples that revealed especially high or low
levels of the respective biomarker were excluded unless a reason
was known.
We used logistic regression analyses in addition to linear
regression because Peters and colleagues (16) had suggested that
effects of air pollutionmay be seen on a small number of subjects
with high values of a particular marker with less effect on the
mean level. Also, some parameters showed a few extreme outli-
ers, which strongly inﬂuenced the regression results.
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Figure 3. Effects of UFPs and PM10 on blood markers of inflammation, endothelial dysfunction, and coagulation; lag 0 to lag 2 and 5-d average
exposure. Fifty-seven male patients with coronary heart disease in Erfurt, Germany, winter 2000/2001. GM  geometric mean; IQR  interquartile
range; OR  odds ratio.
Although the ﬁxed-effect models were adjusted for individual
time-invariant factors, by design no adjustment for time-dependent
individual-level variables was possible.
A variety of pollutants were used for the analyses, because
different pollutants may point toward different properties of the
aerosol, and also represent different sources of air pollution.
However, by testing multiple blood parameters and a set of
air pollutants, the possibility that some effects might have oc-
curred by chance cannot be excluded. Because the air pollution
parameters are closely correlated, we considered especially con-
sistent patterns in the data as actual effects. Moreover, thorough
confounder adjustment for meteorologic variables was done to
rule out the possibility that the detected associations resulted
from meteorologic inﬂuences or seasonal differences.
Only one central measurement site was used for the collection
of ambient air pollution. However, the spatial representativeness
of this site has been analyzed in detail previously by Cyrys and
colleagues (51), whomeasured sulfate and PM10 levels simultane-
ously at three additional monitoring sites in the Erfurt area.
The relatively high intersite correlation between the monitoring
stations (0.69–0.98) indicates that regional episodes of sulfates
and PM10 in Erfurt can be identiﬁed using one ﬁxed monitoring
site and that our site is generally representative for the urban
background level of air pollution within Erfurt. Erfurt is a small
city with one air mass conﬁned by a mountain ridge on three
sides and high rises on the fourth side. Because most of the
participants of our panel were already retired, we assume that
they spent the greater part of their day within the vicinity of
their residence within the city of Erfurt.
Many studies have demonstrated that individual exposures to
PM are poorly correlated spatially with ambient concentrations
(52). Some longitudinal exposure assessment studies of PM and
speciﬁc PM components with repeated measures have found
higher correlations between personal exposures and ambient
concentrations. Janssen and coworkers (53) showed, for exam-
ple, that ambient, indoor, and personal concentrations of PM2.5
were highly correlated in two European cities.
However, the correlationmany epidemiologists are interested
in is not that between total personal exposure and outdoor con-
centrations but the correlation between that component of per-
sonal exposure that can be attributed to outdoor particles and the
outdoor concentrations. Ebelt and colleagues (54) demonstrated
that ambient concentrations and the contribution of ambient
particles to personal PM exposure were highly correlated, with
a Pearson correlation coefﬁcient of 0.81 for PM2.5, of 0.71 for PM10
and of 0.73 for the coarse fraction (PM10PM2.5).Moreover, they
show that ambient concentrations and exposure to nonambient
PM2.5 are independent, which is an important assumption in
epidemiologic studies that use ambient concentration as a surro-
gate for personal exposure. They conclude that their results give
support to the use of ambient monitoring data in time series
analyses. Cyrys and coworkers (55), who compared the relation-
ship of indoor and outdoor levels of ﬁne-particulate mass, parti-
cle number concentrations, and black smoke, concluded that
ambient concentrations of PM2.5 and black smoke can be used
as good approximations of indoor concentrations.
A limitation to the study is that the examined panel consisted
of male patients only, with a history of CHD, who were all taking
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cardiac medication. Therefore, they represent a highly selected
group and the study results might not be generalizable to other
population groups, such as females with CHD or healthy
subjects.
A differentiation between chronic and acute effects of higher
levels of blood markers in the patients is not possible with this
study design. Because of the short observation time, it is not
clear whether these changes can lead to an onset or exacerbation
of the disease. We observed short-term changes in various blood
parameters; however, the implications for patients remain specu-
lative. On the other hand, changes in blood markers due to air
pollution have recently been observed not only in patients with
CHD but also in young and healthy persons (56).
Conclusions
The study adds to the evidence that elevated levels of ambient
air pollution may cause systemic inﬂammatory and coagulation
responses. These changes in bloodmarkers could represent addi-
tional risk factors, which, in susceptible individuals, such as pa-
tients with CHD, could increase the likelihood of serious arterial
vascular thrombotic events on exposure to high levels of air
pollutants.
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(To be completed via interview) 
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Examiner please note that fields marked with   refer to inclusion or exclusion criteria; other 
questions are for baseline characterization! 
 
 
1. Interviewer ID ________________ 
2. ID-Number: ___________ 
3. Date of birth: |___|___|.|___|___|.|___|___| 
          d      d       m    m       y       y 
4. Sex:  Male  Female 
5. Marital Status: 
 married    single    divorced    widowed   
6. Ethnicity (INT: please do not read this question out loud except when you are unsure) 
 caucasian   black   asian   mixed  
7. Education  
7.1. School years (including primary school) |___|___| years 
7.2. Professional Training |___|___| years 
7.3 College/University |___|___| years 
____________________________________________________________________________________  
Inclusion criteria 
8. INT: if known, do not read out loud 
  Did a doctor diagnose a myocardial infarction?  Yes  No 
      (if ‘No’ subject has to be excluded) 
 if ‘Yes’: 
8.1 How many infarctions have you had?     |___| 
 
8.2 When did you have your first infarction?   |___|___|.|___|___|.|___|___| 
                          d    d       m   m      y     y 
8.3  When did you have your last infarction?  |___|___|.|___|___|.|___|___| 
                          d    d       m   m      y     y 
   (if less than 6 months ago or more than 5 ½ years ago subject has to be excluded) 
8.4.  Age at onset of last MI  |___|___| 
 (if less than 35 years or more 74 years subject has to be excluded) 
BASELINE QUESTIONNAIRE           AIRGENE  
 
 - 3 -  
9. Did your mother have a myocardial infarction?  Yes  No 
   don´t know 
9.1 If ‘Yes’ at what age? (first infarction)? 
  at |___|___| years of age 
   don´t know 
10. Did your father have a myocardial infarction?   Yes  No 
   don´t know 
10.1 If ‘Yes’: at what age (first infarction)? 
  at |___|___| years of age 
   don´t know 
11.  Have you had recent (< 6 months) coronary by-pass surgery or a balloon dilatation (PTCA)? 
(if ‘Yes’ subject has to be excluded)       Yes  No 
12.  Have you smoked during the past 3 months?   Yes  No 
(preferably current non-smokers only) 
if ’Yes’: 
12.1 had you less than 1 cigarette, cigar or pipe of tobacco a day?  Yes, less 
   No, one or more 
13.  Do you suffer from any of the following diseases which might prohibit  
 participation in the study: 
(if ‘Yes’ subject has to be excluded) 
13.1 Crohns disease           Yes  No 
13.2 Ulcerative colitis           Yes  No 
13.3 Rheumatoid arthritis          Yes  No 
13.4 Hemophilia          Yes  No 
13.5 HIV             Yes  No 
14.  Do you plan to leave your home for months during the study period? 
(if ‘Yes’ subject has to be excluded)         Yes  No 
15.  Are you able to come to the study center once every four weeks for another 5 visits? 
          (if ‘No’ subject has to be excluded)         Yes  No 
16.  At each visit a blood sample will be taken. Do you agree to have your blood taken? 
          (if ‘No’ subject has to be excluded)          Yes  No 
BASELINE QUESTIONNAIRE           AIRGENE  
 
 - 4 -  
 
Disease History 
17. Did a doctor ever diagnose one or more of the following diseases? 
 Please ask if you don´t understand one of the following: 
17.1  Angina Pectoris  Yes  No 
17.2  Arrhythmias   Yes  No 
17.3  Congestive heart failure  Yes  No 
17.4  Other heart problems  Yes  No 
17.5  Diabetes  Yes  No 
 If ‘yes’: 
17.5.1 Type of diabetes 
  Type I  
 Type II  
 don’t know  
 
 17.5.2 
  Year of diagnosis  |___|___|___|___| 
  or 
  Age at diagnosis         |___|___| 
17.6  Hypertension  Yes  No 
17.7  Stroke  Yes  No 
17.8  Asthma  Yes  No 
17.9  Chronic bronchitis  Yes  No 
17.10  Emphysema  Yes  No 
17.11  Hay fever  Yes  No 
17.12  Chronic renal diseases  Yes  No 
17.13  Arthrosis  Yes  No 
17.14 Other chronic diseases  Yes  No 
Specify: ______________________________________________________________________  
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18.1 Have you had wheezing or whistling in your chest at any time  
          in the last 12 months?   Yes  No 
 
if 'Yes':  
18.1.1  Have you had this wheezing or whistling when you did  
  not have a cold?      Yes  No 
   
18.2 Do you usually cough during the day, or at night, in the winter?  Yes  No 
 
if 'Yes': 
 18.2.1 Do you cough like this on most days for as much as  
  three months each year?   Yes  No 
 
18.3  Do you usually bring up any phlegm from your chest during the day,  
  or at night, in the winter?   Yes  No 
 
if 'Yes': 
 18.3.1  Do you bring up phlegm like this on most days for  
  as much as three months each year ?  Yes  No 
 
Health status and CCS functional class 
19. Do you have a cardiac pacemaker?  Yes  No 
20.  In your opinion, your health status compared to your age group is in general: 
   excellent 
     good 
     moderate 
     bad 
   very bad 
21. Which of the following daily activities can you manage without angina pectoris symptoms? 
 (Only one answer possible) 
21.1  Vigorous activities, such as lifting heavy objects, shoveling snow 
 or participating in strenuous sports such as skiing, ball games or running  
21.2  Moderate activities, such as walking, climbing stairs rapidly or after meals, 
 moving a table, pushing a vacuum cleaner, bowling, or playing golf   
21.3  Ordinary activities, such as walking one or two blocks, or climbing 1 flight 
 of stairs at a normal pace under normal conditions   
21.4  No physical activity without discomfort or angina symptoms even at rest  
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Physical activity 
The following questions refer to physical activity, separate for light physical activity and vigorous 
physical activity.  
22. Light physical activities are activities that make you breathe hard like brisk walking, hiking, 
dancing, light gardening, heavy housework or other light physical activities. 
22.1 On average, on how many days per week do you engage in such activities  
  (0 to 7 days)? |___| 
22.2 On average, how long do you engage in such activities on those days?   min 
22.3 How many years or months have you been doing these activities? 
|___|___| years    |___|___| months 
23. Vigorous physical activities are activities that make you sweat that you perform for at least 20 
min (e.g. jogging, aerobics, swimming, fast cycling, ball games, heavy gardening) 
On average, how many days a week do you pursue vigorous physical activities?   |___| 
 
Work and living conditions 
24. Are you currently working?  Yes  No 
 INT: yes also if currently away from work because of illness 
24.1 if ‘Yes’, do you work: 
  full time  
  part time  
24.2 Are you exposed to fumes, gases or dust at work?  Yes  No 
  if ‘Yes’, specify:  
24.3 Do people smoke regularly in a room where you work?  Yes  No 
25. How old is the house you live in  |___|___|  or  
 when was it built? |___|___|___|___| 
26. Is your home/apartment situated close to a busy road, that is, at most  
 50m away from it?   Yes  No 
(busy road = at least 10.000 vehicles per day) 
? (please provide examples) 
if ‘No’: go to question 28 
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if ‘Yes’: 
27. Does your home/apartment have one or more windows that face 
 a busy canyon road?  Yes  No 
(busy canyon road = at least 10.000 vehicles per day with houses on 
both sides of the street for at least 100m; the width of the space between 
the houses is less than 3 times the average height of the houses 
? (please provide example) 
 if ‘Yes’: 
 27.1 How many floors does the house you live in have? |___|___| floors 
  INT: Including ground floor (basement=0, ground floor=1,  
  one storey up = 2 etc.) 
 27.2 On which floor is your apartment? Floor |___|___|  
  INT: Including ground floor (basement=0, ground floor=1,  
  one storey up = 2 etc.) 
 
28. How much are you annoyed by the traffic noise at home if the windows are kept open? 
(please circle a number from 0-10 on the scale) 
?(please provide a scale and read off the corresponding number)    |___| 
29. How much are you annoyed by air pollution at home, i.e., smell of traffic and industry,  
 when you keep the window open? 
 (please circle a number from 0-10 on the scale) 
?(please provide a scale and read off the corresponding number)    |___| 
30. During the summer months, do you usually sleep with the windows open?  Yes  No 
31. During the winter months, do you usually sleep with the windows open?   Yes  No 
32. Does your home have central heating?  Yes  No 
32.1 If ‘No’, which of the following fuels do you use regularly for heating? 
(more than one answer possible) 
  coal, wood  
  gas  
  electricity  
  oil  
33. Do you regularly use a gas range or gas oven for cooking?  Yes  No 
34. Do you have air conditioning?  Yes  No 
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35. Did you drink any alcoholic beverages in the past 12 months?   Yes  No 
if 'No': go to question 38 
if ‘Yes’: 
36. How much beer, wine and liquor did you drink during the last weekend? 
 (Friday evening, Saturday and Sunday) 
  beer or cider (accurate to 0,5 l) |___|___|,|___| liters 
  light beer (accurate to 0,5 l) |___|___|,|___| liters 
  alcohol free beer (accurate to 0,5 l) |___|___|,|___| liters 
  wine /sparkling wine (accurate to 0,2 l) |___|___|,|___| liters 
  liquor |___|___| glasses à 0,02 l 
37. How much beer, wine and liquor did you drink at the last working day?  
 If this day is a Friday please relate to the day before (Thursday) 
  beer or cider (accurate to 0,5 l) |___|___|,|___| liters 
  light beer (accurate to 0,5 l) |___|___|,|___| liters 
  alcohol free beer (accurate to 0,5 l) |___|___|,|___| liters 
  wine /sparkling wine (accurate to 0,2 l) |___|___|,|___| liters 
  liquor |___|___| glasses à 0,02 l 
 
38. Does anyone, not including yourself, smoke regularly inside your home?  Yes  No 
If ‘Yes’:  
38.1 How many people, not including yourself, in your household smoke? |___|___| 
 
39. Have you ever smoked cigarettes for as long as a year? 
  No 
   Yes, < 1 cig per day 
 (occasional smoker) 
  Yes, >= 1 cig per day  
  
If ‘No’ or ‘< 1 cig per day’: Please go to question 41  
BASELINE QUESTIONNAIRE           AIRGENE  
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If ‘Yes’: 
39.1  How old were you when you started smoking cigarettes? |___|___| years 
39.2  How many years did you smoke 1 to 10 cigarettes per day?  |___|___| years 
39.3  How many years did you smoke 11 to 20 cigarettes per day? |___|___| years 
39.4  How many years did you smoke 21 to 30 cigarettes per day?  |___|___| years 
39.5  How many years did you smoke more than 30 cigarettes per day?  |___|___| years 
if more than 0 years:  
39.5.1 How many cigarettes per day did you smoke on average at that time?  |___|___| 
39.6. Did you stop smoking cigarettes at any time and then start again?   Yes  No 
if ‘Yes’:  
39.6.1 How many years in total did make such cigarette smoking breaks? |___|___| years 
40. Have you now stopped smoking cigarettes?     Yes  No 
40.1  if ‘Yes’, When did you give up smoking cigarettes? Year     |___|___|___|___| 
 or  
 Age    |___|___| years old 
40.2 if ‘No’: How many cigarettes do you currently smoke per day on average? |___|___| 
INT: please check that the whole cigarette smoking history is covered.  
(Calculation: 40.1 (or age today if still smoking cigarettes) minus 39.1 (age at start) minus 39.6.1 
(years of cigarette breaks) should equal 39.2 plus 39.3 plus 39.4 plus 39.5) 
If there are problems, try to ask the patient again 
 
41. Have you ever smoked cigars/cigarillos/pipes for as long as a year?   Yes  No 
    
 If ‘No’:  
Please go to the Food Frequency Questionnaire. 
 if ‘Yes’: 
41.1 How old were you when you started smoking cigars/cigarillos/pipes? |___|___| years 
41.2 How much did you smoke on average during your years of smoking cigarillos,  
 cigars or pipe? 
    Number of cigarillos per day     |___|___| 
    Number of cigars per day     |___|___| 
    Pipes per week      |___|___|___| 
BASELINE QUESTIONNAIRE           AIRGENE  
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41.3 Did you stop smoking cigars/cigarillos/pipe at any time and then start again?   
   Yes  No 
if ‘Yes’:  
41.3.1 How many years in total did you make such smoking breaks?  |___|___| 
years 
42. Have you now stopped smoking cigars/cigarillos/pipe?   Yes  No 
 
42.1 if ‘Yes’: When did you give up smoking cigars/cigarillos/pipe? Year  |___|___|___|___| 
  or 
  Age    |___|___| years old 
42.2 if ‘No’: How much do you currently smoke on average? 
    Number of cigarillos per day     |___|___| 
    Number of cigars per day     |___|___| 
    Pipes per week      |___|___|___| 
 
 
 
Please go to the Food Frequency Questionnaire 
 
 
Evaluation for participation 
 For Nurses and Doctors only, please do not read to participant! 
43.  Is the patient physically and mentally able to participate?  Yes  No 
44.  Is there any other indication to exclude the patient from the study?  Yes  No 
 If ‘Yes’, specify:___________________________________________ 
45. Patient read and signed the consent form and got a copy?    Yes  No 
46. Date   |___|___|.|___|___|.|___|___| 
                d       d       m     m      y       y 
 
Notes/Comments:_________________________________________________________ 
__________________________________________________________________________________ 
 ID-No.:     |__|__|__|__|__|__| 
  
Short Questionnaire AIRGENE     Date:   |___|___|.|___|___|.|___|___| 
                                                                                                            d      d         m    m        y       y 
__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
AIRGENE
DOCTOR VISITS AND SYMPTOMS 
The examinations of the AIRGENE study can only be carried out, if there are no conditions inducing 
inflammation. Please answer the following questions regarding symptoms and doctor’s visits: 
1. Did you have a cold or flu in the past 3 days?   Yes   No 
2. Did you have an acute urinary tract infection during the past 3 days?  Yes   No 
3. Did you have an acute gastro-intestinal infection during the past 3 days?  Yes   No 
4. Did you have an acute respiratory infection during the past 3 days?  Yes   No 
 
   Examiner only, please do not read out loud:  
5. Do you see any sign of a respiratory infection?  Yes   No 
 
6. Did you have a surgery during the past 3 days?   Yes   No 
7. Did you have a severe dental intervention?   Yes   No 
 If any of the above questions is answered with yes, the examination has to be postponed.  
      Please make a new appointment with the patient. 
8. Did you visit a doctor/dentist or were you admitted to a hospital  
for any acute illness during the past week?  Yes   No 
8.1 if Yes, for what reason: 
  Angina Pectoris?        
  Urinary tract infection?      
  Gastro-intestinal infection      
  Respiratory condition?       
  Other condition    (specify):           
   
 
LIVING CONDITIONS/NUTRITION  
 
9.How did you get here? 
          walked    cycled    other 
  
10. Did you smoke during the past 24 hours?  Yes  No 
 
   
 if Yes: 
 10.1 How many cigarettes/cigars/cigarillos/pipes did you smoke? |___|___|  
 10.2 When was your last cigarette/cigar/cigarillo/pipe |___|___|:|___|___| 
        h    h            m      m 
11. Were you in rooms where people smoked during the last 24 hours?  Yes  No 
 if Yes: 
 11.1  How long did you spend there? (1h accuracy) |___|___| hours  
  Less than 1 hour 
 11.2 When did you leave |___|___|:|___|___| 
        h    h            m      m 
12. When did you last have something to eat (including snacks) |___|___|:|___|___| 
 INT: Time the last meal/snack was finished       h    h            m      m 
 
13. Did you drink any black or green tea in the past 24 hours?   Yes  No 
13.1 if yes: At what time was the last tea? |___|___|:|___|___| 
        h    h            m      m 
14. Did you drink any alcoholic beverages in the past 24 hours?   Yes  No 
14.1 if yes: At what time was the last drink? |___|___|:|___|___| 
        h    h            m      m 
15. Did you exert yourself in the past 24 hours?  
(exertion = physical activities that made you breathe hard  
like brisk walking, hiking, dancing, light gardening, heavy housework 
or other physical activities)  Yes  No 
if yes:  
15.1 How long was the exertion? |___|___|___| minutes 
15.2 When was the end of the exertion? |___|___|:|___|___| 
        h    h            m      m 
 
16. Did you feel extreme anger or stress during the past 24 hours?  Yes  No 
 2
 MEDICATION 
17. Have there been any changes in your medication since your last visit?  Yes   No 
17.1if Yes: 
Have you stopped taking a medication?    Yes   No 
    Please enter the date of last intake into the medication sheet. 
 17.2 Did you take or have you started taking a new medication?  Yes   No 
    Please check the diary and update the medication sheet. 
18 Has the dosage of your medication changed since the last visit (more or less tablets, different 
concentration or ingredient?    Yes   No 
  Please enter the date of last intake into the medication sheet and enter the medication with the 
new dosage in the medication sheet, using a new number. 
 
19 Which medication did you take during the past 7 days? 
 
 
Med 
No. 
Full name of medication 
da
ily
 
on
 d
em
an
d 
  
other 
schedule 
 
specify  
  
     
  
     
        
         
       
       
       
       
       
       
       
       
       
       
 
 Please make sure that all medication reported here is also documented in the medication sheet! 
 3
AIRGENE                                                                                                                                                                                    Medication Sheet  
 
Medication sheet                  ID-No.:   |___|___|___|___| 
Do you take any medication?   Yes  No             Sheet Nr:   |___| 
 
Med.
No. 
Full name of medication ATC-
Code  
(7 digits)
Concentration 
of active 
ingredient 
Total dose  
(number of pills etc. 
per day) 
(if not taken daily, use /:
1/week  for 1 pill a 
week) 
O
n
 
d
e
m
a
n
d
 
 
Start (Date) 
dd.mm.yy 
(only if during study)
>
 
7
 
d
a
y
s
 
b
e
f
o
r
e
 
s
t
a
r
t
 
o
f
 
s
t
u
d
y
 
 End (Date) 
dd.mm.yy 
(only if during study) 
C
o
n
t
i
n
u
e
d
 
a
t
 
e
n
d
 
o
f
 
s
t
u
d
y
 
  
 
    |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
       |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
       |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
       |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
       |__|__|.|__|__|.|__|__|    |__|__|.|__|__|.|__|__|   
       |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
       |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
       |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
       |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
       |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
       |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
       |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
       |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
       |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
       |__|__|.|__|__|.|__|__|  |__|__|.|__|__|.|__|__|  
AIRGENE 
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